

**BRADEN MANNS, MD, MSc, FRCPC**

**I. Biographical Data:**

Work address: University of Calgary  
3230 Hospital Drive NW  
Calgary, Alberta, Canada T2N 4Z6  
403-220-6499 (Phone)  
403-210-6660 (Fax)  
Braden.Manns@albertahealthservices.ca

Date of birth: May 1, 1969  
Citizenship: Canadian  
Rank: Professor

**II. Academic Record:**

Post-doctoral fellowship in Health Economics (Oct 2000-June 2001)  
University of Calgary

Masters in Health Economics (August, 1999 – Oct 2000)  
University of York, England

Nephrology fellowship (July, 1997 - June 1999)  
University of Calgary

- Fellow of the Royal College of Physicians and Surgeons of Canada, Nephrology (September 2000)

General Internal Medicine Residency (July, 1994 - June 1997)  
University of Calgary

- Fellow of the Royal College of Physicians and Surgeons of Canada, Internal Medicine (June 1998)

Doctor of Medicine (May 1994)  
University of Toronto

- Honours Standing

Bachelor of Science (May, 1990)  
University of Saskatchewan

- Honours Degree in Biochemistry

**Research Experience:****July, 1999 – June, 2001:      Research fellow***A cost-utility analysis of renal replacement therapy: Accounting for casemix*

- Supervisor: Dr. C. Donaldson, Univ. of Calgary
- Salary support through a combined Kidney Foundation of Canada / Alberta Heritage Foundation for Medical Research fellowship

**July, 1999 – Sept, 2000:      Masters in Health Economics***An economic evaluation of hemodialyser reuse vs conventional single- use hemodialysis*

- University of York, England
- Salary support through a combined Kidney Foundation of Canada / Alberta Heritage Foundation for Medical Research fellowship

**July, 1997 – June, 1999:      Nephrology Fellowship research projects***Hyperhomocysteinemia, vascular access thrombosis and the risk for atherosclerotic vascular disease in patients with end-stage renal disease*

- Supervisor: Dr N. Scott-Douglas, Univ. of Calgary
- Designed and conducted two cross-sectional analyses which demonstrated a strong association between hyperhomocysteinemia and atherosclerosis in patients with renal failure
- Two publications in peer reviewed journals (See publications 5,6)

*The effects of vitamin B12, folic acid, and serine supplementation on homocysteine levels in patients with end-stage renal failure on dialysis*

- Supervisor: Dr N. Scott-Douglas
- Designed and conducted this randomized trial which enrolled 82 patients
- Two publications (See peer-reviewed publications)

**1994-96:      Medical Resident Research Project***Antituberculous drug resistance in Alberta's immigrants with tuberculosis*

- Supervisor: Dr R. Cowie
- Dept of Respiratory Medicine, Univ. of Calgary
- Publication in peer-reviewed journal

### III. Awards and Distinctions

#### *2024 Association of Faculties of Medicine of Canada Mentorship Award*

- Awarded to a Canadian Faculty of Medicine member for excellence in Mentorship

#### *2019 Canadian Academy of Health Sciences (CAHS)*

- Inducted into the prestigious Canadian Academy of Health Sciences for achievements confronting complex health challenges

#### *2017 Kidney Foundation of Canada Gold Medal For Research Excellence*

- Kidney Foundation of Canada
- Awarded to a Canadian researcher who is recognized nationally and internationally for excellence in kidney-related research.

#### *2016 University of Calgary Peak Scholar Nominee*

- Awarded for commitment to the University of Calgary's Eyes High vision

#### *2016 Alberta Venture Magazine's 50 Most Influential People*

- Awarded for making a positive impression on Alberta's political, economic or cultural landscape

#### *2015 University of Calgary Killam Annual Professor Award*

- Awarded in recognition of research and teaching excellence, as well as service to the University and Community
- University of Calgary

#### *2014 Svare Professorship in Health Economics (5 year award)*

- Endowed Chair in Health Economics
- Faculty of Medicine, University of Calgary

#### *2012 Watanabe Distinguished Achievement Award for Overall Excellence*

- Faculty of Medicine, University of Calgary

#### *2012 CIHR-CMAJ Top Achievements in Health Research Awards*

- CIHR-CMAJ
- Co-winner with Dr Hemmelgarn / Tonelli

#### *2012 President's Excellent Award for Outstanding Achievement in Research*

- Alberta Health Services
- Co-winner with Dr Hemmelgarn / Tonelli

#### *2011 Dean's Publication and Mentorship Prize winners*

- Faculty of Medicine, University of Calgary

- Awarded for Mentorship and Publication Excellence by a graduate student (Dr Steve Heitman) for publication in PLOS, Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation

*Letter of Excellence Teaching Award (2010)*

- Faculty of Medicine, University of Calgary
- Awarded for Teaching in Undergraduate Medical Education

*2010 Cochrane Distinguished Achievement Award*

- Faculty of Medicine, University of Calgary
- Awarded to one researcher in the Faculty of Medicine for Excellence in Research, 2010 Academic Year

*2010 Alberta Innovates–Health Solution (formerly AHFMR) Health Scholar Award (5 yr award)*

- Based on grant entitled “Determining the effectiveness and cost-effectiveness of chronic disease management programs for patients with diabetes”
- Alberta Innovates – Health Solutions
- \$100,000 per year plus fringe benefits Salary Award

*Cochrane Distinguished Achievement Award (2003)*

- Faculty of Medicine, University of Calgary
- Awarded to one researcher in the Faculty of Medicine for Excellence in Research, 2003 Academic Year

*CIHR New Investigator Award (2003-2008)*

- Based on grant entitled “Early vs deferred-start dialysis: An Economic Evaluation of a Dialysis Outcomes Quality Initiative (DOQI) Guideline”
- Canadian Institutes of Health Research
- \$50,000 per year plus fringe benefits Salary Award
- Temporary leave granted Jan 1, 2007 – July 1, 2008 during initial tenure as Chair of Canadian Expert Drug Advisory Committee (as such, Salary award extended by to January 1, 2010)

*Research Fellowship Award*

July 1999 – June 2001:

- Jointly funded by *Kidney Foundation of Canada* and *Alberta Heritage Foundation for Medical Research*
- Salary support for two year research program in Health Economics

*“Proud to Support Excellence Kidney Foundation of Canada” Researcher*

September 2000:

- Kidney Foundation of Canada
- featured as a researcher in the 2000 issue of Proud to Support Excellence

*Internal Medicine Residency, University of Calgary*

Sept. 1995: Univ. of Calgary's representative to the Canadian Resident-Fellow Competition in Respiratory Research

- St. Sauveur, Quebec

*Medicine, University of Toronto:*

1993-94: The Chappell Prize in Clinical Medicine

- Awarded to the best student in Clinical Medicine during final year of medical training

1993-94: The Issei Scholarship in Medicine and Surgery

- Awarded for academic excellence in Internal Medicine and Surgery in final year of medical training

1993-94: Medical Society Honour Award

- Awarded for outstanding contribution to the Faculty of Medicine during the undergraduate years

1990-94: William Edward Corlett Memorial Scholarship

- Awarded for high academic standing in premedical training

1990-94: Dr C.S. Wainwright Memorial Scholarship

- Awarded annually for high academic standing

1993: Appointed to Alpha Omega Alpha Honor Medical Society

- Awarded to students performing in the top 25 % of the class academically during years I-III

1993: Medical Athletics Letter

1992: Summer Scholarship from Univ. of Toronto, Faculty of Medicine

*Biochemistry, University of Saskatchewan:*

1986-90: Undergraduate Honours Scholarship

1988: Dorothy Kline Memorial Award

- Awarded for excellence in Biochemistry

1988: Department of Chemistry Book Prize

- Awarded for excellence in Organic Chemistry

**IV. Academic Appointments**

- Interim Vice President (June 2022 – June 11, 2023)  
Provincial Clinical Excellence, Alberta Health Services
- Interim Vice President (July 2021-Sept 2021)  
Physician lead, Provincial Clinical Operations, Alberta Health Services
- Associate Chief Medical Officer (2018-June 11, 2023)  
Alberta Health Services, Strategic Clinical Networks
- Professor (2012 – Present)  
Department of Medicine (Nephrology) and Community Health Sciences  
University of Calgary

- Sware Professorship in Health Economics (April 2014-March, 2024)  
Faculty of Medicine  
University of Calgary
- Scientific Director (2014 – 2017)  
Alberta Health Services Kidney - Strategic Clinical Network
- Past-President (2016-2018)  
Canadian Society of Nephrology
- President (2014-2016)  
Canadian Society of Nephrology

Other affiliations:

- Alberta Innovates – Health Solutions Health Scholar
- Associate Editor, cJASN (2011-2013)

## **V. Educational Activities:**

Post-graduate courses:

*MDSC 643.01: Biostatistics I*

- This course focused on classical statistical methods for the analysis of data in community health
- The Department of Community Sciences, Univ. of Calgary

*MDSC 643.02: Biostatistics II*

- This course focused on model-based statistical methods for the analysis of data in community health.
- The Department of Community Sciences, Univ. of Calgary

Other courses:

*The Evidence for Evidence: Getting value for money in health care*

- The Institute of Health Economics in Edmonton, Alberta (April, 1999)

*An Education Program for Clinicians in the Techniques of Economic Evaluation of Health Care Interventions*

- The Institute of Pharmaco-Economics in Edmonton, Alberta (Jan, 1998)

*Clinical trials course, level I and II* - a week long course on clinical trial methodology during which each student developed a randomized clinical trial

- The Department of Community Sciences, Univ. of Calgary

## **Teaching Experience Courses:**

2021: Health Economics Learning Series: Collecting, measuring, and estimating costs of a health care innovation in Alberta - offered to AHS, SCNs, University researchers and students

Led by me

Co-offered (with much thanks) along with Dr Amity Quinn, and Dr Jenine Leal

2015: Health Economics course offered to 45 senior members of Alberta Health Services Strategic Clinical Network

Co-led by Dr Fiona Clement and myself

**Overview:** *This course was offered over 6 months, with six full-day sessions consisting of interactive lectures and labs. Attendees from Strategic Clinical Networks worked with Health Economics mentors and Research Facilitation team to select a project of high relevance to each SCN to bring forward for analysis. During the first part of the course, the attendees, in collaboration with SCN leadership and the Health Economics mentor, identified the intervention most likely to achieve the aims of the project based on feasibility, strength of clinical and cost-effectiveness evidence and suitability for implementation. During the second part of the course, attendees worked with the Health Economics mentor and the Research Facilitation team to determine the data and possible sources required to demonstrate project success and value for money for the interventions or strategies which will move on to implementation.*

### Objectives

Introduce the key concepts of economic evaluation, including how it can serve as a useful tool in prioritizing interventions or strategies for implementation in the health system;

Determine how to select the intervention given the goals of the project

introduce the skills necessary to perform an economic evaluation, using decision analysis, of a high priority SCN project;

Review useful guidance and guidelines needed to conduct an economic evaluation;

Describe the key data sources available in Alberta that can inform an economic evaluation and can be used to assess value for money; and

Determine what data should be collected or utilized to assess the impact of an intervention or strategy implemented in the health system

2003-2016: Course coordinator for MDCH 663, a graduate course in “Decision Analysis in Health Care Economic Evaluation”

- Community Health Sciences graduate level course
- Half-term course

Jan – June 2002: Course co-coordinator and teacher of MDSC 755.35, a Readings Course on “Economic evaluation in health care”, along with Dr. C. Donaldson

- Community Health Sciences MSc level course
- Half-term course

- 2001 – 2018 Preceptor for Renal course, 1st year medical students
- University of Calgary medical school
  - approximately 20 hours contact time per year
- 2001-2016 Preceptor for final year medical student clinical skills teaching
- University of Calgary medical school
  - Approximately 40 hours contact time per year
- 1996–1999: Preceptor for 1<sup>st</sup> and 2<sup>nd</sup> year medical students' *Clinical Skills* courses
- University of Calgary medical school
  - Approximately 30 hours contact time per year
- 1997-1999: Preceptor for 2<sup>nd</sup> year medical students' Nephrology Clinical Correlates courses and small group tutorials
- University of Calgary medical school
  - Approximately 10 hours contact time per year

### **Graduate Students Supervised:**

Mischa Kowall (Supervisor)

- 2001-2002, MSc, Department of Economics, University of Calgary
- An economic evaluation of continuous renal replacement therapy and intermittent hemodialysis for the treatment of acute renal failure

Helen Lee (Supervisor)

- 2001-2002, MEd, Department of Economics, University of Calgary
- *An economic evaluation of activated protein C in severe sepsis*

Dr. Caren Wu (Supervisor)

- 2002-2005, MSc, Department of Community Health Sciences, University of Calgary
- *Cost effectiveness of Accelerated Management of Transient Ischemic Attack Compared to Standard care*

Dr. Carmen Brauer (Supervisor)

- 2002-2003, MSc, Department of Health Economics, York University, England
- *An economic evaluation of operative versus non-operative treatment of displaced intra-articular calcaneal fractures*

Dr. Brendan Murphy (Supervisor)

- 2002-2003, MSc, Dept. of Community Health Sciences, Univ. of Calgary
- *Identification of the important determinants of successful development of native arteriovenous fistulae in a prospective cohort of incident ESRD patients*



Fiona Shrive (Co-Supervisor)

- 2002-2006, PhD, Department of Community Health Sciences, University of Calgary
- *An economic evaluation of drug-eluting stents in the management of patients with coronary artery disease*

Song Gao (Co-Supervisor)

- 2003-2005, MSc, Department of Community Health Sciences, University of Calgary
- Chronic Kidney Disease Among First Nations people in Southern Alberta: Access and Barriers to Appropriate Care

Mike Walsh (Supervisor)

- 2006-2009, MSc, Department of Community Health Sciences, University of Calgary
- Investigating the validity of surrogate endpoints used in clinical trials of renal vasculitis
- Funded AI-HS / Kidney Foundation of Canada

Luc Berthiame (Co-Supervisor)

- 2005-2009, MSc, Department of Community Health Sciences, University of Calgary
- The cost effectiveness of tight glycemic control in the general intensive care unit

Steve Heitman (Co-Supervisor)

- 2007-2011, MSc, Health Economics, York University
- The impact of including indirect costs on the cost effectiveness of screening for colorectal cancer
- Funded AI-HS / CAGS / CIHR

Fiona Shrive (Supervisor)

- 2006-2007, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The cost effectiveness and economic implications of increasing coronary catheterization rates
- Funded AI-HS / CIHR

Wenjie Wang (Supervisor)

- 2006-2007, Post Doctoral Fellow, Department of Medicine, University of Calgary
- The impact of increasing dialysis adequacy on quality of life

Lauren Bresie (Co-Supervisor)

- 2010-12, Post Doctoral Fellow, Dept of Comm Health Sciences, U of C
- The impact of safety warnings on prescribing of oral hypoglycemic agents in diabetes
- Funded CIHR

Kerry McBrien (Supervisor)

- 2010-13, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The cost effectiveness of intensive blood pressure lowering in diabetes
- Funded AI-HS

Janelle Seah (Supervisor)

- 2010, Master's Health Econ, York University
- The cost and cost effectiveness of chronic disease management programs in diabetes

Erika Penz (Supervisor)

- 2011-2013, MSc, Health Economics, York University
- The cost-effectiveness of pleural catheters in patients with malignant pleural effusion
- Funded AI-HS

Lianne Barnieh (Supervisor)

- 2010-13, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- The cost effectiveness incentives to increase the use of living related kidney transplantation
- Funded AI-HS

Bikaramjit Mann (Supervisor)

- 2011-15, Medical Resident, University of Calgary Internal Medicine Program  
Department of Community Health Sciences, University of Calgary
- The impact of cost-sharing on patients outcome in chronic disease

David Campbell (Supervisor)

- 2012-2016, Graduate Student (PhD), Department of Community Health Sciences, University of Calgary
- The impact of financial barriers on care and outcomes for patients with chronic disease
- Funded AI-HS

Jenine Leal (Co-Supervisor)

- 2014-2019, Graduate Student (PhD), Department of Community Health Sciences, University of Calgary
- The cost-effectiveness of strategies to reduce clostridium difficile

- Funded Eyes High Program

Erik Venos (Supervisor)

- 2014-2016, Graduate Student (Master's), Department of Community Health Sciences, University of Calgary
- The cost and clinical implications of the Diabetic Foot Ulcers in diabetes

Karen Tang (Supervisor)

- 2012-2014, Postdoctoral student, Department of Community Health Sciences, University of Calgary
- Cost related barriers to care in chronic disease

Elissa Rennert-May (Co-Supervisor)

- 2016-2019, Graduate Student, Department of Community Health Sciences, University of Calgary
- The cost effectiveness of an antibiotic bundle to prevent joint infection

Aaron Trachtenberg (Supervisor)

- 2016-2022, Medical Resident, University of Manitoba Internal Medicine Program and now Clinician Investigator Program
- Cost Analysis of Medical Assistance in Dying / The association between change in physician remuneration and use of peritoneal dialysis

Derek Chew (Informal Supervisor/Mentor)

- 2016-2020
- Cardiac Electrophysiology Fellow, Department of Cardiac Sciences, University of Calgary
- Economic evaluation of left ventricular assist devices in patients with end stage heart failure
- Arthur JE Child Fellowship

Amity Quinn (Supervisor)

- 2017-2022, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- Awarded Banting Postdoctoral Fellowship (2018)
- Association of specialist physician payment and health care utilization, quality, and costs for people with chronic diseases
- Funded by Institute for Health Economics and CIHR

Barb Sporinova (Supervisor)

- 2017-2019, Internal Medicine Resident, Department of Medicine, Cumming School of Medicine, University of Calgary
- Health care utilization and costs among those with and without co-occurring mental health disorders and chronic diseases: a retrospective cohort study

Yewande Ogundeji (Supervisor)

- 2019-present, Post Doctoral Fellow, Department of Community Health Sciences, University of Calgary
- Awarded Network of Alberta Health Economics (NOAHE) Fellowship (2019)
- Factors that influence specialist physicians' choice of payment model and the association with quality of care
- Funded by Institute for Health Economics

Siavash Zarezadeh (Supervisor)

- 2021-2023
- Med 440 student, and Understudent research project
- The use of low value cardiac testing in the context of low-risk surgeries

Jane Fletcher (Supervisor)

- 2022-2025, PhD student
- Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary: Detailed analysis on medication adherence and a Policy Analysis

## VI. Administrative Responsibilities

### i. Departmental

**Svare Chair in Health Economics UofC (2014-2024)** – in this role, I serve as the Head of the Health Economics Group within O'Brien Institute of Public Health

**Member:** Search and Selection Committee – Deputy lead, O'Brien Institute of Public Health (2022)

**Member:** Search and Selection Committee – Head, Community Health Sciences (2013-14)

**Member:** Academic Relationship Plan Management Committee (2012-present)

**Member:** Division of Nephrology Research Review Committee (2009 - present)

**Member:** Search and selection committee – Head, Division of General Internal Medicine (2010)

**Member:** graduate student supervisory committees within Community Health Sciences

**Co-Chair:** Department of Medicine; Division of Nephrology Innovation Program (2007-2010)

developing and overseeing the establishment of Nephrology central triage and urgent evaluation clinics

developing and overseeing the establishment of group-based dialysis modality education to increase the use of home-based dialysis (based on the results of our successful randomized trial testing the effectiveness of the group education format).

## ii. Regional Health Authority

Calgary Health Region Pharmacy and Therapeutics committee (2001 to 2004)

## iii. Provincial / National

**Member:** Expert Committee on Drug Evaluation and Therapeutics, an 8-member Committee which makes recommendations to the Alberta Minister of Health as to whether to add new pharmaceutical products to the Alberta Health and Wellness Drug Benefit List based on clinical and cost-effectiveness criteria (Member, January 2002 – 2006 (**Ministerial appointment**))

**Member:** Canadian Expert Drug Advisory Committee (2003-2006), an 11 member Committee that makes recommendations as to whether to add new pharmaceutical products to each of the provincial drug insurance plans based on clinical and cost-effectiveness criteria

**Chair:** Canadian Expert Drug Advisory Committee (2006-2008)

## VII. Professional Activities

### *Associate Editor*

cJASN 2011 - 2014

### *Journal Reviews (no longer tracked)*

Canadian Medical Association Journal	2002 - present
Kidney International	2001 - present
The Canadian Journal of Gastroenterology	2001 – present
Journal of the American Society of Nephrology	2002 – present
American Journal of Kidney Diseases	2002 – present
Nephrology, Dialysis, Transplantation	2002 – present
New England Journal of Medicine	2003 – present
Critical Care Medicine	2003 – present
Pharmacoeconomics	2003 – present
JAMA	2003 – present
Clinical Nephrology	2003 – present
Social Science and Medicine	2007 - present

### *Committees*

- Member Physician Compensation Advisory Committee (2020-2022), Alberta Health
- Co-chair, Scientific Advisory Group (2020-2022)

- Provincial Service Planning Committee (2019-2022)
- Connect Care Contents and Standards Committee (2018-2022)
- Quality Safety & Outcomes Improvement Executive Committee (2018-2023)
- Primary care physician Blended Capitation Evaluation Workgroup (2016-2018)
- Reformulary Drug Expert Committee (2011-2012)
- Canadian Society of Nephrology Scientific Committee (2004-2012)
- Canadian Society of Nephrology Mineral Metabolism Guidelines Committee (2010)
- Canadian Society of Nephrology Anemia Guidelines Committee (2008)
- Canadian Expert Drug Advisory Committee (2003-2008) (Chair 2006-2008)
- Expert Committee on Drug Evaluation and Therapeutics (2002-2006)
- Sub-Committee for the Review of Benefit Status of Products and Categories on the Alberta Health and Wellness Drug Benefit List (2002-2004)
- Pharmacy and Therapeutics committee (2001-2005)
- Scientific Committee, Division of Nephrology Research Group (2001)

#### **Grant Review Committees:**

1. **Member and Scientific Officer**, CIHR Health policy grant  
- Fall 2022
2. **Scientific Officer**, CIHR Health policy grant  
- Fall 2021
3. **Member** and Internal Reviewer for CIHR Committee: “Team Planning and Development Grants – Developing New Research Teams to Enhance Quality of life”
  - January, 2004
4. **Member** and Internal Reviewer for the KRESCENT program
  - March 2005- 2007
5. CIHR Salary Award **Member** and Internal Reviewer
  - 2009 - 2013

6. **Member**, AI-HS Clinical Fellowship Award Review Committee
  - 2011
7. **Chair**, AI-HS Clinical Fellowship Award Review Committee
  - 2012 - 2015

### VIII. Research Support:

#### A) As principal investigator or co-principal investigator:

- 1) *Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in Patients with End-Stage Renal Disease and Hyperhomocysteinemia, Anticardiolipin Antibody Status and the Risk for Vascular Access Thrombosis in Patients with ESRD on Hemodialysis.*

Proposal author: BJ Manns\*  
 Principal investigator: NW Scott-Douglas\*  
 Co-investigators: ED Burgess, HG Parsons, JP Schaefer, ME Hyndman,  
 Funding: \$12,000.00  
 Funding Sources:
 

- Endowment Awards, Faculty of Medicine, Univ. of Calgary  
\$11,000.00
- Centre for the Advancement of Health, Calgary  
\$1000.00

Years: 1996-1999

- 2) *The effects of vitamin B12, folic acid, and serine supplementation on homocysteine levels in patients with end-stage renal failure on dialysis.*

Proposal author: BJ Manns\*  
 Principal investigator: NW Scott-Douglas\*  
 Co-investigators: E. Burgess, HG Parsons, JP Schaefer, ME Hyndman, F Snyder, P Bridge  
 Funding: \$60,000.00  
 Funding Sources:
 

- Kidney Foundation of Canada  
\$40,000.00
- Special Funding Competition, Centre for the Advancement of Health  
\$20,000.00

Years: 1998- 2000

- 3) *A Cost-Utility Analysis of Renal Replacement Therapy: Accounting for casemix.*

Proposal author: BJ Manns\*\*  
 Principal investigator: C. Donaldson\*\*  
 Co-investigators: K. Taub, W. Ghali  
 Funding:
 

1999	\$20,000.00
2000	\$45,660.30
2001	\$45,660.30

## Funding Sources:

1999 Centre for the Advancement of Health, Calgary  
 2000 Health Research Fund, Alberta Heritage Foundation for  
 Medical Research  
 2001 Health Research Fund, Alberta Heritage Foundation for  
 Medical Research

Years: 1999-2001

4) ***An Economic Evaluation of Improving Dialysis Adequacy in Large Hemodialysis Patients***

Proposal author: BJ Manns  
 Principal investigator: BJ Manns  
 Co-investigators: K. Taub, J. Johnson, C. Donaldson  
 Funding: 2001 \$46,650.00  
 2002 \$46,650.00  
 Funding Sources: Kidney Foundation of Canada  
 Years: 2001-2003

5) ***Recombinant Human Activated Protein C for Severe Sepsis in the Intensive Care Unit: A clinical decision analysis***

Proposal author: B. Manns  
 Principal Investigator: B. Manns  
 Coinvestigators: C. Doig, C. Donaldson  
 Funding: \$30,883  
 Funding sources: Institute of Health Economics, Alberta  
 Years: 2002

6) ***Early vs deferred-start dialysis: An Economic Evaluation of a Dialysis Outcomes Quality Initiative (DOQI) Guideline***

Proposal author: B. Manns  
 Principal Investigator: B. Manns  
 Coinvestigators: K. Taub, W. Ghali, J. Johnson  
 Funding: Salary support award; \$50,000 per year plus fringe benefits  
 Funding sources: **CIHR New Investigator Salary Award**  
 Years: 2003-2008

7) ***Cost effectiveness of Accelerated Management of Transient Ischemic Attack Compared to Standard care***

Proposal author: C. Wu  
 Principal Investigator: B. Manns  
 Coinvestigators: A. Buchan, C. Donaldson  
 Funding: 2003 \$24,900  
 Funding sources: Calgary Health Region Annual R&D Funding Competition  
 Years: 2003-2004

8) ***Analysis of the Determinants of Incident Year Costs in End-Stage Renal Disease***

Proposal author: S. Klarenbach and B. Manns



Principal Investigator: B. Manns  
 Coinvestigators: P. Jacobs, M. Tonelli  
 Funding: 2003 \$23,000  
 Funding sources: Health Research Fund, Alberta Heritage Foundation for Medical  
 Research and Calgary Health Region  
 Years: 2003-2004

**9) Establishment and maintenance of a vascular access in incident hemodialysis patients:**

**A prospective cost analysis**

Proposal author: B. Manns  
 Principal Investigator: B. Manns  
 Coinvestigators: M. Tonelli, S. Yilmaz, B. Murphy, V. Radkevich  
 Funding: 2003 \$4,992  
 Funding sources: Center for Advancement of Health, Calgary Health Region  
 Years: 2003-2004

**10) Eliciting preferences for new interventions: A comparison of decision-makers and the public with regards to priority setting**

Proposal author: B. Manns  
 Principal Investigator: B. Manns  
 Coinvestigators: G. Currie, M. vanderPol  
 Funding: 2003 \$9,950  
 Funding sources: Institute of Health Economics, Alberta  
 Years: 2003-2004

**11) Eliciting the public's preferences for priority setting for new pharmaceuticals**

Proposal author: B. Manns  
 Principal Investigator: B. Manns, G. Currie, M. van der Pol  
 Co-investigators: M. Ryan  
 Funding: \$30,249  
 Funding sources: Institute of Health Economics, Alberta  
 Years: 2004-2005

**12) *Optimizing Prevention of Vascular Disease in Alberta: A program of health outcomes research***

Principal Investigator: F. McAlister  
 Co-Principal Investigators: B. Manns, J. Johnson, R. Tsuyuki, S. Majumdar  
 Funding: \$870,000  
 Funding source: Programs of Health Research Competition  
 Alberta Heritage Foundation for Medical Research  
 Years: 2004-2007

**13) *Nocturnal Hemodialysis Versus Conventional Three Times Per Week Hemodialysis: A Randomized Clinical Trial***

Principal Investigator: B. Manns, B. Culleton  
 Co-investigators: M. Tonelli, S. Klarenbach

- |                 |                             |
|-----------------|-----------------------------|
| Funding;        | \$100,000                   |
| Funding source: | Kidney Foundation of Canada |
| Years:          | 2004-2006                   |
- 14) ***Evaluating the impact of a restricted reimbursement policy for selected antimicrobial agents on utilization of targeted antibiotics, clinical outcomes, and costs***  
Principal Investigator: B. Manns  
Co-investigators: B. Hemmelgarn, K. Laupland, C. Mitchell  
Funding; \$47,000  
Funding source: IHE  
Years: 2005-2007
- 15) ***Drug eluting stents for coronary heart disease: A systematic review and economic evaluation***  
Co-Principal Investigators: B. Manns, W. Ghali  
Co-investigators: M. Knudtson  
Funding \$60,000  
Funding Source APPROACH  
Years 2003-2005
- 16) ***Economic evaluation of capsule endoscopy for obscure gastrointestinal bleeding***  
Co-Principal Investigators: B. Manns, R. Hilsden  
Co-investigators: S. Heitman, R. Pannacione  
Funding; \$100,000  
Funding source: AHFMR Health Research Fund  
Years: 2005-2007
- 17) ***Modeling Chronic Kidney Disease: Optimal Modeling Methods & Implications for Screening Programs for CKD***  
Co-Principal Investigators: B. Manns, S. Klarenbach  
Co-investigators: B. Hemmelgarn, B. Culleton  
Funding; \$100,000  
Funding source: AHFMR  
Years: 2006-2008
- 18) ***Sevelamer for patients with end-stage renal disease: A systematic review and economic evaluation***  
Principal Investigator: B. Manns  
Co-investigators: M. Tonelli, S. Klarenbach, B. Culleton  
Funding \$50,000  
Funding Source Canadian Agency for Drugs and Technologies in Health  
Years 2005-2006
- 19) ***A randomized controlled trial evaluating the effects of long-term, low-dose corticosteroid therapy compared to placebo on renal flare rates in during maintenance therapy for proliferative lupus nephritis: a pilot study***

- |                         |   |
|-------------------------|---|
| Principal Investigator: | B. Manns  |
| Co-investigators:       | B. Hemmelgarn, M. Walsh, PJ Devereaux, D. Jayne |
| Funding                 | \$10,000  |
| Funding Source          | Center for Advancement of Health                |
| Years                   | 2005-2007                                       |
- 20) *The impact of using surrogate endpoints on economic evaluations***
- |                         |           |
|-------------------------|-----------|
| Principal Investigator: | B. Manns  |
| Co-investigators:       | F. Shrive |
| Funding                 | \$70,000  |
| Funding Source          | CADTH     |
| Years                   | 2007-2009 |
- 21) *An economic evaluation of colorectal cancer screening options***
- |                         |  |
|-------------------------|--|
| Principal Investigator: | B. Manns   |
| Co-investigators:       | S. Heitman, R. Hilsden                               |
| Funding                 | \$50,000   |
| Funding Source          | Canadian Agency for Drugs and Technologies in Health |
| Years                   | 2008-2009  |
- 22) *An economic evaluation of Nocturnal Hemodialysis***
- |                         |               |
|-------------------------|---------------|
| Principal Investigator: | B. Manns      |
| Co-investigators:       | S. Klarenbach |
| Funding                 | \$100,000     |
| Funding Source          | CIHR          |
| Years                   | 2008-2010     |
- 23) *A systematic review and economic evaluation of statin use in primary prevention***
- |                             |                              |
|-----------------------------|------------------------------|
| Co-Principal Investigators: | B. Manns and M. Tonelli      |
| Co-investigators:           | B. Hemmelgarn, S. Klarenbach |
| Funding                     | \$110,000                    |
| Funding Source              | CADTH                        |
| Years                       | 2009-2010                    |
- 24) *Improving the Efficient and Equitable Care of Patients with Chronic Medical Conditions Interdisciplinary Chronic Disease Collaboration (ICDC)***
- |                  |                                   |
|------------------|-----------------------------------|
| Co-Team Leaders: | Hemmelgarn, Manns, Tonelli        |
| Funding          | \$5,000,000                       |
| Funding Source   | AHFMR 2008 Team Grant Competition |
| Years            | 2009-2014                         |
- 25) *AHFMR Scholar Salary Award for grant entitled: “Determining the effectiveness and cost-effectiveness of chronic disease management programs for patients with diabetes”***
- |                |                                      |
|----------------|--------------------------------------|
| Funding        | \$700,000                            |
| Funding Source | Alberta Innovates – Health Solutions |

- |       |           |
|-------|-----------|
| Years | 2010-2017 |
|-------|-----------|
- 26) ***Coronary angiography and revascularization for patients with Stage 4 and 5 non-dialysis chronic kidney disease: A decision analysis***  
 Co-Principal Investigators: B. Manns, M. James  
 Co-investigators: Hemmelgarn, Tonelli  
 Funding: \$74,876  
 Funding Source: CIHR  
 Years: 2010-2011
- 27) ***A systematic review of drug use optimization and cost-containment measures adopted within the OECD nations***  
 Co-Principal Investigators: F. Clement (nominated PI), B. Manns  
 Co-investigators: L. Jardine  
 Funding: \$100,000  
 Funding Source: CIHR  
 Years: 2012-2013
- 28) ***The Impact of Reduced ICU Bed Availability Due to the H1N1 Pandemic on the Care and Outcomes of Acutely Unwell Hospitalized Patients***  
 Co-Principal Investigators: B. Manns, T. Stelfox,  
 Co-investigators: C. Doig, B. Hemmelgarn, S. Bagshaw  
 Funding: \$92,600  
 Funding Source: CIHR  
 Years: 2010-2011
- 29) ***The impact of primary care networks on the care and outcomes of patients with diabetes***  
 Co-Principal Investigators: B. Manns, M. Tonelli, B. Hemmelgarn  
 Co-investigators: F. Clement, K. McBrien, P. Sargious, J. Johnson,  
 A. Laupacis  
 Funding: \$256,226  
 Funding Source: CIHR  
 Years: 2011-2013
- 30) ***Assessing the acceptability of financial incentives to kidney donation***  
 Principal Investigator: B. Manns  
 Co-investigators: S. Klarenbach  
 Funding: \$25,000  
 Funding Source: Goldlist Foundation  
 Years: 2011-2013
- 31) ***The Canadian KidNey Knowledge Translation and Generation NETwork (CANN-NET)***  
 Principal Investigator: B. Manns  
 Co-investigators: M. Evans, L. Maccallum, F. Madore, M. Tonelli, R. Wald,  
 B. Hemmelgarn, M. Walsh, M. Zappitelli  
 Funding: \$720,000

- |                |   |
|----------------|---|
| Funding Source | CIHR - Network Catalyst - Diabetes, Obesity, Digestive and Kidney |
| Years          | 2011-2014   |
- 32) *Translating evidence to improvements in care and outcomes for people with diabetes***
- |                         |   |
|-------------------------|---|
| Principal Investigator: | B. Manns  |
| Co-investigators:       | A. Edwards, P. Sargious, G. Allan, T. Braun, J. Grimshaw, B. Hemmelgarn, N. Ivers, J. Johnson, S. Long, S Straus, K. McBrien, C. Naugler, M. Tonelli, A Tricco, C Yu. |
| Funding                 | \$24,995  |
| Funding Source          | CIHR – Planning Grant   |
| Years                   | 2012-2013   |
- 33) *Patient navigators and living kidney donor transplantation***
- |                         |                     |
|-------------------------|---------------------|
| Principal Investigator: | B. Manns            |
| Co-investigators:       | S. Klarenbach       |
| Funding                 | \$15,000            |
| Funding Source          | Goldlist Foundation |
| Years                   | 2013-2014           |
- 34) *The Interdisciplinary Chronic Disease Collaboration (ICDC) Team***
- |                  |                                      |
|------------------|--------------------------------------|
| Co-Team Leaders: | Hemmelgarn, Manns, Tonelli           |
| Funding          | \$5,000,000                          |
| Funding Source   | AHFMR 2013/14 Team Grant Competition |
| Years            | 2014-2019                            |
- 35) *Screening for Chronic Kidney Disease – the SEEKD study***
- |                |                             |
|----------------|-----------------------------|
| Co-PIs:        | Manns, Hemmelgarn           |
| Funding        | \$90,000                    |
| Funding Source | Kidney Foundation of Canada |
| Years          | 2014-2015                   |
- 36) *The Access Study***
- |                         |                |
|-------------------------|----------------|
| Principal Investigator: | Manns          |
| Funding                 | \$1,450,000    |
| Funding Source          | Alberta Health |
| Years                   | 2014-2017      |
- 37) *Canadian Innovative Methods involving Patients and Researchers in Outcome Improvements for Chronic Kidney Disease (Can-IMPROVE CKD): a strategic planning meeting***
- |                         |          |
|-------------------------|----------|
| Principal Investigator: | Manns    |
| Funding                 | \$20,000 |
| Funding Source          | CIHR     |
| Years                   | 2015     |

- 38) ***Listening, Learning and Leading: Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD)***  
 Co-Principal Investigator: Levin, Manns  
 Funding \$50,000  
 Funding Source CIHR SPOR letter of intent  
 Years 2015
- 39) ***Assessing outcomes of enhanced Chronic disease Care through patient Education and a value-based formulary Study (ACCESS)***  
 Principal Investigator: Manns  
 Funding \$300,000  
 Funding Source Univ of Calgary Major Grants Clinical Research Fund  
 Years 2016-2018
- 40) ***Listening, Learning and Leading: Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD)***  
 Co-Principal Investigators: Levin, Manns  
 Funding \$25,000,000  
 Funding Source CIHR SPOR Network Team competition  
 Years 2016-2021
- 41) ***Informing health care policy makers on health care financing and sustainability***  
 Principal Investigator: Manns  
 Funding \$2,076,290  
 Funding Source CIHR Foundation Grant  
 Years 2016-2026
- 42) ***Comparing cost sharing models for publicly funded formularies***  
 Principal Investigators Manns, Clement  
 Funding \$134,200  
 Funding Source Alberta Health  
 Years 2016-2017
- 43) ***Factors that influence specialist physician's payment model preferences and the association with practice patterns and quality of care***  
 Principal Investigator: B. Manns  
 Funding: \$10,000 (2 years)  
 Funding Source: Clinical Research Fund (CRF) Grant  
 Years: 2020-2022
- 40) ***Listening, Learning and Leading: Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD)***  
 Co-Principal Investigators: Levin, Manns, Scholey  
 Funding \$11,800,000  
 Years 2022-2026

**B) As co-investigator:****1) *Impact of multiple organ dysfunction syndrome in the intensive care unit on quality of life and costs***

Proposal author: C. Doig  
 Principal Investigator: C. Doig  
 Coinvestigators: B. Manns, D. Sandham, C. Eagle, G. Fick, C. Donaldson, W. Ghali, L. Sutherland.  
 Funding: 2001 \$50,000  
 2002 \$50,000  
 Funding sources: Health Research Fund, Alberta Heritage Foundation for Medical Research  
 Years: 2001-2003

**2) *The effect of continuous positive airway pressure on health resource utilization among patients with obstructive sleep apnea: A multi-dimensional analysis***

Proposal author: S. Heitman  
 Principal Investigator: W. Tsai  
 Coinvestigators: B. Manns, W. Flemons, W. Ghali  
 Funding: 2002 \$50,000  
 2003 \$50,000  
 Funding sources: Health Research Fund, Alberta Heritage Foundation for Medical Research and Calgary Health Region  
 Years: 2001-2003

**3) *A Computerized Chronic Kidney Disease Network: A Database for Accessing Care and Determining Progression***

Proposal author: K. Taub, B. Manns, B. Culleton and B. Hemmelgarn  
 Principal Investigator: K. Taub  
 Coinvestigators: B. Manns, B. Culleton, B. Hemmelgarn, K. McLaughlin  
 Funding: 2003-2006 \$480,000 total  
 Funding sources: Amgen Canada  
 Years: 2003-2006

**4) *Progression of CKD in the Elderly***

Principal Investigator: B. Hemmelgarn  
 Co- Investigators: B. Manns, B. Culleton, M. Tonelli, K. Taub  
 Funding: \$100,000  
 Funding source: Health Research Fund  
 Alberta Heritage Foundation for Medical Research  
 Years: 2004-2006

**5) *Societal costs of colorectal cancer screening in Alberta***

Principal Investigator: R. Hilsden  
 Co-investigators: B. Manns, S. Heitman, C. Mitchell

- |                 |                            |
|-----------------|----------------------------|
| Funding;        | \$129,755                  |
| Funding source: | AHFMR Health Research Fund |
| Years:          | 2005-2007                  |
- 6) ***Progression and management of chronic kidney disease among First Nations People***  
Principal Investigator: B. Hemmelgarn  
Co-investigators: B. Manns, M. Tonelli, S. Ahmed, W. Ghali  
Funding \$184,000  
Funding Source CIHR  
Years 2008-2010
- 7) ***A systematic review and economic evaluation of continuous renal replacement therapy in patients with acute renal failure***  
Principal Investigator: M. Tonelli  
Co-investigators: B. Manns, R. Padwal, S. Klarenbach  
Funding \$96,025  
Funding Source Canadian Agencies for Drugs and Technologies in Health  
Years 2006
- 8) ***Hematopoietic hormones in the treatment of anemia related to cancer***  
Principal Investigator: M. Tonelli  
Co-investigators: B. Manns, S. Klarenbach  
Funding \$115,282  
Funding Source Canadian Agencies for Drugs and Technologies in Health  
Years 2007
- 9) ***A systematic review and economic evaluation of hematopoietic therapies in patients with chronic renal failure***  
Principal Investigator: M. Tonelli  
Co-investigators: B. Manns, S. Klarenbach  
Funding \$119,525  
Funding Source Canadian Agencies for Drugs and Technologies in Health  
Years 2007
- 10) ***Bariatric surgery for severe obesity***  
Principal Investigator: M. Tonelli  
Co-investigators: B. Manns, R. Padwal, S. Klarenbach  
Funding \$140,760  
Funding Source Canadian Agencies for Drugs and Technologies in Health  
Years 2009
- 11) ***Access to Kidney Transplantation in British Columbia and Alberta***  
Principal investigator: J. Gill  
Co-Investigators: M. Tonelli, S. Gourishankar, B. Manns, K. McLaughlin.  
Funding: 129,000  
Funding sources: CIHR



- Years: 2005-2010
- 12) ***Trace element status in chronic hemodialysis patients***  
 Principal investigator: M. Tonelli  
 Co-Investigators: B. Culleton, S. Klarenbach, B. Hemmelgarn, B. Manns, K. Jindal, C. Field, G. Cembrowski, D. Holmes, N. Wiebe, K. Oseen, J. Gill  
 Funding: \$992,811  
 Funding sources: CIHR  
 Years: 2007-2012
- 13) ***Validation of a coding algorithm to define chronic kidney disease using admin data***  
 Principal investigator: B Hemmelgarn  
 Co-Investigators: H Quan, B Manns, M Tonelli  
 Funding: \$96,725/year x 1 years  
 Funding sources: Public Health Agency of Canada  
 Years: 2008 - 2009
- 14) ***Progression and management of chronic kidney disease among First Nations People***  
 Principal investigator: B Hemmelgarn  
 Co-Investigators: S Ahmed, L Crowshoe, P Faris, W Ghali, B Manns, M Tonelli  
 Funding: \$79,421/year x 2 years  
 Funding sources: CIHR  
 Years: 2008 - 2010
- 15) ***A cost-effectiveness study of exercise-based Cardiac Rehabilitation***  
 Principal Investigators: F. Clement  
 Co-investigator: B. Manns, W. Ghali, T. Hauer, J. Stone, S. Aggarwal, M. Knudtson, C. Norris  
 Funding: \$100,000  
 Funding Source: M.S.I Foundation  
 Years: 2011-2013
- 16) ***A Systematic Review of Drug Use Optimization and Cost-Containment Measures Adopted Within the OECD Nations***  
 Principal Investigators: F. Clement  
 Co-investigators: B. Manns  
 Funding: \$18,000  
 Funding Source: University of Calgary Grant Committee Seed Grant  
 Years: 2011-2012
- 17) ***Improving risk prediction in older adults using eGFR and proteinuria***  
 Principal Investigator: B Hemmelgarn  
 Team members: F Clement, M James, B Manns, R Quinn, P Ravani, M Tonelli

- Funding: \$166,448 over 2 years (\$83,224 per year)  
 Funding sources: CIHR  
 Years: 2011 – 2013
- 18) *Complications of arteriovenous fistulas, arteriovenous grafts and tunneled cuffed catheters for hemodialysis: Risk patterns, comparability and impact on patient outcomes***  
 Principal Investigator: P Ravani  
 Team members: B Hemmelgarn, M James, B Manns, R Quinn, P Ravani, M Tonelli  
 Funding: \$130,000 over 2 years (\$65,000 per year)  
 Funding sources: CIHR  
 Years: 2011 – 2013
- 19) *The BK: KIDNI Trial (BK:Kinase inhibition to decrease nephropathy intervention trial)***  
 Co-Principal Investigators: LA Tibbles, B Hemmelgarn  
 Team members: P Ravani, B Manns,  
 Funding: \$3,319,686 over 4 years  
 Funding sources: CIHR  
 Years: 2009 - 2013
- 20) *Access to and quality of cardiac care for First Nations***  
 Principal investigator: B Hemmelgarn  
 Co-Investigators: S Ahmed, W Ghali, M Knudtson, M Tonelli, B Manns, P Faris, H Quan.  
 Funding: \$215,875 over 3 years  
 Funding sources: CIHR  
 Years: 2009 – 2012
- 21) *Role of residence location in the care of elderly Canadians with kidney failure***  
 Principal investigator: M Tonelli  
 Co-Investigators: S Davison, J Gill, B Hemmelgarn, S Klarenbach, B Manns, N Pannu, N Wiebe, K Yeates  
 Funding: \$130,476/year x 5 years  
 Funding sources: CIHR  
 Years: 2008 - 2013
- 22) *Influence of deficiency and excess of trace elements on outcomes in HD patients***  
 Principal investigator: M Tonelli  
 Co-Investigators: B Hemmelgarn, G Cembrowski, B Culleton, C Field, J Gill, K Jindal, S Klarenbach, B Manns, N Wiebe  
 Funding: \$996,000  
 Funding sources: CIHR  
 Years: 2007 - 2012

- 23) ***Chronic kidney disease among First Nations people in Alberta: Prevalence, progression and access to care***  
 Principal investigator: B Hemmelgarn  
 Co-Investigators: B Manns, B Culleton, M Tonelli, L Crowshoe, L Svenson, WA Ghali, S Bertazzon,  
 Funding: \$210,000  
 Funding sources: CIHR  
 Years: 2005 - 2008
- 24) ***The role of place and relocation in the care of Canadians with end-stage renal disease***  
 Principal investigator: M Tonelli  
 Co-Investigators: B Manns, B Culleton, B Hemmelgarn, J Gill,  
 Funding: \$180,000  
 Funding sources: CIHR  
 Years: 2005 – 2008
- 25) ***Chronic kidney disease among the elderly in Alberta: Prevalence and access to care***  
 Principal investigator: B Hemmelgarn  
 Co-investigators: B Manns, B Culleton, M Tonelli, S Bertazzon  
 K Taub, M Visser  
 Funding: \$98,572  
 Funding sources: AHFMR  
 Years: 2004 – 2006
- 26) ***Risk of adverse effects among elderly statin users***  
 Principal Investigator: M. Tonelli  
 Co-investigators: B. Manns, B. Hemmelgarn, P. Muntner  
 Funding \$100,000  
 Funding Source CIHR  
 Years 2012-2015
- 27) ***Seeing the forests and the trees - Innovative approaches to exploring heterogeneity in systematic reviews of complex knowledge translation interventions to enhance policy decision making***  
 Principal Investigator: J. Grimshaw  
 Co-investigators: B. Manns, A. Edwards, N. Ivers, J. Lavis, D. Moher, A. Paprica, T. Ramsay, P. Sargious, K. Shojania, S. Straus, M Tonelli, A Tricco, C, Yu.  
 Funding \$600,000  
 Funding Source CIHR  
 Years 2012-2015
- 28) ***Implementation and evaluation of a clinical pathway for chronic kidney disease in primary care***  
 Principal Investigator: B. Hemmelgarn  
 Co-investigators: T. Braun, T. Noseworthy, B. Manns, M. Tonelli, K. Jindal,

- M. Jun, K. King-Shier, A. Levin, R. Lewanczuk, C. Naugler, P. Sargious, N. Scott-Douglas, S. Straus  
 Funding: 674,412 total (3 years)  
 Funding Source: CIHR  
 Years: 2013 – 2016
- 29) ***Epidemiology, costs and consequences of multimorbidity***  
 Principal Investigator: M. Tonelli  
 Co-investigators: B. Manns, T. Braun, M. Fortin, B. Hemmelgarn, M. James, S. Klarenbach, R. Lewanczuk, H. Quan, N Wiebe.  
 Funding: 663,000 total (3 years)  
 Funding Source: CIHR  
 Years: 2014 – 2017
- 30) ***STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial***  
 Principal Investigator: S. Bagshaw  
 Co-investigators: N. Adhikari, R. Bellomo, D. Dreyfuss, S. Gaudry, M. Gallagher, A. Higgins, E. Hoste, M. Joannidis, F. Lamontagne, K. Liu, B. Manns, S. McGuinness, T. Nguyen, A. Nichol, M. Ostermann, P. Palevsky, O. Smith, K. Thorpe, S. Vaara, M. Weir  
 Funding: 1,556,776 (4 years)  
 Funding Source: CIHR  
 Years: 2017-2021
- 31) ***C. difficile near patient testing versus centralized laboratory testing: a cluster randomized trial***  
 Principal Investigator: D. Pillai  
 Co-investigators: J. Kim, B. Manns, E. Spackman  
 Funding: 328,950 (3 years)  
 Funding Source: CIHR  
 Years: 2017-2020
- 32) ***ENCOMPASS: ENhancing COMMunity health through Patient navigation, Advocacy and Social Support***  
 Principal Investigator: K. McBrien  
 Co-investigators: C. Chen, A. Erfan, N. Gleeson, Z. Rafiq, G. Fabreau, B. Manns  
 Funding: \$1,500,000 (4 years)  
 Funding Source: CIHR  
 Years: 2018-2022
- 33) ***Can Symptom monitoring With Feedback to clinicians improve the lives of people on dialysis? (SWIFT)***

- Principal Investigator: R. Morton  
 Co-investigators: A.Tong, A. Tran, B. Manns, C. Hawley, D. Harris, D. Johnson, E. Coiera
- Funding: \$1,732,011 (5 years)  
 Funding Source: NHMRC  
 Years: 2018-2023
- 34) *Co-designing a Patient and Family Caregiver-Oriented Transitions in Care Bundle***  
 Principal Investigator: K. Fiest  
 Co-investigators: CE. Farrier, NK. Foster, S. Kupsch, D. Niven, PR. Oxland, JJ. Parsons Leigh, BG. Sept, HT. Stelfox, SE. Straus, SE. A Amaral, S. Au, S. Bagshaw, I. Ball, C. Bell, K. Benzies, R. Bourne, K. Burns, F. Clement, J. Davidson, P. Dodek, C. Doig, EW. Ely, A. Forster, R. Fowler, A. Fox-Robichaud, N. Fraser, C. Grant, J. Holroyd-Leduc, S. Kashuba, J. King, K. Kyeremanteng, V. Lau, B. Manns, K. McBrien, J. Muscedere, E. Papatathanasoglou, D. Piskulic, J. Rasiah, O. Rewa, N. Roumeliotis, A. Roze des Ordon, K. Sauro, S Sinnadurai, A Soo, M Taljaard, A Turgeon
- Funding: \$1,107,400 (4 years)  
 Funding Source: CIHR  
 Years: 2019-2023
- 35) *Innovative Clinical Trials Program - Interdisciplinary Chronic Disease Collaboration***  
 Principal Investigator: M. James, B. Manns, D. Campbell, B. Hemmelgarn, N. Pannu, W. Pearson, C. Tonelli  
 Co-investigators: A. Bello, S. Butalia, M. Elliott, P. Faris, M. Graham, K. Helmle, M. Hill, S. Klarenbach, E. Lang, J. Lee, K. McBrien, E. Minty, C. Norris, M. Parilla Lopez, H. Quan, R. Quinn, P. Ravani, P. Ronksley, T. Sajobi, P. Sargious, N. Scott-Douglas, R. Tsuyuki, S. Wilton
- Funding: \$750,000 (4 years)  
 Funding Source: CIHR  
 Years: 2019-2023
- 36) *Promoting the patient voice: understanding the implementation of patient-reported outcome measures in hemodialysis care***  
 Principal Investigator: M. Elliott  
 Co-investigators: Kara Schick-Makaroff, Braden Manns, Maoliosa Donald, Maria Santana, Juli Finlay
- Funding: \$120,000 (2 years)  
 Funding Source: KFOC  
 Years: 2020-2022

37) ***High needs, high cost patients: A precision public health approach to improve lives and system sustainability***

Principal Investigator: P. Ronksley  
 Co-investigators: B. Manns, R. Beall, D. Campbell, W. Ghali, B. Hemmelgarn, M. Tonelli  
 Funding: \$218,025 (3 years)  
 Funding Source: CIHR  
 Years: 2020-2023

38) ***Characterizing emergency department utilization and perceived avoidability among patients with end-stage kidney disease***

Principal Investigator: M. Elliott  
 Co-investigators: Paul Ronksley, Brenda Hemmelgarn, Maoliosa Donald, Eddy Lang, Andrew McRae, Jennifer MacRae, Braden Manns, Nairne Scott-Douglas, Nancy Verdin  
 Funding: \$98,161 (2 years)  
 Funding Source: MSI Foundation Grant  
 Years: 2020-2022

39) ***Use of Administrative Health Data to Assess the Feasibility of a Surveillance System for Cardiac Implantable Electronic Device Infections: An Alberta Pilot***

Principal Investigator: Dr. Elissa Rennert-May, Dr. Derek Chew, Dr. Jenine Leal  
 Co- Investigatiors: Dr. John Conly, Dr. Derek Exner, Dr. Braden Manns, Dr. Khara Sauro, Dr. Stephanie Smith, Dr. Tyler Williamson  
 Funding: \$ 107,625  
 Funding Source: Canadian Institutes of Health Research  
 Years: 2023-2024

40) ***Addressing cost-related nonadherence of prescription medications through evidence-informed cost-sharing policies in public drug plans to advance health equity in Canada***

Principal Investigator: Campbell DJT  
 Co- Investigators: Dr. Braden Manns, Dr Amity Quinn, and others  
 Funding: \$ 149,804  
 Funding Source: Canadian Institutes of Health Research  
 Years: 2023-2024

**IX. Invited Addresses:**

June 2023 Learning Health systems  
 AbSPORU Learning Health systems conference

Calgary, AB

- March 2023 Eliminating medication copayments for low-income older adults at high cardiovascular risk: A randomized controlled trial  
Late Breaking Clinical Trials, American College of Cardiology  
New Orleans, USA
- Oct 2022 An overview of Strategic Clinical Networks: Opportunities to collaborate with Lab and Pathology  
Grand Rounds, Alberta Precision Labs, University of Calgary
- March 2022 "The impact of the pandemic on Albertans with other health conditions"  
Calgary Zone Medical Staff association
- March 2022 "COVID Corner - Indirect Impact of the COVID-19 Pandemic on Albertans with other health conditions"  
Calgary, AB
- February 2021 "Indirect Impact of the COVID-19 Pandemic on Albertans with other health conditions"  
Clinical Operations Executive Committee (COEC)  
Calgary, AB
- January 2021 "COVID Corner - Indirect Impact of the COVID-19 Pandemic on Albertans with other health conditions"  
Calgary, AB
- April 2020 "COVID Corner - Scientific Advisory Group Update"  
Calgary, AB
- May 2020 "Updates & Controversies - Scientific Advisory Group"  
CMO - All Physician Town Hall  
Calgary, AB
- January 2020 "Reimagining the College of Physician and Surgeon's Role in Public Policy"  
CPSA Council Retreat  
Edmonton, AB
- Nov 2019 "Alberta's Strategic Clinical Networks – Creating Synergy with Academic Researchers"  
Community Health Science Rounds, University of Calgary  
Calgary, AB
- October 2019 "Alberta's Strategic Clinical Networks – Lessons Learned"

## New Brunswick Ministry of Health

- June 2019 “Can Alberta’s SCNs Solve Wicked Problems? What Do They Mean For You?”  
Department of Medicine Grand Rounds, University of Alberta  
Edmonton, AB
- May 2019 “START Project – Economic Modelling: Business Case”  
Alberta Kidney Care  
Calgary, AB
- May 2019 “Heart Failure & COPD Provincial Clinical Pathways Welcome/Setting the Stage”  
Alberta Health Services  
Edmonton, AB
- April 2019 “Can Alberta’s SCNs Solve Wicked Problems?”  
Medical Grand Rounds  
Calgary, AB
- April 2019 “Physician Audit and Feedback”  
Nephrology City Wide Renal Rounds  
Calgary, AB
- March 2019 “Helping Physician’s Be Stewards of Resources”  
Institute of Health Economics  
Edmonton, AB
- March 2019 “Strategic Clinical Network Roadmap”  
Zone Medical Administrative Committee (ZMAC) meeting  
Calgary, AB
- March 2019 “Strategic Clinical Network Roadmap”  
Executive Team Leaders (ELT) meeting  
Edmonton, AB
- June 2018 “The implications of PD technique failure, including PD Catheter Patency  
and Function, for patients and the health care system: the Alberta Perspective”  
Ontario Renal Network "Kidney Talks" meeting  
Toronto, ON
- May 2018 “Kidney Foundation of Canada Gold Medal address”  
Canadian Society of Nephrology Annual General meeting  
Vancouver, BC
- May 2018 “Health economics for policy makers”  
Canadian Association of Nephrology Administrators



- Vancouver, BC
- May 2018 “Should patients and family members be paid to do PD?”  
International Society of Peritoneal Dialysis  
Vancouver BC
- May 2018 “Research setting priorities of patients”  
International Society of Peritoneal Dialysis  
Vancouver BC
- April 2018 “Cost isn't a 4 letter word in Health care: Physicians as stewards of resources”  
Calgary Grand Medicine Rounds, Calgary, AB
- April 2018 “Incorporating cost-effectiveness within primary care and chronic  
disease management”  
Alberta Health, Edmonton AB
- April 2018 “Health Economics, health care payers, guidelines and the inherent tension:  
Can they ever agree?”  
KDIGO Guideline Implementation conference  
Tokyo, Japan
- April 2018 “How to change physician, health system, and patient behavior: the  
knowledge to action cycle”  
KDIGO Guideline Implementation conference  
Tokyo, Japan
- March 2018 “Key performance indicators for Kidney Health”  
Kidney Health Strategic Clinical Network Core Committee meeting, Calgary AB
- March 2018 “Overview of Quality Indicators for Kidney Health in Alberta”  
Alberta Kidney Days, Edmonton, AB
- March 2018 “Screening Indigenous communities in Alberta for diabetes and kidney disease”  
PPIH Strategic Clinical Network, Calgary, AB
- July 2017 “An evaluation of blended capitation for primary care”  
Alberta Health / Alberta Medical Association steering committee; Edmonton, AB
- June 2017 “The ACCESS Study - implications for health policy”  
Presentation to Libin Institute Board  
Calgary, AB
- May 2017 “The cost of caring for patients with chronic kidney disease”  
Canadian Society of Nephrology Free Communications

Montreal, QC

- Apr 2017 “Cost isn’t a four letter word: Health care providers as stewards of resources”  
Southern Alberta Nephrology Rounds  
Calgary, AB
- Mar 2017 “Key performance indicators for publicly funded drug formularies”  
Key performance indicator workshop – including 5 provincial health ministries  
Toronto, ON
- Mar 2017 “Kidney health Strategic Clinical Network: Setting the stage”  
Invited speaker, Alberta Kidney Days  
Calgary, AB
- Feb 2017 “Quality indicators in kidney care: A Kidney health SCN update”  
Invited speaker, Northern Alberta Nephrology rounds  
Edmonton, AB
- Jan 2017 “Quality indicators in kidney care: Lessons for Alberta”  
Invited speaker, Saskatchewan Nephrology rounds  
Regina, SK
- Jan 2017 “Can-SOLVE CKD: an update on patient engagement”  
Can-SOLVE CKD webinar  
Calgary, AB
- Nov 2017 “How can we drive increased use of home dialysis through consideration of  
economic incentives?”  
CSN at the ASN Session (Organizer and speaker)  
Chicago, IL
- Nov 2017 “Moderator at Standardized Outcomes in Nephrology Implementation Workshop”  
American Society of Nephrology Meeting;  
New Orleans, LA
- Nov 2017 “Implementing patient-reported outcome measures in the Southern Alberta Renal”  
Program: the EMPATHY project  
Nephrology Grand Rounds  
Calgary, AB
- Oct 2016 “The impact of social media on study dissemination to academics”  
Invited speaker, Saskatchewan Nephrology rounds  
Regina, SK
- Oct 2016 “Health Economics Study group: a welcome”

- Calgary, AB
- Sept 2016 “Pragmatic Trials: Why and why now?”  
Emerging Research Methods and the Consent Challenge  
Banff, AB
- June 2016 “Anemia management in CKD: An update”  
Southern Alberta Nephrology rounds  
Calgary, AB
- May 2016 “An update on the Canadian Society of Nephrology: President’s Address”  
Canadian Society of Nephrology Annual General Meeting  
Halifax, NS
- April 2016 “Introduction to Patient-Oriented Research”  
Invited speaker, University of Calgary Faculty of Medicine retreat  
Kananaskis, AB
- Jan 2016 “Introduction to Patient-Oriented Research”  
Invited speaker, Alberta SPOR support unit speaker series  
Calgary, AB
- Jan 2016 “Overcoming cost barriers: The ACCESS study”  
Visiting speaker, University of Toronto City-wide Nephrology rounds  
Toronto, ON
- Oct 2015: “Optimizing timing of dialysis initiation”  
Division of Nephrology, University of Alberta  
Edmonton, Alberta
- Sept 2015 “Leveraging clinical registries as tools for pragmatic randomized trials”  
Plenary session – APPROACH annual general meeting  
Calgary, AB
- June 2015 “An overview of Health Economics”  
Health Economics Course – Final Presentations and Overview to AHS  
Edmonton, AB
- June 2015 “An overview of activity based funding”  
Activity based funding workshop – Institute of Health Economics  
Edmonton, AB
- June 2015 “Listening, Learning and Leading: Canadians Seeking Solutions and Innovations  
to Overcome Chronic Kidney Disease (Can-SOLVE CKD)”  
National Kidney Foundation of Canada meeting  
Mont Tremblant, QC

- June 2015 “Using the knowledge to action cycle to improve timing of dialysis initiation”  
Ontario Renal Network Annual Conference  
Toronto, ON
- May 2015 “Health economics needs assessment, Alberta 2015” - Alberta Health  
Edmonton, Alberta
- May 2015 “Overcoming cost barriers: The ACCESS study”  
CIHR Institute of Nutrition, Metabolism and Diabetes Board meeting  
Calgary, Alberta
- April 2015 “An update on the Canadian Society of Nephrology: President’s Address”  
Canadian Society of Nephrology Annual General Meeting  
Montreal, QC
- April 2015 “Standardizing PD education”  
British Columbia Peritoneal Dialysis Days  
Vancouver, BC
- March 2015 “Timing of Dialysis Initiation”  
Alberta Nursing education day  
Calgary, AB
- Nov 2014 “The Canadian Society of Nephrology – an update on priorities”  
American Society of Nephrology Annual General Meeting  
Philadelphia, PA
- Nov 2014 “Comparing the health research priorities of researchers and patients”  
Canadian Health Funders Consortium Annual Meeting  
Ottawa, ON
- Oct 2014 “Increasing appropriate Timing of Dialysis Initiation”  
Lethbridge Nephrology group -- Lethbridge, AB
- Sept 2014 “Developing an evaluation strategy for Strategic Clinical Network Priorities”  
Alberta Health Services, Strategic Clinical Network Connects Conference  
Banff, AB
- Apr 2014 “From data to best practice: an overview of increasing the use of home dialysis  
therapies”  
Canadian Society of Nephrology Annual General Meeting  
Vancouver, BC
- Apr 2014 “Patient oriented research”  
Kidney Foundation of Canada Annual General Meeting

Vancouver, BC

- Feb 2014 “Health Economics: An overview for clinicians”  
University of Calgary Master Clinician course  
Calgary, Alberta
- Dec 2013 “Patient engagement in setting research priorities”  
CIHR Institute of Nutrition, Metabolism and Diabetes conference  
Edmonton, AB
- Oct 2013 Using the knowledge to action cycle to improve management of patients with  
severe CKD nearly dialysis  
British Columbia Nephrology Days  
Vancouver, BC
- Oct 2013 “Copayment Elimination and Patient Education for the Prevention of Adverse  
Events in Chronic Disease StudY” (CoPAY), Alberta Health  
Calgary, AB
- June 2013 “Priority Setting Partnership for People with Kidney Failure on Dialysis”  
St Michael’s Hospital,  
Toronto, Ontario
- May 2013 “The impact of cost sharing for drugs on health outcomes and costs”  
Alberta Health  
Calgary, AB
- May 2013 “Timing of dialysis initiation”  
Presenter and organizer of symposium held at Annual CSN meeting,  
Montreal, Quebec
- March 2013 “Survey on the Barriers to Care for People with Chronic Health Conditions”  
Alberta Health Lunch and Learn  
Calgary, AB
- Feb 2013 “The role of mentoring in career progression”  
University of Calgary Internal Medicine Retreat Guest Speaker  
Calgary, AB
- Nov 2012 “Knowledge Translation in Nephrology”  
University of Calgary Citywide Nephrology Rounds  
Calgary, AB
- Nov 2012 “Knowledge Translation in Nephrology”  
University of Toronto Sunnybrook Hospital Nephrology Rounds

Toronto, Ontario

- Nov 2012 “The impact of a management based eGFR report in CKD”  
Visiting Professor in the Division of Nephrology at the University of Toronto  
University of Toronto Grand Rounds  
Toronto, Ontario
- Oct 2012 “The impact of financial barriers on adherence to prescription drugs”  
Alberta Employers Committee on Health  
Edmonton, Alberta
- Oct 2012 “Peritoneal dialysis vs hemodialysis: A debate  
American Society of Nephrology  
San Diego, USA
- Sept 2012 “Using quality of life as a measure within studies to improve care in kidney  
failure” - Alberta EQ-5D workshop  
Canmore, Alberta
- April 2012 The Canadian Kidney Knowledge Translation and Generation Network  
Canadian Society of Nephrology Annual Meeting,  
St John’s, NFLD
- March 2012 “An overview of the Interdisciplinary Chronic Disease Collaboration”  
Alberta Health and Alberta Health Services  
Edmonton, AB
- Oct 2011 “Funding new pharmaceuticals: Seeking the right balance in publicly funded  
health care”  
Grand Medical rounds, Dalhousie University  
Halifax, NS
- Oct 2011 The impact of a management based eGFR report in CKD  
Nephrology rounds, Dalhousie University  
Halifax, NS
- June 2011 The impact of a management based eGFR report in CKD  
AKTN, University of Brisbane  
Queensland, Australia
- May 2011 The impact of a management based eGFR report in CKD  
Monash Medical Center, Monash University  
Victoria, Australia
- Mar 2011 Enzyme replacement therapy for Fabry’s Disease: Does it matter?  
World Congress of Nephrology

- Vancouver, BC
- Mar 2011 The cost-effectiveness of statins in people at low cardiovascular risk  
Centre for Health Economics, Monash University  
Victoria, AustraliaAus
- Feb 2011 The impact of a management based eGFR report in CKD  
George Institute Camperdown, University of Sydney  
New South Wales, Australia
- Nov 2010 Improving Efficiency in Hospital Care  
Hospital Medicine Conference  
Calgary, Alberta
- Sept 2010 Recommendations for Commonly used Drugs in patients with Chronic Kidney  
Disease - Rural Continuing Medical Education  
Calgary, Alberta
- Sept 2010 Approaches to mitigating against methodologic bias in economic evaluations  
Invited presentation at *Methodology Forum: Prioritizing Methodological Research  
in Evaluation of Health Technologies* - Institute of Health Economics  
Edmonton, Alberta
- Mar 2010 Lunch and Learn – ICDC  
Alberta Health and Wellness  
Calgary, Alberta
- Oct 2009 “Will there be new cardiovascular therapies in the future: The perspective of the  
Common Drug Review”  
Invited presentation at the Annual Meeting of the Canadian Hypertension Society  
Edmonton, Alberta
- Oct 2009 “Evaluating the cost and cost-effectiveness of nocturnal hemodialysis”  
Invited podium presentation at the Amer. Society of Nephrology Annual meeting  
San Diego, California
- May 2008 “Funding new pharmaceuticals: Seeking the right balance in publicly funded  
health care”  
Keynote speaker, Resident Research Day  
Ottawa, ON
- Nov. 2008 “QALYs in Action: A Canadian Perspective” – Top of the Hill,  
Washington, DC
- Nov. 2008 “Randomized controlled Trials: Good as Gold” – Pre-course, American Society of  
Nephrology, Philadelphia, PA

- May 2008 “Therapeutics Debate”  
Chair of the “Therapeutics Debate” session  
Canadian Society of Nephrology Meeting  
London, ON
- May 2008 “Controversies in Mineral Metabolism”  
Visiting Speaker, Canadian Society of Nephrology Meeting  
London, ON
- May 2008 “The Canadian Common Drug Review: Past, present and future”  
ISPOR symposium (International Experiences of Centralized Reimbursement  
Reviews: Identifying Best Practices)  
Toronto, ON
- Mar 2008 “An update on anemia management in CKD”  
Visiting Speaker, Province-wide Nephrology Grand Rounds  
Saskatoon, SK
- Mar 2008 “CEDAC: Progress and Challenges”  
Pharmaceutical Directors Forum  
Ottawa, ON
- Oct. 2007 “Cost effectiveness of ESAs in CKD”  
Visiting Speaker, Nephrology Grand Rounds  
London, ON
- Oct. 2007 “Effect of Frequent NHD on LVH and Quality of Life”  
Annual PreASN Visiting Speaker  
London, ON
- Oct. 2007 “Economic Evaluation: The nuts and bolts of “Why and how”?”  
Visiting Speaker, Department of Clinical Epidemiology  
St John, NFLD
- Oct. 2007 “CEDAC: Annual Update”  
CADTH Board of Directors Meeting  
Whitehorse, YK
- May 2007 “Updated CSN Anemia Clinical Practice Guidelines”  
Canadian Society of Nephrology Annual Meeting  
Halifax, Nova Scotia
- May 2007 “Surrogates Endpoints: Challenges Created for Post-Licensing Advisory Bodies”  
CADTH Annual Symposium Precourse  
Ottawa, Ontario



- May 2007 “Expensive Drugs for Rare Diseases: Perspectives from CEDAC”  
Invited podium presentation at CADTH Annual Symposium  
Ottawa, Ontario
- Nov. 2006 “The impact of education on the use of self care dialysis”  
Invited podium presentation at the Amer. Society of Nephrology Annual meeting  
San Francisco, California
- Nov. 2006 “The cost effectiveness of nocturnal hemodialysis”  
Invited podium presentation at the Amer. Society of Nephrology Annual meeting  
San Francisco, California
- Nov. 2005 “Enzyme Replacement Therapy for Fabry's Disease should be Publicly Funded:  
Yes or No”  
Presentation as a debater at the 2005 "CSN in America" event  
American Society of Nephrology Annual Meeting, Philadelphia, PA
- Sept. 2005 Health Economics for Clinicians: 2 day course  
Two-hour lecture on “Using Decision Analysis in Economic Evaluation”  
NewCastle, UK
- May 2005 The cost of maintaining vascular access in hemodialysis patients  
Presentation at a symposium at the Can. Society of Nephrology Annual Meeting  
Calgary, AB
- May 2005 Chair of a symposium at the Canadian Society of Nephrology Annual Meeting  
Symposium on Clinical Research in Kidney Diseases  
Calgary, AB
- April 2005 Balancing Economics, Science and Ethics: Considerations for the Approval of  
Novel Therapies in CKD  
Presentation at Alberta Nephrology Days  
Banff, AB
- Mar 2005 Surrogate markers and their implications for funding new pharmaceuticals  
Presentation to CEDAC at annual retreat  
Victoria, BC
- Jan 2004 Activated Protein C in Severe Sepsis: A policy perspective  
Presentation to the Calgary Caucus of the Alberta Government (including Ralph  
Klein, Premier and Gary Mar, Health Minister)  
Calgary, Alberta
- Sept. 2003 Economic implications of population-based chronic kidney disease intervention  
Prevention in Renal Disease Annual Conference

Toronto, Ontario

- Sept. 2003 Cost-effectiveness of Activated Protein C  
Plenary session at International Congress meeting of the German Sepsis Society  
Weimar, Germany
- May 2003 Costs: Normalization of Hemoglobin with Erythropoietin  
Presented at the Canadian Society of Nephrology Annual meeting  
St. John's, Newfoundland
- May 2003 Economic considerations in Choices of End Stage Renal Disease Therapeutic  
Modality  
Presented at Alberta Nephrology Days  
Kananaskis, Alberta
- April 2003 Economic evaluation in health care: An introduction and application to patients  
with liver and gastrointestinal disease. Alberta GI retreat  
Banff, Alberta
- Mar. 2003 Interpretation and Health Policy Implications of Cost Effectiveness Analysis: A  
case study of Activated Protein C for severe sepsis  
Pre-conference workshop at Canadian Association for Population Therapeutics  
Annual Conference  
Quebec City, Quebec
- Sept. 2002 The cost of acute renal failure requiring dialysis in the intensive care unit: The  
clinical and resource implications of renal recovery.  
Presented at Alberta Nephrology Days  
Calgary, Alberta
- Feb. 2002 An Education Program for Clinicians in the Evaluation of Economic and  
Humanistic Outcomes of Health Care Interventions  
Presented two lectures on decision analysis within economic evaluation at a six  
day course attended by physicians with an interest in health economics  
Edmonton, Alberta
- July 2001 Methodological issues in the economic evaluation of end-stage renal disease  
Presented at the International Health Economics Association meeting  
York, United Kingdom
- Mar 2001 To reuse or not to reuse? An economic evaluation of hemodialyser reuse vs  
conventional single use hemodialysis  
Presented at the Canadian Society of Nephrology annual meeting  
Vancouver, Canada
- Nov. 2000 Economic Evaluation of Xenotransplantation

Presented at a conference entitled “The Perils and Promise of Xenotransplantation”, a citizen’s jury commissioned by Health Canada  
Calgary, Alberta

- Sept. 1998    Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in Patients with End-Stage Renal Disease  
Presented at the annual meeting of the Royal College of Physicians and Surgeons  
Toronto, Ontario
- May 1998    Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in Patients with End-Stage Renal Disease  
Resident Research Day  
Dept of Internal Medicine, Univ. of Calgary
- April 1996:    Antituberculous drug resistance in immigrants  
Resident Research Day  
Dept of Internal Medicine, Univ. of Calgary
- Sept. 1995    Resistance to antituberculous medications in immigrants to Alberta with tuberculosis  
Canadian Resident-Fellow Competition in Respiratory Research  
St. Sauveur, Quebec

**X. Publications (peer reviewed, in press)**

1. Liang X, Tang M, **Manns B**, Babiuk LA, Zamb TJ. Identification and Deletion Mutagenesis of the Bovine Herpesvirus 1dUTPase Gene and a Gene Homologous to Herpes Simplex Virus UL49.5. *Virology* **1993**; 195: 42-50.
2. **Manns BJ**, Baylis BW, Urbanski SJ, Gibb AP, Rabin HR. Paracoccidioidomycosis: Case report and review of the literature. *Clinical Infectious Diseases* **1996**; 23: 1026-32.
3. **Manns BJ**, Fanning EA, Cowie RL. Antituberculous drug resistance in immigrants to Alberta, Canada with tuberculosis, 1982 - 1994. *International Journal of Tuberculosis and Lung Disease* **1997**; 1: 225-230.
4. **Manns BJ**, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas, NW. Hyperhomocysteinemia, Anticardiolipin Antibody Status and the Risk for Vascular Access Thrombosis in Patients with End-Stage Renal Disease on Hemodialysis. *Kidney International* **1999**; 55: 315-320.
5. **Manns BJ**, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas, NW. Hyperhomocysteinemia and the Risk for Atherosclerotic Vascular Disease in Patients with End-Stage Renal Disease. *American Journal of Kidney Diseases*, **1999**; 34: 669-677
6. **Manns BJ**, Taub K, Donaldson C. Economic evaluation and end-stage renal disease: From basics to bedside. *American Journal of Kidney Diseases* **2000**; 36: 12-28. (In-Depth Review)
7. **Manns BJ**, Mortis GP, Taub KJ, McLaughlin K, Donaldson C, Ghali WA. Overview of the Southern Alberta Renal Program Database: A prototype for patient management and research initiatives. *Clin Invest Med* **2001**; 24(4): 164-170.
8. **Manns BJ**, Taub K, Donaldson C. Economic evaluation and the treatment of end-stage renal disease. *Current Opinion in Nephrology and Hypertension*. **2001**; 10: 295-299. (Special Article)
9. **Manns BJ**, Hyndman ME, Burgess ED, Parsons HG, Schaefer JP, Snyder F, Scott-Douglas NW. Oral vitamin B12 and high-dose folic acid in hemodialysis patients with hyperhomo-cyst(e)inemia: A randomized clinical trial. *Kidney International*. **2001**; 59: 1103-09.
10. Devereaux PJ, **Manns BJ**, Ghali WA, Quan H, Guyatt GH. Reviewing the reviewers: the quality of reporting in three review journals. *Canadian Medical Association Journal* **2001**; 11: 1573-1576.

11. Devereaux PJ, **Manns BJ**, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari M, Guyatt GH. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. *JAMA*. **2001**; 285: 2000-2003.
12. McLaughlin K, **Manns BJ**, Culleton B, Donaldson C, Taub K. Early referral of patients with progressive renal insufficiency is cost-effective. *Am J Kidney Dis* **2001**; 38: 1122-1128. (Fast-tracked)
13. Devereaux PJ, Bhandari M, Montori VM, **Manns BJ**, Ghali WA, Guyatt GH. Double blind, you are the weakest link -- good-bye! [Editorial]. *ACP J CLUB*. **2002. Jan-Feb**; A11-12
14. **Manns BJ**, Taub K, Richardson, R, Donaldson C. To reuse or not to reuse? An economic evaluation of hemodialyser reuse vs conventional single use hemodialysis for chronic hemodialysis patients. *Intl. J. Tech Ass Health Care* **2002**; 18: 81-94.
15. Helen Lee, **Braden J. Manns**, Ken Taub, William A. Ghali, Stafford Dean, David Johnson, Cam Donaldson. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. *Am J Kidney Diseases* **2002**; 40: 611-622.
16. Montori VM, Bhandari M, Devereaux PJ, **Manns BJ**, Ghali WA, Guyatt GH. In the dark: the reporting of blinding status in randomized controlled trials. *J Clin Epidemiol* **2002**; 55:42-45.
17. Devereaux PJ, **Manns BJ**, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the consolidated standards of reporting trials (CONSORT) checklist. *Controlled Clinical Trials*. **2002**; 23: 380-388
18. **Manns BJ**, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Dialysis adequacy and health-related quality of life in patients on hemodialysis. *ASAIO* **2002**; 48: 565-9.
19. Marcello Tonelli, **Braden J. Manns**, David Feller-Kopman. Acute Renal Failure in the Intensive Care Unit: A Meta-Analysis of the Impact of Dialytic Modality on Mortality and Renal Recovery. *Am J Kidney Dis* **2002**; 40: 875-885.
20. **Braden J. Manns**, Helen Lee, Christopher James Doig, David Johnson, Cam Donaldson. An Economic Evaluation of Activated Protein C Treatment in Severe Sepsis. *New England Journal of Medicine*, **2002**; 347: 993-1000 (Special Article).
21. Matthew Eric Hyndman, **Braden J. Manns**, Floyd F.Snyder, Peter J. Bridge, Nairne W. Scott-Douglas, Ernest Fung, Howard G. Parsons. Vitamin B12 decreases but does not normalize Homocysteine and Methylmalonic Acid in End-Stage Renal Disease (ESRD):

A Link with Glycine Metabolism and possible explanation of hyperhomocysteinemia in ESRD. *Metabolism* **2003**; 52(2):168-72.

22. **Braden J. Manns**, Christopher James Doig, Helen Lee, Stafford Dean, Marcello Tonelli, David Johnson, Cam Donaldson. The cost of acute renal failure requiring dialysis in the intensive care unit: The clinical and resource implications of renal recovery. *Critical Care Medicine* **2003**; 31(2):449-55.
23. Kevin McLaughlin, **Braden Manns**, Garth Mortis, Ronald Hons, Ken Taub. Why Patients With End-Stage Renal Disease Do Not Select Self-Care Dialysis As A Treatment Option. *Am J Kidney Dis* **2003** 41(2):380-5.
24. **Manns BJ**, Meltzer D, Taub K, Donaldson C. Illustrating the impact of including future costs in economic evaluations: An application to end-stage renal disease care. *Health Economics* **2003**; 12(11), 949-958.
25. Marcello Tonelli, Wolfgang Winkelmayr, Kailash K. Jindal, William F. Owen, Jr., **BJ Manns**. The Cost Effectiveness of Different Hemoglobin Targets in Hemodialysis Patients Treated with Erythropoietin. *Kidney Int*, **2003**; 64: 295-304.
26. Kaplan G, **Manns B**. Renal regulation. The keys to preventing chronic renal failure. *The Canadian Journal of CME* **2003**; 15(2): 55-64.
27. **Manns BJ**, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis: What are the important determinants? *Clinical Nephrology* **2003**; 60: 341-51.
28. Hemmelgarn B, **Manns B**, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. *Am J Kidney Dis*, **2003**; 42:125-132.
29. Pannu N, **Manns B**, Lee H, Tonelli M. Systematic Review of the Impact of N-Acetylcysteine on Contrast Nephropathy. *Kidney Int*, **2004**; 65:1366-74.
30. Doig CJ, Laupland KB, Zygun DA, **Manns BJ**. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C. *Expert Opinion in Pharmacotherapy*, **2003**; 4:1789-99.
31. Doig CJ, Zygun DA, Delaney A, **Manns BJ**. Drotrecogin alfa (activated): an effective and cost efficient treatment for severe sepsis. *Expert Review of Pharmacoeconomics & Outcomes Research*, **2004**; 4: 15–26.
32. Lee H, Donaldson C, Doig C, Ghali WA, Johnson D, **Manns B**. A detailed cost analysis of the care for survivors of severe sepsis: An opportunity to improve efficiency? *Crit Care Med* **2004**; 32: 981-5.

33. Devereaux PJ, Choi PTL, El-Dika S, Bhandari M, Montori VM, Schünemann HJ, Garg AX, Busse JW, Heels-Ansdell D, Ghali WA, **Manns BJ**, Guyatt GH. An observational study found that authors of randomized controlled trials frequently used concealment of randomization and blinding, despite the failure to report these methods. *J Clin Epidemiol.* **2004**; 57: 1232-1236
34. Marcello Tonelli, Brenda Hemmelgarn, **Braden Manns**, George Pylypchuk, Clara Bohm, Karen Yeates, Sita Gourishankar, John S. Gill. Death and Renal Transplantation Rates In Aboriginal Canadians Receiving Dialysis Treatment. *CMAJ*; 2004; 171: 577-82.
35. Manns BJ, Stevens, L, Miskulin D, Owen WF, Winkelmayer WW, Tonelli M. A critical appraisal of sevelamer in ESRD and its potential economic impact in Canada and the United States. *Kidney Int*, **2004**; 66(3):1239-47
36. Fiona M Shrive, **Braden J Manns**, P. Diane Galbraith, Merrill L Knudtson, William A Ghali. An Economic Evaluation of Sirolimus-Eluting Stents. *CMAJ*, **2005**;172(3):345-51.
37. **Braden Manns**, Marcello Tonelli, Serdar Yilmaz, Helen Lee, Kevin Laupland, Scott Klarenbach, Val Radkevich, Brendan Murphy. Establishment and maintenance of vascular access in incident hemodialysis patients: A prospective cost analysis. *JASN*; **2005**; 16: 201-9.
38. Walsh M, Culleton BA, Tonelli M, **Manns BJ**. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism and health-related quality of life. *Kidney Int*, **2005**; 67: 1500-1508.
39. Tonelli M, Hemmelgarn B, **Manns BJ**, Pylypchuk G, Bohm C, Yeates K, Gourishankar S, Gill J for the Canadian Nephrology Young Investigators Group. Technique Failure and Mortality in Aboriginal Canadians on Peritoneal Dialysis. *JASN* **2005**; 16: 484-8.
40. **Manns BJ**, Taub K, VanderStraeten C, Jones H, Mills C, Visser M. A patient-centered educational intervention to improve the utilization of “self-care dialysis” among predialysis patients: A randomized controlled trial. *Kidney Int* **2005** 68:1777-83
41. Fiona M Shrive, William A Ghali , Steven Lewis, Cam Donaldson, Merrill L Knudtson, **Braden J Manns**. Sirolimus-eluting Stents at 58 K per QALY: Now What? *Can J Card* **2005**; 21: 783-788.
42. Brauer C, **Manns BJ**, Donaldson C, Buckley R. An economic evaluation of operative versus non-operative management of displaced intra-articular calcaneal fractures. *Journal of Bone and Joint Surgery*, **2005**; 87: 2741-9.

43. Kaplan GG, **Manns BJ**, McLaughlin K. Heparin Induced Thrombocytopenia Secondary to Intraperitoneal Heparin Exposure. *Nephrol Dial Transplant*, **2005**; 20: 2561-2.
44. Heitman S, **Manns BJ**, Hilsden R, Fong A, Dean S, Romagnuolo J. Cost-Effectiveness of CT Colonography vs Colonoscopy for Colorectal Cancer Screening. *CMAJ* **2005**; 173:877-81.
45. Delaney A, Bagshaw S, Ferland A, **Manns BJ**, Laupland K, Doig CJ. A Systematic Evaluation of the Quality of Meta-analyses in the Critical Care Literature. *Crit Care Med* **2005**; 9: R575-82.
46. Devereaux PJ, Bhandari M, Montori VM, **Manns BJ**, Ghali WA, Guyatt GH. Double blind, you are the weakest link--goodbye! *Equine Vet J*. **2005**; 37: 557-8.
47. Bagshaw SM, McAlister FA, **Manns BJ**, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. *Arch Intern Med*. **2006**; 166:161-6.
48. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. *Blood*. **2006**;107:3841-6.
49. Klarenbach SW, Pannu N, Tonelli MA, **Manns BJ**. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. *Crit Care Med*. **2006**; 34: 1044-51.
50. Walsh M, **Manns BJ**, Klarenbach S, Quinn R, Tonelli M, Culleton BF. The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study. *BMC Nephrol*. **2006**; 7: 2.
51. Hemmelgarn BR, Moist L, Pilkey RM, Lok C, Dorval M, Tam PY, Berall MJ, Leblanc M, Toffelmire EB, **Manns BJ**, Scott-Douglas N. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): Study protocol of a randomized trial. *BMC Nephrol*. **2006**; 11;7:8.
52. Walsh M, **Manns BJ**. Oral mycophenolate led to more complete remissions than intravenous cyclophosphamide for active lupus nephritis. *ACP J Club*. **2006**; 144(3):74.
53. Hemmelgarn BR, Zhang J, **Manns BJ**, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF. Progression of kidney dysfunction in the community-dwelling elderly. *Kidney Int*. **2006 June**;69(12):2155-61.



54. Tonelli M, Klarenbach S, Jindal K, **Manns BJ**. Economic implications of screening strategies in arteriovenous fistulae. *Kidney Int*, **2006 Jun**;69(12):2219-26.
55. Cox H, Laupland K, **Manns BJ**. Economic Evaluation in Critical Care Medicine. *Journal of Critical Care*, **2006 Jun**;21(2):117-24.
56. Barnieh L, Baxter D, Boiteau P, **Manns BJ**, Doig C. Benchmarking performance in organ donation programs: dependence on demographics and mortality rates. *Can J Anaesth*, **2006 July**;53(7):727-31.
57. **Manns BJ**, Owen WF, Winkelmayr W, Devereaux PJ, Tonelli, M. Surrogate Markers in Clinical Studies. Problems Solved or Created? *Am J Kidney Dis* **2006 Jul** 48(1):159-66.
58. Tonelli M, Hemmelgarn B, Kim AK, Bertazzon S, Klarenbach S, **Manns BJ**, Wiebe N, Culleton B, Gill JS; Alberta Kidney Disease Network. Association between residence location and likelihood of kidney transplantation in Aboriginal patients treated with dialysis in Canada. *Kidney Int*. **2006 Sep**;70(5):924-30.
59. James M, **Manns BJ**. N-acetylcysteine prevented contrast-medium-induced nephropathy in primary angioplasty. *ACP J Club*. **2006 Nov-Dec**;145(3):63.
60. Hemmelgarn BR, Chu S, Wiebe N, Culleton BF, **Manns BJ**, Klarenbach S, Khan NA, Gourishankar S, Yeates KE, Gill JS, Tonelli M. Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada. *Am J Kidney Dis*. **2006 Dec**;48(6):964-71.
61. Laupland KB, Lee H, Gregson DB, **Manns BJ**. Cost of intensive care unit-acquired bloodstream infections. *J Hosp Infect*. **2006; 1 June**;63(2):124-32.
62. Tonelli M, Klarenbach S, **Manns BJ**, Culleton B, Hemmelgarn B, Bertazzon S, Wiebe N, Gill JS; Alberta Kidney Disease Network. Residence location and likelihood of kidney transplantation. *CMAJ*. **2006 Aug 29**;175(5):478-82.
63. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas, N, Quinn R, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, and **Manns BJ**. The Impact of Frequent Nocturnal Hemodialysis and Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. *JAMA*, **2007**; 298(11): 1291-99
64. Oliver M, Quinn R, Richardson E, Kiss A, Lamping D, **Manns BJ**. Home care assistance and the utilization of peritoneal dialysis. *Kidney Int*. **2007**; 71: 673-8.
65. Komenda P, Levin A, **Manns B**. The economics of home nocturnal hemodialysis: how should we cost the benefits? *Clin Nephrol* **2007**; 68(3):151-8.

66. Walsh M, James M, Jayne D, Tonelli M, **Manns B**, Hemmelgarn B. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* **2007**;2(5):968-75.
67. Brar SS, **Manns BJ**. Activated protein C: cost-effective or costly? *Crit Care* **2007**; 11(5):164.
68. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, **Manns B**; AKDN. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. *Nephrol Dial Transplant* **2007**; 22(10): 2856-66.
69. Tonelli M, **Manns B**, Culleton B, Klarenbach S, Hemmelgarn B, Wiebe N, Gill JS; AKDN. Association between proximity to the attending nephrologist and mortality among patients receiving hemodialysis. *CMAJ* **2007**; 177(9):1039-44.
70. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, **Manns BJ**, Ghali WA. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. *Arch Intern Med* **2007**; 167(22):2417-22.
71. Gao S, **Manns BJ**, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR; Alberta Kidney Disease Network. Prevalence of chronic kidney disease and survival among aboriginal people. *J Am Soc Nephrol* **2007**; 18(11): 2953-9.
72. Delaney A, Baghaw SM, Ferland A, Laupland K, **Manns BJ**, Doig C. The quality of reports of critical care meta-analyses in the Cochrane Database of Systemic Reviews: an independent appraisal. *Crit Care Med*. **2007 Feb**;35(2):589-94.
73. Shrive F, Ghali W, Johnson J, Donaldson C, **Manns BJ**. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care. *Med Care*. **2007 Mar**;45(3):269-73
74. Gooch K, Culleton B, **Manns BJ**, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn B. NSAID use and progression of chronic kidney disease. *Am J Med*. **2007 Mar**;120(3):280.e1-7.
75. Hemmelgarn BR, **Manns BJ**, Zhang J, Tonelli M, Klarenbach S, Walsh M, Culleton BF. Association between Multidisciplinary care and survival for elderly patients with chronic kidney disease. *J Am Soc Nephrol*, **2007 Mar**;18(3):993-9.
76. Walsh M, Tonelli M, Jayne D, **Manns BJ**. Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. *J Nephrol* **2007 Mar-Apr**;20(2):119-29.

77. Graham A, Shrive F, Ghali W, **Manns BJ**, Grondin S, Finley R, Clifton J. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. *Ann Thorac Surg.* **2007 Apr**;83(4):1257-64.
78. Joffres M, Campbell N, **Manns BJ**, Tu K. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. *Can J Cardiol.* **2007 May** 1;23(6):437-43.
79. Quinn RR, **Manns BJ**, McLaughlin KM. Restricting cadaveric kidney transplantation based on age: the impact on efficiency and equity. *Transplant Proc.* **2007 Jun**;39(5):1362-7.
80. **Manns BJ**, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. *Nephrol Dial Transplant* **2007 June**; 22(10):2867-78.
81. Mendelssohn DC, Muirhead N, Manns BJ. Managing anemia. What do we do now? Views from Canada. *Nephrol News Issues.* **2007 June**;21(7):55-7.
82. Tonelli M, Hemmelgarn B, Gill JS, Chou S, Culleton B, Klarenbach S, **Manns BJ**, Wiebe N, Gorishankar S. Patient and allograft survival of Indo Asian and East Asian dialysis patients treated in Canada. *Kidney Int* **2007 Jun 6**.
83. Tonelli M, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, **Manns BJ**. Mortality of Canadians treated by peritoneal dialysis in remote locations. *Kidney Int* **2007 Jul 18**.
84. **Manns BJ**, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. *Int J Health Care Finance Econ.* **2007 July 20**.
85. Wang W, Murphy B, Yilmaz S, Tonelli M, Macrae J, **Manns BJ**. Comorbidities do not influence primary fistula success in incident hemodialysis patients: a prospective study. *Clin J Am Soc Nephrol* **2008**; 3(1): 78-84.
86. Wang W, Tonelli M, Hemmelgarn B, Gao S, Johnson JA, Taub K, **Manns B**. The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized cross over trial. *Amer J Kidney Dis* **2008** 51(5):796-803.
87. Pannu N, Klarenbach S, Wiebe N, **Manns B**, Tonelli M. Renal replacement in patients with acute renal failure: A systematic review. *JAMA* **2008**; 20; 299(7):793-805

88. Shane Sinclair, Neil A. Hagen, Carole Chambers, **Braden Manns**, Anita Simone, George P. Browman. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding. *Health Policy* **2008**; 86: 381–390.
89. Tierney M, **Manns B**, Members of the Canadian Expert Drug Advisory Committee. Optimizing the use of prescription drugs in Canada through the Common Drug Review. *CMAJ* **2008**, 178(4):432-5.
90. Al-Ghonaim M, **Manns BJ**, Hirsch DJ, Gao Z, Tonelli M; Alberta Kidney Disease Network. Relation between access blood flow and mortality in chronic hemodialysis patients. *Clin J Am Soc Nephrol*, **2008**, 3(2):387-91.
91. James MT, Conley J, Tonelli M, **Manns BJ**, MacRae J, Hemmelgarn BR; Alberta Kidney Disease Network. Meta – analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. *Ann Intern Med*, **2008, April**;148(8):596-605.
92. McLaughlin K, Jones H, Vanderstraeten C, Mills C, Visser M, Taub K, **Manns BJ**. Why do patients choose self-care dialysis? *Nephrol Dial Transplant*, **2008 June**.
93. Heitman SJ, Au F, **Manns BJ**, McGregor SE, Hilsden RJ. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy. *Clin Gastroenterol Hepatol* **2008 August**;6(8):912-917.
94. **BJ Manns**, CT White, F Madore, LM Moist, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Introduction to the Canadian Society of Nephrology Clinical Practice Guidelines for the management of anemia associated with chronic kidney disease. *Kidney Int* **August 2008**;74(110):S1-S3.
95. CT White, **BJ Manns**, F Madore, LM Moist, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for evaluation of anemia. *Kidney Int* **August 2008**;74(110):S4-S6.
96. F Madore, CT White, **BJ Manns**, LM Moist, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for assessment and management of iron deficiency. *Kidney Int* **August 2008**;74(110):S7-S11.
97. LM Moist, F Madore, CT White, **BJ Manns**, SW Klarenbach, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for evidence-based use of erythropoietic-stimulating agents. *Kidney Int* **August 2008**;74(110):S12-S18.
98. SW Klarenbach, LM Moist, F Madore, CT White, **BJ Manns**, BJ Barrett, RN Foley, BF Culleton, M Tonelli. Clinical Practice Guidelines for supplemental therapies and issues. *Kidney Int* **August 2008**;74(110):S19-S24.

99. Clement 'nee Shrive' FM, Ghali WA, Donaldson C, **Manns BJ**. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. *Health econ.* **2008 July 10**.
100. James MT, Laupland KB, Tonelli M, **Manns BJ**, Culleton BF, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. *Arch Intern Med.* **2008 Nov. 24**;168(21):2333-9.
101. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Burns K, Manns B, White C, Madore F, Moist L, Klarenbach S, Barrett B, Foley R, Jindal K, Senior P, Pannu N, Shurraw S, Akbari A, Cohn A, Reslerova M, Deved V, Mendelssohn D, Nesrallah G, Kappel J, Tonelli M; Canadian Society of Nephrology. Guidelines for the management of chronic kidney disease. *CMAJ.* **2008 Nov 18**;179(11):1154-62.
102. Gao S, **Manns BJ**, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Ahmed S, Hemmelgarn BR; Alberta Kidney Disease Network. Access to health care among status Aboriginal people with chronic kidney disease. *CMAJ.* **2008 Nov 4**;179(10):1007-12.
103. **Manns BJ**. Brand-name drugs are not more effective than generic versions for treating cardiovascular disease. *Ann Intern Med.* **2009** 150(8):JC4-6.
104. **Manns BJ**, Walsh M, Culleton B, Hemmelgarn B, Tonelli M, Schorr M, Klarenbach S; Alberta Kidney Disease Network. Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. *Kidney Int* **2009**;75: 542–549.
105. Muntner P, Mann D, Razzouk L, Klarenbach S, **Manns B**, Tonelli M, Farkouh ME. Is measuring C-reactive protein useful for guiding treatment in women  $\geq 60$  years and men  $\geq 50$  years of age? *Am J Cardiol* **2009**; 104: 354-8.
106. Walsh M, **Manns BJ**, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. *Hemodial Int.* **2009**
107. Barnieh L, McLaughlin K, **Manns B**, Klarenbach S, Yilmaz S, Hemmelgarn B; Alberta Kidney Disease Network. Development of a survey to identify barriers to living donation in kidney transplant candidates. *Prog Transplant.* **2009**; 19: 304-311.
108. Klarenbach S, **Manns B**, Pannu N, Clement FM, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Economic evaluation of continuous renal replacement therapy in acute renal failure. *Int J Technol Assess Health Care.* **2009**; 25: 331-8.
109. Tonelli M, Wiebe N, Hemmelgarn B, Klarenbach S, Field C, **Manns B**, Thadhani R, Gill J; Alberta Kidney Disease Network. Trace elements in hemodialysis patients: a systematic review and meta-analysis. *BMC Med.* **2009 May** 19;7:25

110. James MT, Quan H, Tonelli M, **Manns BJ**, Faris P, Laupland KB, Hemmelgarn BR; Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. *Am J Kidney Dis.* **2009 Jul**;54(1):24-32
111. Wu CM, **Manns BJ**, Hill MD, GHali WA, Donaldson C, Buchan AM. Rapid evaluation after high risk TIA is associated with lower stroke risk. *Can J Neurol Sci* **2009 July**; 36: 450-5.
112. Klarenbach S, **Manns B**. Economic evaluation of dialysis therapies. *Semin Nephrol.* **2009 Sep**;29(5):524-32.
113. James MT, **Manns BJ**, Hemmelgarn BR, Ravani P; Alberta Kidney Disease Network. What's next after fistula first: is an arteriovenous graft or central venous catheter preferable when an arteriovenous fistula is not possible? *Semin Dial.* **2009 Sep-Oct**;22(5):539-44.
114. Tonelli M, Wang W, Hemmelgarn B, Lloyd A, **Manns B**; Alberta Kidney Disease Network. Phosphate removal with several thrice weekly dialysis methods in overweight hemodialysis patients. *Am J Kidney Dis.* **2009 Dec**;54(6):1108-15.
115. Deved V, Poyah P, James MT, Tonelli M, **Manns BJ**, Walsh M, Hemmelgarn BR; Alberta Kidney Disease Network. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. *Am J Kidney Dis.* **2009 Dec**;54(6):1089-97.
116. Tonelli M, Hemmelgarn B, Reiman T, **Manns B**, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. *CMAJ.* **2009 May 26**;180(11):E62-71
117. Heitman SJ, Ronksley PE, Hilsden RJ, **Manns BJ**, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* **2009 Jun 9**. [Epub ahead of print]
118. Clement FM, Klarenbach S, Tonelli M, Johnson JA, **Manns BJ**. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. *Arch Intern Med.* **2009 Jun 22**;169(12):1104-12.
119. Chiasson TC, **Manns BJ**, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. *PLoS Med.* **2009 Jun 23**;6(6):e1000098. Epub 2009 Jun 23

120. Clement FM, Harris A, Li JJ, Yong K, Lee KM, **Manns BJ**. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. *JAMA*. **2009 Oct 7**;302(13):1437-43.
121. Hemmelgarn BR, Clement F, **Manns BJ**, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M. Overview of the Alberta Kidney Disease Network. *BMC Nephrol*. **2009 Oct 19**;10:30.
122. Hemmelgarn B, **Manns B**, Lloyd A, James MT, Klarenbach S, Quinn R, et al. Relation Between Kidney Function, Proteinuria, and Adverse Outcomes. *JAMA*. **2010**;303:423-29.
123. Al-Ghamdi G, Hemmelgarn B, Klarenbach S, **Manns B**, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Dialysate potassium and risk of death in chronic hemodialysis patients. *J Nephrol*. **2010**;23:33-40
124. Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, **Manns B**, Hemmelgarn B. Histopathologic features aid in predicting risk for progression of IgA Nephropathy. *Clin J Am Soc Nephrol*. **2010**;e-pub.
125. Walsh M, Jayne D, Moist L, Tonelli M, Pannu N, **Manns B**. Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. *Lupus*. **2010**;19(5):628-33. Epub 2010 Jan 12
126. Tonelli M, Pannu N, **Manns B**. Drug Therapy Article: Oral Phosphate Binders in Patients With Kidney Failure. *N Engl J Med*, **2010**, 362:1312-24.
127. Hemmelgarn BR, Zhang J, **Manns BJ**, James MT, Quinn RR, Ravani P, Klarenbach SW, Culleton BF, Krause R, Thorlacius L, Jain AK, Tonelli M. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. *JAMA*. **2010**; 303: 1151-8.
128. Tai DJ, Lim TW, James MT, **Manns BJ**, Tonelli M, Hemmelgarn BR; Alberta Kidney Disease Network. Cardiovascular effects of Angiotensin converting enzyme inhibition or Angiotensin receptor blockade in hemodialysis: a meta-analysis. *Clin J Am Soc Nephrol*. **2010**; 5: 623-30.
129. James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, Klarenbach SW, **Manns BJ**, Hemmelgarn BR. Acute kidney injury and long-term decline in kidney function following coronary angiography. *Kidney Int*. **2010**;78(8):803-9.

130. Mustata S, Groeneveld S, Davidson W, Ford G, Kiland K, **Manns BJ**. Effects of exercise training on physical impairment, arterial stiffness, and health-related quality of life in patients with ESRD, *Int Urol Nephrol* **2010**; Epub ahead of print.
131. Penz ED, **Manns BJ**, Hebert PC, Stanbrook MB. Governments, pay for smoking cessation. *CMAJ*. **2010**; Epub ahead of print.
132. James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, Klarenbach SW, **Manns BJ**, Hemmelgarn B. Acute kidney injury following coronary angiography I associated with a long-term decline in kidney function. *Kidney Int* **2010**; 78:803-9.
133. Heitman S, Hilsden R, Au F, Dowden S, **Manns BJ**. Colorectal cancer screening for average risk North Americans: an economic evaluation. *PLOS Med*. **2010**; 23;7(11): e1000370.
134. **Manns BJ**, Hodzman A, Zimmerman DL, Mendelssohn DC, Soroka SD, Chan C, Jindal K, Klarenbach S. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). *Am J Kidney Dis*. **2010 May**;55(5):800-12.
135. Ravani P, Parfrey P, MacRae J, James M, Quinn R, Malberti F, Brunori G, Mandolfo S, Tonelli M, Hemmelgarn B, **Manns BJ**, Barrett B. Modeling survival of arteriovenous accesses for hemodialysis: semiparametric versus parametric methods. *Clin J Am Soc Nephrol*. 2010 Jul;5(7):1243-8. Epub **2010 Apr 22**.
136. Khangura J, Culleton BF, **Manns BJ**, Zhang J, Barnieh L, Walsh M, Klarenbach SW, Tonelli M, Sarna M, Hemmelgarn BR; Alberta Kidney Disease Network. Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis. *BMC Nephrol*. **2010 Jun 24**;11:13.
137. Klarenbach S, **Manns BJ**, Reiman T, Reaume MN, Lee H, Lloyd A, Wiebe N, Hemmelgarn B, Tonelli M. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer. *Cancer*. **2010 Jul 1**;116(13):3224-32.
138. Barnieh L, McLaughlin K, **Manns BJ**, Klarenbach S, Yilmaz S, Hemmelgarn BR; For the Alberta Kidney Disease Network. Barriers to living kidney donation identified by eligible candidates with end-stage renal disease. *Nephrol Dial Transplant*. **2010 Jul 5**.
139. Schorr M, **Manns BJ**, Culleton B, Walsh M, Klarenbach S, Tonelli M, Sauve L, Chin R, Barnieh L, Hemmelgarn BR; the Alberta Kidney Disease Network. The Effect of Nocturnal and Conventional Hemodialysis on Markers of Nutritional Status: Results From a Randomized Trial. *J Ren Nutr*. **2010 Jul 20**. [Epub ahead of print]



140. Rucker D, Hemmelgarn BR, Lin M, **Manns BJ**, Klarenbach SW, Ayyalasomayajula B, James MT, Bello A, Gordon D, Jindal KK, Tonelli M. Quality of care and mortality are worse in chronic kidney disease patients living in remote areas. *Kidney Int.* 2011 Jan; 79(2):210-17. Epub **2010 Oct 6**.
141. Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, **Manns BJ**. An economic evaluation of erythropoiesis-stimulating agents in CKD. *Am J Kidney Dis.* 2010 Dec; 56(6):1050-61. Epub **2010 Oct 8**.
142. **Manns BJ**, Hemmelgarn B, Tonelli M, Chiasson C, Au F, Dong J, Klarenbach S. Population based screening for chronic kidney disease: cost effectiveness study. *BMJ* **2010, Nov 8**;341:c5869
143. James MT, Hemmelgarn BR, Wiebe N, Pannu N, **Manns BJ**, Klarenbach SW, Tonelli M; Alberta Kidney Disease Network. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. *Lancet.* 2010 Dec 18;376(9758):2096-103. Epub **2010 Nov 20**.
144. Heitman SJ, Au F, **Manns BJ**, Pattison P, Hilsden RJ. Nonmedical costs of colorectal cancer screening using CT colonography. *J Am Coll Radiol.* **2010 Dec, 7** (12):943-8.
145. Tonelli M, Muntner P, Lloyd A, **Manns BJ**, James M, Klarenbach S, Quinn R, Wiebe N, Hemmelgarn B. Using proteinuria and estimated glomerular filtration rate to classify risk in people with chronic kidney disease. *Ann Intern Med* **2011**; 4;154(1):12-21
146. Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, **Manns BJ**, Holden RM, LeBlanc M, Faris P, Barre P, Zhang J, Scott-Douglas N. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. *N Engl J Med* **2011**;364:303-12.
147. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, **Manns BJ**, Klarenbach SW, Hemmelgarn BR. Association between acute kidney injury and cardiovascular and renal outcomes after coronary angiograph. *Circulation.* **2011** 123(4): 409-416.
148. Barnieh L, **Manns BJ**, Klarenbach S, McLaughlin K, Yilmaz S, Hemmelgarn BR. A description of the costs of living and standard criteria deceased donor kidney transplantation. *Am J Transplant.* **2011 Mar**;11(3):478-88.
149. Barnieh L, McLaughlin K, **Manns BJ**, Klarenbach S, Yilmaz S, Taub K, Hemmelgarn BR; Alberta Kidney Disease Network. Evaluation of an education intervention to increase the pursuit of living kidney donation: a randomized controlled trial. *Prog Transplant.* **2011 Mar**;21(1):36-42.

150. Tonelli M, **Manns BJ**. Supplementing creatinine-based estimates of risk in chronic kidney disease: is it time? *JAMA*. **2011 Apr 20**;305(15):1593-5.
151. **Manns BJ**, Quinn RR. Early dialysis of no benefit to the patient or the health care system. *Am J Kidney Dis*. **2011 May**;57(5):649-50.
152. Bello AK, Hemmelgarn B, Lloyd A, James MT, **Manns BJ**, Klarenbach S, Tonelli M; Alberta Kidney Disease Network. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. *Clin J Am Soc Nephrol*. **2011 Jun**;6(6):1418-26.
153. Mendelssohn DC, **Manns BJ**. A Proposal for Improving Evidence Generation in Nephrology. *Am J Kidney Dis*. **2011 Jul**;58(1):13-8.
154. Padwal R, Klarenbach S, Wiebe N, Birch D, Karmali S, **Manns BJ**, Hazel M, Sharma AM, Tonelli M. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. *Obes Rev*. **2011 Aug**;12(8):602-21.
155. Tonelli M, Klarenbach SW, Lloyd AM, James MT, Bello AK, **Manns BJ**, Hemmelgarn BR. Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria. *Kidney Int*. **2011 Dec**;80(12):1306-14.
156. Clement FM, James MT, Chin R, Klarenbach SW, **Manns BJ**, Quinn RR, Ravani P, Tonelli M, Hemmelgarn BR; Alberta Kidney Disease Network. Validation of a case definition to define chronic dialysis using outpatient administrative data. *BMC Med Res Methodol*. **2011 Mar 1**;11:25.
157. Ronksley PE, Hemmelgarn BR, Heitman SJ, Flemons WW, Ghali WA, **Manns BJ**, Faris P, Tsai WH. Excessive daytime sleepiness is associated with increased health care utilization among patients referred for assessment of OSA. *Sleep*. **2011 Mar 1**;34(3):363-70.
158. McAlister FA, Zhang J, Tonelli M, Klarenbach S, **Manns BJ**, Hemmelgarn BR; on behalf of the Alberta Kidney Disease Network. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. *CMAJ*. **2011 Apr 5**;183(6):655-662.
159. Ahmed SB, Ronksley PE, Hemmelgarn BR, Tsai WH, **Manns BJ**, Tonelli M, Klarenbach SW, Chin R, Clement FM, Hanly PJ. Nocturnal hypoxia and loss of kidney function. *PLoS One*. **2011 Apr 29**;6(4):e19029.
160. Ayyalasomayajula B, Wiebe N, Hemmelgarn BR, Bello A, **Manns BJ**, Klarenbach S, Tonelli M. A Novel Technique to Optimize Facility Locations of New Nephrology

- Services for Remote Areas. *Clin J Am Soc Nephrol*. 2011 Sep.6(9):2157-64. **Epub 2011 Aug 4.**
161. Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, **Manns BJ**; Alberta Kidney Disease Network. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. *CMAJ*. 2011 Nov 8;183(16):E1180-8. **Epub 2011 Oct 11.**
  162. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, **Manns BJ**; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. *CMAJ*. 2011 Nov 8;183(16):E1189-202. **Epub 2011 Oct 11.** Review.
  163. Ronksley PE, Tonelli M, Quan H, **Manns BJ**, James MT, Clement FM, Samuel S, Quinn RR, Ravani P, Brar SS, Hemmelgarn BR; For the Alberta Kidney Disease Network. Validating a case definition for chronic kidney disease using administrative data. *Nephrol Dial Transplant*. **2011 Oct 19.** [Epub ahead of print]
  164. Padwal R, Klarenbach S, Wiebe N, Hazel M, Birch D, Karmali S, Sharma AM, **Manns BJ**, Tonelli M. Bariatric Surgery: A Systematic Review of the Clinical and Economic Evidence. *J Gen Intern Med*. **2011 Oct. 26** (10): 1183-94.
  165. Bello A, Thompson S, Lloyd A, Hemmelgarn B, Klarenbach S, **Manns BJ**, Tonelli M; Alberta Kidney Disease Network. Multiple Versus Single and Other Estimates of Baseline Proteinuria Status as Predictors of Adverse Outcomes in the General Population. *Am J Kidney Dis*. **2011 Nov 4.**
  166. Conley J, Tonelli M, Quan H, **Manns BJ**, Palacios-Derflingher L, Bresee LC, Khan N, Hemmelgarn BR; Alberta Kidney Disease Network. Association Between GFR, Proteinuria, and Adverse Outcomes Among White, Chinese, and South Asian Individuals in Canada. *Am J Kidney Dis*. **2011 Nov 23.** [Epub ahead of print]
  167. Clement FM, Ghali WA, Rinfret S, **Manns BJ**; the APPROACH Investigators. Economic evaluation of increasing population rates of cardiac catheterization. *BMC Health Serv Res*. **2011 Nov 24**;11(1):324.
  168. Clement FM, **Manns BJ**, Brownell B, Faris PD, Graham MM, Humphries K, Love M, Knudtson ML, Ghali WA; the APPROACH Investigators. A multi-region assessment of population rates of cardiac catheterization and yield of high-risk coronary artery disease. *BMC Health Serv Res*. **2011 Nov 24**;11(1):323.
  169. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, **Manns BJ**, Bello A, James M, Turin TC, Tonelli M; Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic

- kidney disease a population-based cohort study. *Arch Intern Med.* **2011 Nov** **28**;171(21):1920-7.
170. Wiebe N, Klarenbach SW, Chui B, Ayyalasomayajula B, Hemmelgarn BR, Jindal K, **Manns BJ**, Tonelli M; on behalf of the Alberta Kidney Disease Network. Adding Specialized Clinics for Remote-Dwellers with Chronic Kidney Disease: A Cost-Utility Analysis. *Clin J Am Soc Nephrol.* **2012 Jan**;7(1):24-34.
  171. **Manns BJ**, Tonelli M. The new FDA labeling for ESA--implications for patients and providers. *Clin J Am Soc Nephrol.* **2012 Feb**;7(2):348-53.
  172. **Manns B**, Tonelli M, Culleton B, Faris P, McLaughlin K, Chin R, Gooch K, McAlister FA, Taub K, Thorlacius L, Krause R, Kearns M, Hemmelgarn B; Alberta Kidney Disease Network. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. *Clin J Am Soc Nephrol.* **2012 Apr**;7(4):565-72.
  173. Krahn AD, Morillo CA, Kus T, **Manns BJ**, Rose S, Brignole M, Sheldon RS. Empiric pacemaker compared with a monitoring strategy in patients with syncope and bifascicular conduction block--rationale and design of the Syncope: Pacing or Recording in The Later Years (SPRITELY) study. *Europace.* **2012 Jul**;14(7):1044-8.
  174. Turin TC, Tonelli M, **Manns BJ**, Ravani P, Ahmed SB, Hemmelgarn BR. Chronic kidney disease and life expectancy. *Nephrol Dial Transplant.* **2012 Aug**;27(8):3182-6.
  175. Turin TC, Tonelli M, **Manns BJ**, Ahmed SB, Ravani P, James M, Hemmelgarn BR. Lifetime risk of ESRD. *J Am Soc Nephrol.* **2012 Sep**;23(9):1569-78.
  176. Bello A, Hemmelgarn B, **Manns B**, Tonelli M; Alberta Kidney Disease Network. Use of administrative databases for health-care planning in CKD. *Nephrol Dial Transplant.* **2012 Oct**;27 Suppl 3:iii12-8.
  177. Bello AK, Hemmelgarn B, Lin M, **Manns B**, Klarenbach S, Thompson S, James M, Tonelli M; for the Alberta Kidney Disease Network. Impact of remote location on quality care delivery and relationships to adverse health outcomes in patients with diabetes and chronic kidney disease. *Nephrol Dial Transplant.* **2012 Oct**;27(10):3849-3855.
  178. Hemmelgarn BR, **Manns BJ**, Tonelli M; Interdisciplinary Chronic Disease Collaboration. A Decade After the KDOQI CKD Guidelines: A Perspective From Canada. *Am J Kidney Dis.* **2012 Nov**;60(5):723-4.
  179. Heitman SJ, Hilsden RJ, Au F, Dowden S, **Manns BJ**. Correction: Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation. *PLoS Med.* **2012 Nov**;9(11).

180. Hemmelgarn BR, **Manns BJ**, Straus S, Naugler C, Holroyd-Leduc J, Braun TC, Levin A, Klarenbach S, Lee PF, Hafez K, Schwartz D, Jindal K, Ervin K, Bello A, Turin TC, McBrien K, Elliott M, Tonelli M, Collaboration ICDC. Knowledge translation for nephrologists: strategies for improving the identification of patients with proteinuria. *J Nephrol.* **2012 Nov-Dec**;25(6):933-43.
181. Thompson S, Hemmelgarn B, Wiebe N, Majumdar S, Klarenbach S, Jindal K, **Manns B**, Mortis G, Campbell P, Tonelli M; Alberta Kidney Disease Network. Clinical decision support to improve blood pressure control in hemodialysis patients: a nonrandomized controlled trial. *J Nephrol.* **2012 Nov-Dec**;25(6):944-53.
182. Barnieh L, Klarenbach S, Gill JS, Caulfield T, **Manns B**. Attitudes Toward Strategies to Increase Organ Donation: Views of the General Public and Health Professionals. *Clin J Am Soc Nephrol.* **2012 Dec**;7(12):1956-63
183. **Manns BJ**, Tonelli M, Zhang J, Campbell DJ, Sargious P, Ayyalasomayajula B, Clement F, Johnson JA, Laupacis A, Lewanczuk R, McBrien K, Hemmelgarn BR. Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes. *CMAJ.* **2012 Feb 7**;184(2):E144-52
184. Stelfox HT, Hemmelgarn BR, Bagshaw SM, Gao S, Doig CJ, Nijssen-Jordan C, **Manns BJ**. Intensive care unit bed availability and outcomes for hospitalized patients with sudden clinical deterioration. *Arch Intern Med.* **2012 Mar 26**;172(6):467-74.
185. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, **Manns B**, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. *Lancet.* **2012 Jun 16**;379(9833):2252-61.
186. Hemmelgarn BR, James MT, **Manns BJ**, O'Hare AM, Muntner P, Ravani P, Quinn RR, Turin TC, Tan Z, Tonelli M; Alberta Kidney Disease Network. Rates of treated and untreated kidney failure in older vs younger adults. *JAMA.* **2012 Jun 20**;307(23):2507-15.
187. Bass A, Ahmed SB, Klarenbach S, Culleton B, Hemmelgarn BR, **Manns B**. The impact of nocturnal hemodialysis on sexual function. *BMC Nephrol.* **2012 Jul 26**;13:67.
188. **Manns B**, Laupland K, Tonelli M, Gao S, Hemmelgarn B. Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: A time series analysis. *BMC Health Serv Res.* **2012 Aug 30**;12:290.
189. Tonelli M, Muntner P, Lloyd A, **Manns BJ**, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of coronary events in people

- with chronic kidney disease compared with those with diabetes: a population-level cohort study. *Lancet*. **2012 Sep 1**;380(9844):807-14.
190. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, Tonelli M, Leiter LA, Klarenbach SW, **Manns BJ**. Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. *Arch Intern Med*. **2012 Sep 24**;172(17):1296-303.
  191. Turin TC, Tonelli M, **Manns BJ**, Ahmed SB, Ravani P, James M, Hemmelgarn BR. Proteinuria and Life Expectancy. *Am J Kidney Dis*. **2012 Dec 7**.
  192. Tong A, Palmer S, **Manns B**, Craig JC, Ruospo M, Gargano L, Johnson DW, Hegbrant J, Olsson M, Fishbane S, Strippoli GF. Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. *BMJ Open*. **2012 Dec 12**;2(6).
  193. Chui BK, **Manns B**, Pannu N, Dong J, Wiebe N, Jindal K, Klarenbach SW. Health Care Costs of Peritoneal Dialysis Technique Failure and Dialysis Modality Switching. *Am J Kidney Dis*. **2013 Jan**;61(1):104-11.
  194. Ravani P, Palmer SC, Oliver MJ, Quinn RR, Macrae JM, Tai DJ, Pannu NI, Thomas C, Hemmelgarn BR, Craig JC, **Manns B**, Tonelli M, Strippoli GF, James MT. Associations between Hemodialysis Access Type and Clinical Outcomes: A Systematic Review. *J Am Soc Nephrol*. **2013 Feb**;24(3):465-73.
  195. Campbell DJ, Sargious P, Lewanczuk R, McBrien K, Tonelli M, Hemmelgarn B, **Manns B**. Use of chronic disease management programs for diabetes: In Alberta's primary care networks. *Can Fam Physician*. **2013 Feb**;59(2):e86-92.
  196. McBrien KA, **Manns BJ**. Haemodiafiltration: not effective or cost-effective compared with haemodialysis. *Nephrol Dial Transplant*. **2013 April**
  197. Tonelli M, Muntner P, Lloyd A, **Manns B**, Klarenbach S, Pannu N, James M, Hemmelgarn B; Alberta Kidney Disease Network. Association between LDL-C and Risk of Myocardial Infarction in CKD. *J Am Soc Nephrol*. 2013 May;24(6):979-86. **Epub 2013 May**.
  198. McBrien KA, **Manns BJ**, Chui B, Klarenbach SW, Rabi D, Ravani P, Hemmelgarn B, Wiebe N, Au F, Clement F. Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function. *Diabetes Care*. **2013 May**;36(5):1172-80.
  199. Elliott MJ, James MT, Quinn RR, Ravani P, Tonelli M, Palacios-Derflingher L, Tan Z, **Manns BJ**, Kline GA, Ronksley PE, Hemmelgarn BR. Estimated GFR and Fracture Risk: A Population-Based Study. *Clin J Am Soc Nephrol*. **2013 May**.

200. McBrien KA, **Manns B**. Approach to economic evaluation in primary care: review of a useful tool for primary care reform. *Can Fam Physician*. **2013 Jun**;59(6):619-27.
201. Faruque LI, Hemmelgarn BR, Wiebe N, **Manns BJ**, Ravani P, Klarenbach S, Pelletier R, Tonelli M; Alberta Kidney Disease Network. Factors associated with initiation of chronic renal replacement therapy for patients with kidney failure. *Clin J Am Soc Nephrol*. **2013 Jul**;8(8):1327-35.
202. Schorr M, Hemmelgarn BR, Tonelli M, Soo A, **Manns BJ**, Bresee LC; Alberta Kidney Disease Network. Assessment of Serum Creatinine and Kidney Function among Incident Metformin Users. *Can J Diabetes*. **2013 Aug**;37(4):226-30.
203. Hemmelgarn BR, Zhang J, **Manns BJ**, Tonelli M. Multidisciplinary care and immortal time bias. *Kidney Int*. **2013 Nov**;84(5):1052.
204. Majumdar SR, Hemmelgarn BR, Lin M, McBrien K, **Manns BJ**, Tonelli M. Hypoglycemia Associated With Hospitalization and Adverse Events in Older People: Population-based cohort study. *Diabetes Care*. **2013 Nov**;36(11):3585-90.
205. Bello A, Padwal R, Lloyd A, Hemmelgarn B, Klarenbach S, **Manns B**, Tonelli M; Alberta Kidney Disease Network. Using linked administrative data to study periprocedural mortality in obesity and chronic kidney disease (CKD). *Nephrol Dial Transplant*. **2013 Nov**;28 Suppl 4:iv57-iv64.
206. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, Harwood L, Sood MM, Soroka SD, Bass A, **Manns BJ**. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. *Am J Kidney Dis*. **2013 Nov**;62(5):860-73.
207. Tong A, Palmer S, **Manns B**, Craig JC, Ruospo M, Gargano L, Johnson DW, Hegbrant J, Olsson M, Fishbane S, Strippoli GF. The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study. *BMJ Open*. **2013 Jan 24**;3(1).
208. Ronksley PE, Sanmartin C, Quan H, Ravani P, Tonelli M, **Manns B**, Hemmelgarn BR. Association between perceived unmet health care needs and risk of adverse health outcomes among patients with chronic medical conditions. *Open Med*. **2013 Feb 26**;7(1):e21-30. Print 2013.
209. Deved V, Jette N, Quan H, Tonelli M, **Manns B**, Soo A, Barnabe C, Hemmelgarn BR; for the Alberta Kidney Disease Network. Quality of Care for First Nations and Non-First Nations People with Diabetes. *Clin J Am Soc Nephrol*. **2013 Feb 28**.

210. Thompson S, Bello A, Wiebe N, **Manns B**, Hemmelgarn B, Klarenbach S, Pelletier R, Tonelli M; Alberta Kidney Disease Network. Quality-of-Care Indicators Among Remote-Dwelling Hemodialysis Patients: A Cohort Study. *Am J Kidney Dis.* **2013 Mar 18**
211. Turin TC, James M, Ravani P, Tonelli M, **Manns BJ**, Quinn R, Jun M, Klarenbach S, Hemmelgarn BR. Proteinuria and Rate of Change in Kidney Function in a Community-Based Population. *J Am Soc Nephrol.* **2013 Jul 5.** [Epub ahead of print]
212. James MT, Tonelli M, Ghali WA, Knudtson ML, Faris P, **Manns BJ**, Pannu N, Galbraith PD, Hemmelgarn BR; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) and Alberta Kidney Disease Network Investigators. Renal outcomes associated with invasive versus conservative management of acute coronary syndrome: propensity matched cohort study. *BMJ.* **2013 Jul 5;**347:f4151.
213. Ravani P, Gillespie BW, Quinn RR, Macrae J, **Manns B**, Mendelssohn D, Tonelli M, Hemmelgarn B, James M, Pannu N, Robinson BM, Zhang X, Pisoni R. Temporal Risk Profile for Infectious and Noninfectious Complications of Hemodialysis Access. *J Am Soc Nephrol.* **2013 Jul 11.** [Epub ahead of print]
214. Wong BC, Ravani P, **Manns BJ**, Lewin A, Zhang X, Chin R, Hemmelgarn BR, Tonelli M, Oliver MJ, Quinn RR. Association of a Change in Erythropoiesis-Stimulating Agent Dose During Hospitalization and Subsequent Hemoglobin Levels and Transfusions in Hemodialysis Patients. *Am J Kidney Dis.* **2013 Jul 12.** [Epub ahead of print]
215. Tang KL, Ghali WA, **Manns BJ.** Addressing cost-related barriers to prescription drug use in Canada. *CMAJ.* **2013 Sep 16.** [Epub ahead of print]
216. Ronksley PE, Ravani P, Sanmartin C, Quan H, **Manns B**, Tonelli M, Hemmelgarn BR. Patterns of engagement with the health care system and risk of subsequent hospitalization among patients with diabetes. *BMC Health Serv Res.* **2013 Oct 9;**13:399.
217. **Manns B**, Braun T, Edwards A, Grimshaw J, Hemmelgarn B, Husereau D, Ivers N, Johnson J, Long S, McBrien K, Naugler C, Sargious P, Straus S, Tonelli M, Tricco A, Yu C for the Alberta Innovates – Health Solutions Interdisciplinary Chronic Disease Collaboration. Identifying strategies to improve diabetes care in Alberta, Canada using the knowledge-to-action cycle: Results of a collaborative workshop. *CMAJ Open* **2013 Nov 20.**
218. Barnieh L, **Manns B**, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Clement F. A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries. *Value Health.* **2014 Jan;**17(1):98-108.



219. Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H, Hemmelgarn B, **Manns B**. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. *J Am Soc Nephrol*. **2014 Mar**;25(3):587-94.
220. Nesrallah G, Barnieh L, **Manns B**, Clase C, Mendelssohn D, Guyatt G. A charitable donation incentive did not increase physician survey response rates in a randomized trial. *J Clin Epidemiol*. **2014 Apr**;67(4):482-3.
221. Nesrallah G, **Manns B**. Do socioeconomic factors affect dialysis modality selection? *Clin J Am Soc Nephrol*. **2014 May**;9(5):837-9.
222. Sood MM, **Manns B**, Nesrallah G; Canadian Kidney Knowledge Translation, Generation Network. Using the knowledge-to-action framework to guide the timing of dialysis initiation. *Curr Opin Nephrol Hypertens*. **2014 May**;23(3):321-7.
223. Tang KL, Barnieh L, **Mann B**, Clement F, Campbell DJ, Hemmelgarn BR, Tonelli M, Lorenzetti D, Manns BJ. A systematic review of value-based insurance design in chronic diseases. *Am J Manag Care*. **2014 Jun**;20(6):e229-41.
224. Barnieh L, Yilmaz S, McLaughlin K, Hemmelgarn BR, Klarenbach S, **Manns BJ**, For The Alberta Kidney Disease Network. The cost of kidney transplant over time. *Prog Transplant*. **2014 Sep**;24(3):257-62.
225. Negrón ME, Kaplan GG, Barkema HW, Eksteen B, Clement F, **Manns BJ**, Coward S, Panaccione R, Ghosh S, Heitman SJ. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. *Inflamm Bowel Dis*. **2014 Nov**;20(11):2046-55.
226. Klarenbach SW, Tonelli M, Chui B, **Manns BJ**. Economic evaluation of dialysis therapies. *Nat Rev Nephrol*. **2014 Nov**;10(11):644-652.
227. Levin A, Soroka S, Allu S, Au F, Gil S, **Manns B**. Canadian chronic kidney disease clinics: a national survey of structure, function and models of care. *Canadian Journal of Kidney Health and Disease* **2014**, 1: 29.
228. Mann, B, **Manns B**, Dart A, Kappel A, Molzahn A, Naimark D, Nessim S, Soroka S, Zappitelli, M, Sood M, on behalf of CANN-NET. An assessment of dialysis provider's attitudes towards timing of dialysis initiation in Canada. *Canadian Journal of Kidney Health and Disease* **2014**, 1: 3.
229. Samuel SM, Palacios-Derflingher L, Tonelli M, **Manns B**, Crowshoe L, Ahmed SB, Jun M, Saad N, Hemmelgarn BR; Alberta Kidney Disease Network. Association between First Nations ethnicity and progression to kidney failure by presence and severity of albuminuria. *CMAJ*. **2014 Feb** 4;186(2):E86-94.

230. Weaver RG, **Manns BJ**, Tonelli M, Sanmartin C, Campbell DJ, Ronksley PE, Lewanczuk R, Braun TC, Hennessy D, Hemmelgarn BR. Access to primary care and other health care use among western Canadians with chronic conditions: a population-based survey. *CMAJ Open*. **2014 Mar 7**;2(1):E27-34.
231. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, **Manns B**. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. *PLoS One*. **2014 Mar 11**;9(3):e90434.
232. Mann BS, Barnieh L, Tang K, Campbell DJ, Clement F, Hemmelgarn B, Tonelli M, Lorenzetti D, **Manns BJ**. Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. *PLoS One*. **2014 Mar 25**;9(3):e89168.
233. Sood MM, Tangri N, Hiebert B, Kappel J, Dart A, Levin A, **Manns B**, Molzahn A, Naimark D, Nessim SJ, Rigatto C, Soroka SD, Zappitelli M, Komenda P; Canadian Kidney Knowledge Translation; Generation Network. Geographic and facility-level variation in the use of peritoneal dialysis in Canada: a cohort study. *CMAJ Open*. **2014 Mar 27**;2(1):E36-44.
234. Campbell DJ, Ronksley PE, **Manns BJ**, Tonelli M, Sanmartin C, Weaver RG, Hennessy D, King-Shier K, Campbell T, Hemmelgarn BR; Interdisciplinary Chronic Disease Collaboration. The association of income with health behavior change and disease monitoring among patients with chronic disease. *PLoS One*. **2014 Apr 10**;9(4):e94007.
235. Wiebe N, Klarenbach SW, Allan GM, **Manns BJ**, Pelletier R, James MT, Bello A, Hemmelgarn BR, Tonelli M; Alberta Kidney Disease Network. Potentially Preventable Hospitalization as a Complication of CKD: A Cohort Study. *Am J Kidney Dis*. **2014 Apr 12**.
236. Afshar AE, Weaver RG, Lin M, Allan M, Ronksley PE, Sanmartin C, Lewanczuk R, Rosenberg M, **Manns B**, Hemmelgarn B, Tonelli M; Interdisciplinary Chronic Disease Collaboration. Capacity and willingness of patients with chronic noncommunicable diseases to use information technology to help manage their condition: a cross-sectional study. *CMAJ Open*. **2014 Apr 16**;2(2):E51-9.
237. Ronksley PE, Sanmartin C, Campbell DJT, Weaver RG, Allan GM, McBrien K, Tonelli M, **Manns B**, Hennessy D, Hemmelgarn B. Perceived barriers to primary care among Western Canadians with chronic disease. *Health Rep*. **2014 Apr 16**;25(4):3-10.

238. Tonelli M, Muntner P, Lloyd A, **Manns B**, Klarenbach S, Pannu N, James M, Hemmelgarn B; Alberta Kidney Disease Network. Impact of Age on the Association Between CKD and the Risk of Future Coronary Events. *Am J Kidney Dis.* **2014 Apr 18.**
239. **Manns B**, Hemmelgarn B, Lillie E, Dip SC, Cyr A, Gladish M, Large C, Silverman H, Toth B, Wolfs W, Laupacis A. Setting Research Priorities for Patients on or Nearing Dialysis. *Clin J Am Soc Nephrol.* **2014 May 15**
240. Penz ED, Mishra EK, Davies HE, **Manns BJ**, Miller RF, Rahman NM. Comparing Cost of Indwelling Pleural Catheter vs. Talc Pleurodesis for Malignant Pleural Effusion. *Chest.* **2014 May 15.**
241. Campbell DJ, King-Shier K, Hemmelgarn BR, Sanmartin C, Ronksley PE, Weaver RG, Tonelli M, Hennessy D, **Manns BJ**. Self-reported financial barriers to care among patients with cardiovascular-related chronic conditions. *Health Rep.* **2014 May 21;25(5):3-12.**
242. Weaver RG, Hemmelgarn BR, Rabi DM, Sargious PM, Edwards AL, **Manns BJ**, Tonelli M, James MT. Association between participation in a brief diabetes education programme and glycaemic control in adults with newly diagnosed diabetes. *Diabet Med.* **2014 Jun 3.** [Epub ahead of print]
243. Bresee LC, Knudtson ML, Zhang J, Crowshoe LL, Ahmed SB, Tonelli M, Ghali WA, Quan H, **Manns B**, Fabreau G, Hemmelgarn BR; Alberta Kidney Disease Network (AKDN) and the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH). Likelihood of coronary angiography among First Nations patients with acute myocardial infarction. *CMAJ.* **2014 July 8;186(10):E372-80.**
244. **Manns B**, Scott-Douglas N, Tonelli M, Ravani P, LeBlanc M, Dorval M, Holden R, Moist L, Lok C, Zimmerman D, Au F, Hemmelgarn B. An economic evaluation of rt-PA locking solution in dialysis catheters. *JASN* **2014 July 10.** [Epub ahead of print]
245. Ivers N, Tricco AC, Trikalinos TA, Dahabreh IJ, Danko KJ, Moher D, Straus SE, Lavis JN, Yu CH, Shojania K, **Manns B**, Tonelli M, Ramsay T, Edwards A, Sargious P, Paprica A, Hillmer M, Grimshaw JM. Seeing the forests and the trees-innovative approaches to exploring heterogeneity in systematic reviews of complex interventions to enhance health system decision-making: a protocol. *Syst Rev.* **2014 Aug 12;3(1):88.**
246. Turin TC, James MT, Jun M, Tonelli M, Coresh J, Manns BJ, Hemmelgarn BR. Short-term change in eGFR and risk of cardiovascular events. *J Am Heart Assoc.* **2014 Sep 11;3(5).**

247. Campbell DJ, Lacny SL, Weaver RG, **Manns BJ**, Tonelli M, Barnabe C, Hemmelgarn BR. Age modification of diabetes-related hospitalization among First Nations adults in Alberta, Canada. *Diabetol Metab Syndr*. **2014 Oct 2**;6(1):108.
248. Sood MM, **Manns B**, Dart A, Hiebert B, Kappel J, Komenda P, Molzahn A, Naimark D, Nessim S, Rigatto C, Soroka S, Zappitelli M, Tangri N; Canadian Kidney Knowledge Translation and Generation Network (CANN-NET). Variation in the Level of eGFR at Dialysis Initiation across Dialysis Facilities and Geographic Regions. *Clin J Am Soc Nephrol*. **2014 Oct 7**;9(10):1747-56.
249. Barnieh L, Jun M, Laupacis A, **Manns B**, Hemmelgarn B. Determining Research Priorities Through Partnership with Patients: An Overview. *Semin Dial*. **2014 Nov 30**.
250. Wolfger B, **Manns BJ**, Barkema HW, Schwartzkopf-Genswein KS, Dorin C, Orsel K. Evaluating the cost implications of a radio frequency identification feeding system for early detection of bovine respiratory disease in feedlot cattle. *Prev Vet Med*. **2014 Dec 11**.
251. Bello AK, Levin A, **Manns BJ**, Feehally J, Druke T, Faruque L, Hemmelgarn BR, Kernahan C, Mann J, Klarenbach S, Remuzzi G, Tonelli M; Kidney Health for Life Initiative. Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. *Am J Kidney Dis*. **2015 Jan**;65(1):15-25.
252. Akbari A, Clase CM, Acott P, Battistella M, Bello A, Feltmate P, Grill A, Karsanji M, Komenda P, Madore F, **Manns BJ**, Mahdavi S, Mustafa RA, Smyth A, Welcher ES. Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management. *Am J Kidney Dis*. **2015 Feb**;65(2):177-205.
253. **Manns, BJ**. Evidence-based decision-making 7: knowledge translation. *Methods Mol Biol*. **March 2015**;1281:485-500.
254. **Manns, BJ**. Health economics in clinical research. *Methods Mol Biol*. **March 2015**;1281:315-30.
255. Leggett LE, Hauer T, Martin BJ, **Manns B**, Aggarwal S, Arena R, Austford LD, Meldrum D, Ghali W, Knudtson ML, Norris CM, Stone JA, Clement F. Optimizing Value From Cardiac Rehabilitation: A Cost-Utility Analysis Comparing Age, Sex, and Clinical Subgroups. *Mayo Clin Proc*. **2015 Aug**;90(8):1011-20.
256. Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, Klarenbach SW, Sargious P, Straus S, Lewanczuk R, Ronksley PE, **Manns BJ**, Hemmelgarn BR. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. *Kidney Int*. **2015 Oct**;88(4):859-66.

257. Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, **Manns BJ**, Tonelli M, Hemmelgarn BR. Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. *J Am Soc Nephrol*. **2015 Jan 2**. pii: ASN.
258. Tong A, Chando S, Crowe S, **Manns B**, Winkelmayr WC, Hemmelgarn B, Craig JC. Research Priority Setting in Kidney Disease: A Systematic Review. *Am J Kidney Dis*. **2015 Jan 9**.
259. Jun M, James MT, **Manns BJ**, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayr WC, Ma Z, Hemmelgarn BR; Alberta Kidney Disease Network. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. *BMJ*. **2015 Feb 3**;350:h246.
260. Thompson S, James M, Wiebe N, Hemmelgarn B, **Manns B**, Klarenbach S, Tonelli M; for the Alberta Kidney Disease Network. Cause of Death in Patients with Reduced Kidney Function. *J Am Soc Nephrol*. **2015 Mar 2**. pii: ASN.2014070714. [Epub ahead of print]
261. Kelly E, Ivers N, Zawi R, Barnieh L, **Manns B**, Lorenzetti DL, Nicholas D, Tonelli M, Hemmelgarn B, Lewanczuk R, Edwards A, Braun T, McBrien KA. Patient navigators for people with chronic disease: protocol for a systematic review and meta-analysis. *Syst Rev*. **2015 Mar 14**;4:28.
262. James MT, Pannu N, Barry R, Karsanji D, Tonelli M, Hemmelgarn BR, **Manns BJ**, Bagshaw SM, Stelfox HT, Dixon E. A modified Delphi process to identify process of care indicators for the identification, prevention and management of acute kidney injury after major surgery. *Can J Kidney Health Dis*. **2015 Apr 9**;2:11.
263. Tonelli M, Wiebe N, Thompson S, Kinniburgh D, Klarenbach SW, Walsh M, Bello AK, Faruque L, Field C, **Manns BJ**, Hemmelgarn BR; Alberta Kidney Disease Network. Trace element supplementation in hemodialysis patients: a randomized controlled trial. *BMC Nephrol*. **2015 Apr 11**;16:52.
264. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, Klarenbach SW, Lewanczuk R, **Manns BJ**, Ronksley P, Sargious P, Straus S, Quan H; Alberta Kidney Disease Network. Methods for identifying 30 chronic conditions: application to administrative data. *BMC Med Inform Decis Mak*. **2015 Apr 17**;15:31.
265. Tonelli M, Molzahn AE, Wiebe N, Davison SN, Gill JS, Hemmelgarn BR, **Manns BJ**, Pannu N, Pelletier R, Thompson S, Klarenbach SW; Alberta Kidney Disease Network. Relocation of remote-dwellers living with hemodialysis: a time trade-off survey. *Nephrol Dial Transplant*. **2015 Jun 1**. pii: gfv112. [Epub ahead of print]

266. Harrison TG, Wick J, Ahmed SB, Jun M, **Manns BJ**, Quinn RR, Tonelli M, Hemmelgarn BR. Patients with chronic kidney disease and their intent to use electronic personal health records. *Can J Kidney Health Dis.* **2015 Jun 9**;2:23.
267. Tong A, **Manns B**, Hemmelgarn B, Wheeler DC, Tugwell P, Winkelmayr WC, van Biesen W, Crowe S, Kerr PG, Polkinghorne KR, Howard K, Pollock C, Hawley CM, Johnson DW, McDonald SP, Gallagher MP, Urquhart-Secord R, Craig JC; SONG-HD Collaboration. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. *Trials.* **2015 Aug 19**;16:364.
268. Walsh M, **Manns B**, Garg AX, Bueti J, Rabbat C, Smyth A, Tyrwhitt J, Bosch J, Gao P, Devereaux PJ, Wald R. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. *Clin J Am Soc Nephrol.* **2015 Sep 4**;10(9):1602-8.
269. Turin TC, Jun M, James MT, Tonelli M, Coresh J, **Manns BJ**, Hemmelgarn BR. Magnitude of rate of change in kidney function and future risk of cardiovascular events. *Int J Cardiol.* **2015 Sep 28**;202:657-665.
270. Jun M, **Manns B**, Laupacis A, Manns L, Rehal B, Crowe S, Hemmelgarn BR. Assessing the extent to which current clinical research is consistent with patient priorities: a scoping review using a case study in patients on or nearing dialysis. *Can J Kidney Health Dis.* **2015 Oct 1**;2:35.
271. McBrien KA, **Manns BJ**, Hemmelgarn BR, Weaver R, Edwards AL, Ivers N, Rabi D, Lewanczuk R, Braun T, Naugler C, Campbell D, Saad N, Tonelli M. The association between sociodemographic and clinical characteristics and poor glycaemic control: a longitudinal cohort study. *Diabet Med.* **2015 Nov 3**
272. Rigatto C, Walsh M, Zalunardo N, Clase CM, **Manns BJ**, Madore F, Samuel SM, Morgan CJ, Wolfs W, Suri RS. Establishing a Canadian national clinical trials network for kidney disease: proceedings of a planning workshop. *Can J Kidney Health Dis.* **2015 Nov 17**;2:46.
273. Klarenbach S, Lee K, Boucher M, So H, **Manns B**, Tonelli M. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; **2016 Mar**.
274. Raj SR, Faris PD, Semeniuk L, **Manns B**, Krahn AD, Morillo CA, Benditt DG, Sheldon RS; POST5 Investigators. Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). *Am Heart J.* **2016 Apr**;174:89-94

275. McBrien KA, **Manns BJ**, Hemmelgarn BR, Weaver R, Edwards AL, Ivers N, Rabi D, Lewanczuk R, Braun T, Naugler C, Campbell D, Saad N, Tonelli M. The association between sociodemographic and clinical characteristics and poor glycaemic control: a longitudinal cohort study. *Diabet Med.* **2016 Nov**;33(11):1499-1507.
276. Campbell DJ, **Manns BJ**, Leblanc P, Hemmelgarn BR, Sanmartin C, King-Shier K. Finding resiliency in the face of financial barriers: Development of a conceptual framework for people with cardiovascular-related chronic disease *Medicine (Baltimore).* **2016 Dec**;95(49).
277. Urquhart-Secord R, Craig JC, Hemmelgarn B, Tam-Tham H, **Manns B**, Howell M, Polkinghorne KR, Kerr PG, Harris DC, Thompson S, Schick-Makaroff K, Wheeler DC, van Biesen W, Winkelmayr WC, Johnson DW, Howard K, Evangelidis N, Tong A. Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. *Am J Kidney Dis.* **2016 Mar 8.**
278. Hemmelgarn BR, Pannu N, Ahmed SB, Elliott MJ, Tam-Tham H, Lillie E, Straus SE, Donald M, Barnieh L, Chong GC, Hillier DR, Huffman KT, Lei AC, Villanueva BV, Young DM, Fowler EA, **Manns BJ**, Laupacis A. Determining the research priorities for patients with chronic kidney disease not on dialysis. *Nephrol Dial Transplant.* **2016 Apr 15.**
279. Van der Pol M, Hennessy D, **Manns B**. The role of time and risk preferences in adherence to physician advice on health behavior change. *Eur J Health Econ.* **2016 Apr 16**
280. Thompson S, **Manns B**, Lloyd A, Hemmelgarn B, MacRae J, Klarenbach S, Unsworth L, Courtney M, Tonelli M. Impact of using two dialyzers in parallel on phosphate clearance in hemodialysis patients: a randomized trial. *Nephrol Dial Transplant.* **2016 Apr 21.**
281. Devoe DJ, Wong B, James MT, Ravani P, Oliver MJ, Barnieh L, Roberts DJ, Pauly R, **Manns BJ**, Kappel J, Quinn RR. Patient Education and Peritoneal Dialysis Modality Selection: A Systematic Review and Meta-analysis. *Am J Kidney Dis.* **2016 Apr 26.**
282. Ward DR, **Manns B**, Gil S, Au F, Kappel JE. Results of the 2014-2015 Canadian Society of Nephrology workforce survey. *Can J Kidney Health Dis.* **2016 May 12**;3:25.
283. Tong A, Budde K, Gill J, Josephson MA, Marson L, Pruettt TL, Reese PP, Rosenbloom D, Rostaing L, Warrens AN, Wong G, Craig JC, Crowe S, Harris T, Hemmelgarn B, **Manns B**, Tugwell P, Van Biesen W, Wheeler DC, Winkelmayr WC, Evangelidis N, Sautenet B, Howell M, Chapman JR. Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. *Transplant Direct.* **2016 May 19**;2(6):e79.

284. Elliott MJ, Gil S, Hemmelgarn BR, **Manns BJ**, Tonelli M, Jun M, Donald M. A scoping review of adult chronic kidney disease clinical pathways for primary care. *Nephrol Dial Transplant*. **2016 Jun 2**.
285. Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, Haynes R, **Manns B**, Perkovic V, Rabbat CG, Wald R, Walsh M. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. *Am J Kidney Dis*. **2016 Jun 3**.
286. Rash JA, Lavoie KL, Sigal RJ, Campbell DJ, **Manns BJ**, Tonelli M, Campbell TS. The OPTIMIZE trial: Rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. *Contemp Clin Trials*. **2016 Jun 6**;49:47-56.
287. Galbraith LE, Ronksley PE, Barnieh LJ, Kappel J, **Manns BJ**, Samuel SM, Jun M, Weaver R, Valk N, Hemmelgarn BR. The See Kidney Disease Targeted Screening Program for CKD. *Clin J Am Soc Nephrol*. **2016 Jun 6**;11(6):964-72
288. Campbell DJ, **Manns BJ**, Hemmelgarn BR, Sanmartin C, King-Shier KM. Development of a conceptual framework for understanding financial barriers to care among patients with cardiovascular-related chronic disease: a protocol for a qualitative (grounded theory) study. *CMAJ Open*. **2016 Jun 8**;4(2):E304-8.
289. Hennessey D, Sanmartin C, Ronksley P, Weaver R, Campbell D, **Manns B**, Tonelli M, Hemmelgarn B. Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease. *Health Rep*. **2016 Jun 15**;27(6):3-8.
290. Saban JA, Zappitelli M, Samuel SM, Sood MM, Alexander RT, Arora S, Erickson RL, Kroeker K, **Manns BJ**, Dart AB. Perceptions of pediatric nephrologists regarding timing of dialysis initiation in children in Canada. *Can J Kidney Health Dis*. **2016 Jul 1**;3:31.
291. Leal JR, Heitman SJ, Conly JM, Henderson EA, **Manns BJ**. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. *Infect Control Hosp Epidemiol*. **2016 Jul 5**:1-8.
292. Galbraith L, Hemmelgarn B, **Manns B**, Samuel S, Kappel J, Valk N, Ronksley P. The association between individual counselling and health behaviour change: the See Kidney Disease (SeeKD) targeted screening programme for chronic kidney disease. *Can J Kidney Health Dis*. **2016 Jul 20**;3:35.



293. Tong A, Samuel S, Zappitelli M, Dart A, Furth S, Eddy A, Groothoff J, Webb NJ, Yap HK, Bockenbauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Hanson CS, Evangelidis N, Crowe S, Harris T, Hemmelgarn BR, **Manns B**, Gill J, Tugwell P, Van Biesen W, Wheeler DC, Winkelmayr WC, Craig JC; SONG-Kids Investigators. Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. *Trials*. **2016 Aug 12**;17:401.
294. Donald M, McBrien K, Jackson W, **Manns BJ**, Tonelli M, King-Shier K, Jindal K, Lewanczuk RZ, Scott-Douglas N, Braun T, Straus SE, Naugler C, Elliott MJ, Jun M, Hemmelgarn BR. Development and implementation of an online clinical pathway for adult chronic kidney disease in primary care: a mixed methods study. *BMC Med Inform Decis Mak*. **2016 Aug 17**;16:109.
295. Tonelli M, Lloyd A, Pannu N, Klarenbach S, Ravani P, Jindal K, MacRae J, Unsworth L, **Manns B**, Hemmelgarn B. Extracellular fluid management and hypertension in urban dwelling versus rural dwelling hemodialysis patients. *J Nephrol*. **2016 Aug 23**. [Epub ahead of print]
296. Elliott MJ, Straus SE, Pannu N, Ahmed SB, Laupacis A, Chong GC, Hillier DR, Huffman KT, Lei AC, Villanueva BV, Young DM, Tam-Tham H, Donald M, Lillie E, **Manns BJ**, Hemmelgarn BR. A randomized controlled trial comparing in-person and wiki-inspired nominal group techniques for engaging stakeholders in chronic kidney disease research prioritization. *BMC Med Inform Decis Mak*. **2016 Aug 24**;16:113.
297. Chau EM, **Manns BJ**, Garg AX, Sood MM, Kim SJ, Naimark D, Nesrallah GE, Soroka SD, Beaulieu M, Dixon S, Alam A, Tangri N; Canadian Kidney Knowledge Translation and Generation Network (CANN-NET). Knowledge Translation Interventions to Improve the Timing of Dialysis Initiation: Protocol for a Cluster Randomized Trial. *Can J Kidney Health Dis*. **2016 Sep 14**;3:2054358116665257. doi: 10.1177/2054358116665257. eCollection 2016
298. Campbell DJ, Tonelli M, Hemmelgarn B, Mitchell C, Tsuyuki R, Ivers N, Campbell T, Pannu R, Verkerke E, Klarenbach S, King-Shier K, Faris P, Exner D, Chaubey V, **Manns B**; Interdisciplinary Chronic Disease Collaboration. Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2×2 factorial randomized trial. *Implement Sci*. **2016 Sep 26**;11(1):131.
299. Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, **Manns BJ**, Tonelli M; Alberta Kidney Disease Network.. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. *CMAJ*. **2016 Oct 31**.

300. Turin TC, Saad N, Jun M, Tonelli M, Ma Z, Barnabe CC, **Manns B**, Hemmelgarn B. Lifetime risk of diabetes among First Nations and non-First Nations people. *CMAJ*. **2016 Nov 1**;188(16):1147-1153.
301. Ronksley PE, Hemmelgarn BR, **Manns BJ**, Wick J, James MT, Ravani P, Quinn RR, Scott-Douglas N, Lewanczuk R, Tonelli M. Potentially Preventable Hospitalization among Patients with CKD and High Inpatient Use. *Clin J Am Soc Nephrol*. **2016 Nov 7**;11(11):2022-2031.
302. Wick JP, Turin TC, Faris PD, MacRae JM, Weaver RG, Tonelli M, **Manns BJ**, Hemmelgarn BR. A Clinical Risk Prediction Tool for 6-Month Mortality After Dialysis Initiation Among Older Adults. *Am J Kidney Dis*. **2016 Nov 14**. (16)30553-4. [Epub ahead of print]
303. Ganesh A, King-Shier K, **Manns BJ**, Hill MD, Campbell DJ. Money is Brain: Financial Barriers and Consequences for Canadian Stroke Patients. *Can J Neurol Sci*. **2016 Nov 21**:1-6. [Epub ahead of print]
304. Olfert JA, Penz ED, **Manns BJ**, Mishra EK, Davies HE, Miller RF, Luengo-Fernandez R, Gao S, Rahman NM. Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion. *Respirology*. **2016 Dec 16**. [Epub ahead of print]
305. Jun M, James MT, Ma Z, Zhang J, Tonelli M, McAlister FA, **Manns BJ**, Ravani P, Quinn RR, Wiebe N, Perkovic V, Wilton SB, Winkelmayr WC, Hemmelgarn BR; Alberta Kidney Disease Network. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. *Am J Kidney Dis*. **2016 Dec 17**.
306. Tong A, **Manns B**, Hemmelgarn B, Wheeler DC, Evangelidis N, Tugwell P, Crowe S, Van Biesen W, Winkelmayr WC, O'Donoghue D, Tam-Tham H, Shen JI, Pinter J, Larkins N, Youssouf S, Mandayam S, Ju A, Craig JC; SONG-HD Investigators. Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop. *Am J Kidney Dis*. **2017 Jan**;69(1):97-107.
307. Campbell DJ, Tam-Tham H, Dhaliwal KK, **Manns BJ**, Hemmelgarn BR, Sanmartin C, King-Shier K. Use of Mixed Methods Research in Research on Coronary Artery Disease, Diabetes Mellitus, and Hypertension: A Scoping Review. *Circ Cardiovasc Qual Outcomes*. **2017 Jan**;10(1).
308. Campbell DJ, **Manns BJ**, Hemmelgarn BR, Sanmartin C, Edwards A, King-Shier K. Understanding Financial Barriers to Care in Patients With Diabetes. *Diabetes Educ*. **2017 Feb**;43(1):78-86

309. Dart AB, Zappitelli M, Sood MM, Alexander RT, Arora S, Erickson RL, Kroeker K, Soo A, **Manns BJ**, Samuel SM. Variation in estimated glomerular filtration rate at dialysis initiation in children. *Pediatr Nephrol*. **2017 Feb**;32(2):331-340.
310. Mann BS, **Manns BJ**, Barnieh L, Oliver MJ, Devoe D, Lorenzetti D, Pauly R, Quinn RR. Peritoneal Dialysis: A Scoping Review of Strategies to Maximize PD Utilization. *Perit Dial Int*. **2017 Mar-Apr**;37(2):159-164. doi: 10.3747/pdi.2016.00057. Review.
311. Sinclair A, Cimon K, Loncar M, Sood M, Komenda P, Severn M, Klarenbach S, So H, Tsoi B, Quinn R, Pauly R, Tonelli M, **Manns B**, Rader T, Moulton K, Moulton K, Helis E, Crain J, Pullman D. Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; **2017 Mar**. PMID: 30325617
312. Klarenbach S, So H, **Manns B**, Tonelli M. Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non-Orthopedic Surgical Patients [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; **2017 Apr**. PMID: 29384616
313. Wick J, Hemmelgarn B, **Manns B**, Tonelli M, Quan H, Lewanczuk R, Ronksley P. Comparison of Methods to Define High Use of Inpatient Services Using Population-Based Data. *J Hosp Med*. **2017 Aug**;12(8):596-602. doi: 10.12788/jhm.2778. PMID: 28786424
314. Wald R, Rabbat CG, Girard L, Garg AX, Tennankore K, Tyrwhitt J, Smyth A, Rathe-Skafel A, Gao P, Mazzetti A, Bosch J, Yan AT, Parfrey P, **Manns BJ**, Walsh M. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. *Clin J Am Soc Nephrol*. **2017 May 26**. pii: CJN.10941016. doi: 10.2215/CJN.10941016. [Epub ahead of print]
315. Chew DS, **Manns B**, Miller RJH, Sharma N, Exner DV. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation. *Can J Cardiol*. 2017 Oct;33(10):1283-1291. doi:10.1016/j.cjca.2017.07.012. **Epub 2017 Jul 21**. PMID: 28941608
316. Tonelli M, Wiebe N, Bello A, Field CJ, Gill JS, Hemmelgarn BR, Holmes DT, Jindal K, Klarenbach SW, **Manns BJ**, Thadhani R, Kinniburgh D; Alberta Kidney Disease Network. Concentrations of Trace Elements in Hemodialysis Patients: A Prospective Cohort Study. *Am J Kidney Dis*. 2017 Nov;70(5):696-704. doi: 10.1053/j.ajkd.2017.06.029. **Epub 2017 Aug 31**. PMID: 28838766
317. Trachtenberg AJ, **Manns B**. Cost analysis of medical assistance in dying in Canada. *CMAJ*. **2017 Jan 23**;189(3):E101-E105. doi: 10.1503/cmaj.160650.

318. Ronksley PE, Tonelli M, **Manns BJ**, Weaver RG, Thomas CM, MacRae JM, Ravani P, Quinn RR, James MT, Lewanczuk R, Hemmelgarn BR. Emergency Department Use among Patients with CKD: A Population-Based Analysis. *Clin J Am Soc Nephrol*. **2017 Feb 7**;12(2):304-314
319. Dhaliwal KK, King-Shier K, **Manns BJ**, Hemmelgarn BR, Stone JA, Campbell DJ. Exploring the impact of financial barriers on secondary prevention of heart disease. *BMC Cardiovasc Disord*. **2017 Feb 14**;17(1):61. doi: 10.1186/s12872-017-0495-4
320. Campbell DJ, **Manns BJ**, Weaver RG, Hemmelgarn BR, King-Shier KM, Sanmartin C. Financial barriers and adverse clinical outcomes among patients with cardiovascular-related chronic diseases: a cohort study. *BMC Med*. **2017 Feb 15**;15(1):33. doi: 10.1186/s12916-017-0788-6.
321. Tong A, Winkelmayr WC, Wheeler DC, van Biesen W, Tugwell P, **Manns B**, Hemmelgarn B, Harris T, Crowe S, Ju A, O'Lone E, Evangelidis N, Craig JC; SONG-HD Initiative. Nephrologists' Perspectives on Defining and Applying Patient-Centered Outcomes in Hemodialysis. *Clin J Am Soc Nephrol*. 2017 Mar 7;12(3):454-466. doi: 10.2215/CJN.08370816. **Epub 2017 Feb 21**
322. Evangelidis N, Tong A, **Manns B**, Hemmelgarn B, Wheeler DC, Tugwell P, Crowe S, Harris T, Van Biesen W, Winkelmayr WC, Sautenet B, O'Donoghue D, Tam-Tham H, Youssouf S, Mandayam S, Ju A, Hawley C, Pollock C, Harris DC, Johnson DW, Rifkin DE, Tentori F, Agar J, Polkinghorne KR, Gallagher M, Kerr PG, McDonald SP, Howard K, Howell M, Craig JC; Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Initiative. Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. *Am J Kidney Dis*. **2017 Feb 23**. pii: S0272-6386(17)30035-5. doi: 10.1053/j.ajkd.2016.11.029. [Epub ahead of print]
323. Chan E, Hemmelgarn B, Klarenbach S, **Manns B**, Mustafa R, Nesrallah G, McQuillan R. Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question. *Can J Kidney Health Dis*. **2017 Feb 28**;4:2054358117695570. doi: 10.1177/2054358117695570. eCollection 2017.
324. Bello AK, Molzahn AE, Girard LP, Osman MA, Okpechi IG, Glassford J, Thompson S, Keely E, Liddy C, **Manns B**, Jinda K, Klarenbach S, Hemmelgarn B, Tonelli M. Patient and provider perspectives on the design and implementation of an electronic consultation system for kidney care delivery in Canada: a focus group study. *BMJ Open*. **2017 Mar 2**;7(3):e014784. doi: 10.1136/bmjopen-2016-014784
325. Donald M, King-Shier K, Tsuyuki RT, Al Hamarneh YN, Jones CA, **Manns B**, Tonelli M, Tink W, Scott-Douglas N, Hemmelgarn BR. Patient, family physician and community pharmacist perspectives on expanded pharmacy scope of practice: a qualitative study.

- CMAJ Open. **2017 Mar 6**;5(1):E205-E212. doi: 10.9778/cmajo.20160135. eCollection 2017 Jan-Mar
326. Chong CC, Tam-Tham H, Hemmelgarn BR, Weaver RG, Scott-Douglas N, Tonelli M, Quinn RR, Manns L, **Manns BJ**. Trends in the Management of Patients With Kidney Failure in Alberta, Canada (2004-2013). *Can J Kidney Health Dis.* **2017 Mar 22**;4:2054358117698668. doi: 10.1177/2054358117698668. eCollection 2017.
  327. **Manns B**, McKenzie SQ, Au F, Gignac PM, Geller LI; Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD) Network. The Financial Impact of Advanced Kidney Disease on Canada Pension Plan and Private Disability Insurance Costs. *Can J Kidney Health Dis.* **2017 Apr 17**;4:2054358117703986. doi: 10.1177/2054358117703986. eCollection 2017
  328. McBrien KA, Naugler C, Ivers N, Weaver RG, Campbell D, Desveaux L, Hemmelgarn BR, Edwards AL, Saad N, Nicholas D, **Manns BJ**. Barriers to care in patients with diabetes and poor glycemic control-A cross-sectional survey. *PLoS One.* **2017 May 1**;12(5):e0176135. doi: 10.1371/journal.pone.0176135. eCollection 2017.
  329. Ravani P, Quinn R, Oliver M, Robinson B, Pisoni R, Pannu N, MacRae J, **Manns B**, Hemmelgarn B, James M, Tonelli M, Gillespie B. Examining the Association between Hemodialysis Access Type and Mortality: The Role of Access Complications. *Clin J Am Soc Nephrol.* **2017 May 18**. pii: CJN.12181116. doi: 10.2215/CJN.12181116. [Epub ahead of print]
  330. Leal JR, Conly J, Henderson EA, **Manns BJ**. How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations. *Antimicrob Resist Infect Control.* **2017 Jun 2**;6:53. doi: 10.1186/s13756-017-0211-2. eCollection 2017. Review. PMID: 28588766
  331. Tonelli M, Wiebe N, Straus S, Fortin M, Guthrie B, James MT, Klarenbach SW, Tam-Tham H, Lewanczuk R, **Manns BJ**, Quan H, Ronksley PE, Sargious P, Hemmelgarn B; Alberta Kidney Disease Network. Multimorbidity, dementia and health care in older people:a population-based cohort study. *CMAJ Open.* **2017 Aug 14**;5(3):E623-E631. doi: 10.9778/cmajo.20170052. PMID: 28811281
  332. Barnieh L, Collister D, **Manns B**, Lam NN, Shojai S, Lorenzetti D, Gill JS, Klarenbach S. A Scoping Review for Strategies to Increase Living Kidney Donation. *Clin J Am Soc Nephrol.* 2017 Sep 7;12(9):1518-1527. doi: 10.2215/CJN.01470217. **Epub 2017 Aug 17**. PMID: 28818845
  333. Al Hamarneh YN, Tsuyuki RT, Jones CA, **Manns B**, Tonelli M, Scott-Douglass N, Jindal K, Tink W, Hemmelgarn BR. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized

- Controlled RxEACH Trial. *Am J Kidney Dis.* **2017 Sep 11**. pii: S0272-6386(17)30890-9. doi: 10.1053/j.ajkd.2017.07.012. [Epub ahead of print] PMID: 28912054
334. Gill S, Quinn R, Oliver M, Kamar F, Kabani R, Devoe D, Mysore P, Pannu N, MacRae J, **Manns B**, Hemmelgarn B, James M, Tonelli M, Lewin A, Liu P, Ravani P. Multi-Disciplinary Vascular Access Care and Access Outcomes in People Starting Hemodialysis Therapy. *Clin J Am Soc Nephrol.* **2017 Sep 14**. pii: CJN.03430317. doi: 10.2215/CJN.03430317. [Epub ahead of print] PMID: 28912248
335. Karsanji DJ, Pannu N, **Manns BJ**, Hemmelgarn BR, Tan Z, Jindal K, Scott-Douglas N, James MT. Disparity between Nephrologists' Opinions and Contemporary Practices for Community Follow-Up after AKI Hospitalization. *Clin J Am Soc Nephrol.* **2017 Oct 12**. pii: CJN.01450217. doi: 10.2215/CJN.01450217. [Epub ahead of print] PMID: 29025786
336. Collister D, Pannu N, Ye F, James M, Hemmelgarn B, Chui B, **Manns B**, Klarenbach S; Alberta Kidney Disease Network. Health Care Costs Associated with AKI. *Clin J Am Soc Nephrol.* **2017 Oct 19**. pii: CJN.00950117. doi: 10.2215/CJN.00950117. [Epub ahead of print] PMID: 29051143
337. James MT, Pannu N, Hemmelgarn BR, Austin PC, Tan Z, McArthur E, **Manns BJ**, Tonelli M, Wald R, Quinn RR, Ravani P, Garg AX. Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury. *JAMA.* **2017 Nov 14**;318(18):1787-1797. doi: 10.1001/jama.2017.16326.PMID: 29136443
338. Campbell DJT, **Manns BJ**, Soril LJJ, Clement F. Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs. *CMAJ Open.* **2017 Nov 22**;5(4):E808-E813. doi: 10.9778/cmajo.20170065. PMID: 29180377
339. Thompson S, Wiebe N, Klarenbach S, Pelletier R, Hemmelgarn BR, Gill JS, **Manns BJ**, Tonelli M; Alberta Kidney Disease Network. Catheter-related blood stream infections in hemodialysis patients: a prospective cohort study. *BMC Nephrol.* **2017 Dec 8**;18(1):357. doi: 10.1186/s12882-017-0773-5. PMID:29221439
340. Buse GL, **Manns B**, Lamy A, Guyatt G, Polanczyk CA, Chan MTV, Wang CY, Villar JC, Sigamani A, Sessler DI, Berwanger O, Biccard BM, Pearse R, Urrútia G, Szczeklik W, Garutti I, Srinathan S, Malaga G, Abraham V, Chow CK, Jacka MJ, Tiboni M, Ackland G, Macneil D, Sapsford R, Leuwer M, Le Manach Y, Devereaux PJ. Troponin T monitoring to detect myocardial injury after noncardiac surgery: a cost-consequence analysis. *Can J Surg.* **2018 Jun**;61(3):185-194. PMID: 29806816
341. Habbous S, Sarma S, Barnieh LJ, McArthur E, Klarenbach S, **Manns B**, Begen MA, Lentine KL, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Healthcare Costs for the Evaluation, Surgery, and Follow-Up Care of Living Kidney

- Donors. Transplantation. **2018 Aug**;102(8):1367-1374. doi: 10.1097/TP.0000000000002222. PMID: 30044364
342. Hemmelgarn BR, **Manns BJ**, Soroka SD, Levin A, MacRae J, Tennankore K, Wilson JS, Weaver RG, Ravani P, Quinn RR, Tonelli M, Kiaii M, Mossop P, Scott-Douglas N. Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution. *Clin J Am Soc Nephrol*. 2018 Mar 7;13(3):429-435. doi: 10.2215/CJN.08510817. **Epub 2018 Jan 15**. PMID: 29335321
  343. Hemmelgarn BR, Smekal MD, Weaver RG, Thomas C, Benterud E, Tam K, **Manns BJ**, Tonelli M, Finlay J, Donald M, Tam-Tham H, Bello A, Tangri N, Quinn RR. Implementation and Evaluation of a Risk-Based Approach to Guide Chronic Kidney Disease Care: Protocol for a Multiphase Mixed-Methods Study. *Can J Kidney Health Dis*. **2018 Jan 17**;5:2054358117753618. doi: 10.1177/2054358117753618. eCollection 2018. PMID: 29375884
  344. Levin A, Adams E, Barrett BJ, Beanlands H, Burns KD, Chiu HH, Chong K, Dart A, Ferera J, Fernandez N, Fowler E, Garg AX, Gilbert R, Harris H, Harvey R, Hemmelgarn B, James M, Johnson J, Kappel J, Komenda P, McCormick M, McIntyre C, Mahmud F, Pei Y, Pollock G, Reich H, Rosenblum ND, Scholey J, Sochett E, Tang M, Tangri N, Tonelli M, Turner C, Walsh M, Woods C, **Manns B**. Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function. *Can J Kidney Health Dis*. **2018 Jan 17**;5:2054358117749530. doi: 10.1177/2054358117749530. eCollection 2018. PMID: 29372064
  345. McBrien KA, Ivers N, Barnieh L, Bailey JJ, Lorenzetti DL, Nicholas D, Tonelli M, Hemmelgarn B, Lewanczuk R, Edwards A, Braun T, **Manns B**. Patient navigators for people with chronic disease: A systematic review. *PLoS One*. **2018 Feb 20**;13(2):e0191980. doi: 10.1371/journal.pone.0191980. eCollection 2018. Review. PMID: 29462179
  346. Sautenet B, Tong A, Williams G, Hemmelgarn BR, **Manns B**, Wheeler DC, Tugwell P, van Biesen W, Winkelmayr WC, Crowe S, Harris T, Evangelidis N, Hawley CM, Pollock C, Johnson DW, Polkinghorne KR, Howard K, Gallagher MP, Kerr PG, McDonald SP, Ju A, Craig JC. Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. *Am J Kidney Dis*. **2018 Feb 21**. pii: S0272-6386(17)31129-0. doi: 10.1053/j.ajkd.2017.11.010. [Epub ahead of print] PMID: 29475768
  347. Vieceilli AK, Tong A, O'Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, **Manns B**, Howell M, Chemla E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Hawley CM; SONG-HD Vascular Access Workshop Investigators. Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome

- Measure for Hemodialysis Vascular Access. *Am J Kidney Dis.* **2018 Feb 22**. pii: S0272-6386(18)30005-2. doi: 10.1053/j.ajkd.2017.12.003. [Epub ahead of print] PMID: 29478866
348. Rennert-May E, Conly J, Leal J, Smith S, **Manns B**. Economic evaluations and their use in infection prevention and control: a narrative review. *Antimicrob Resist Infect Control.* **2018 Feb 27**;7:31. doi: 10.1186/s13756-018-0327-z. eCollection 2018. Review. PMID: 29492261
349. Rennert-May E, **Manns B**, Smith S, Puloski S, Henderson E, Au F, Bush K, Conly J. Validity of administrative data in identifying complex surgical site infections from a population-based cohort after primary hip and knee arthroplasty in Alberta, Canada. *Am J Infect Control.* 2018 Oct;46(10):1123-1126. doi: 10.1016/j.ajic.2018.03.018. **Epub 2018 Apr 27**. PMID: 29709393
350. Tam-Tham H, Quinn RR, Weaver RG, Zhang J, Ravani P, Liu P, Thomas C, King-Shier K, Fruetel K, James MT, **Manns BJ**, Tonelli M, Murtagh FEM, Hemmelgarn BR. Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not. *Kidney Int.* 2018 Sep;94(3):582-588. doi: 10.1016/j.kint.2018.03.007. **Epub 2018 May 24**. PMID: 29803405
351. Tong A, **Manns B**, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, Crowe S, Harris T, Van Biesen W, Winkelmayr WC, Levin A, Thompson A, Perkovic V, Ju A, Gutman T, Bernier-Jean A, Viecelli AK, O'Lone E, Shen J, Josephson MA, Cho Y, Johnson DW, Sautenet B, Tonelli M, Craig JC; SONG Implementation Workshop Investigators. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. *Kidney Int.* 2018 Dec;94(6):1053-1068. doi: 10.1016/j.kint.2018.08.018. **Epub 2018 Oct 22**. PMID: 30360959
352. Tonelli M, Wiebe N, James MT, Klarenbach SW, **Manns BJ**, Ravani P, Strippoli GFM, Hemmelgarn BR; Alberta Kidney Disease Network. A population-based cohort study defines prognoses in severe chronic kidney disease. *Kidney Int.* **2018 Mar 7**. pii: S0085-2538(18)30057-7. doi: 10.1016/j.kint.2017.12.013. [Epub ahead of print] PMID: 29525394
353. Ju A, Unruh M, Davison S, Dapuelto J, Dew MA, Fluck R, Germain M, Jassal SV, Obrador G, O'Donoghue D, Josephson MA, Craig JC, Viecelli A, O'Lone E, Hanson CS, **Manns B**, Sautenet B, Howell M, Reddy B, Wilkie C, Rutherford C, Tong A; SONG-HD Fatigue Workshop Collaborators. Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop Report. *Am J Kidney Dis.* **2018 Mar 15**. pii: S0272-6386(18)30118-5. doi: 10.1053/j.ajkd.2017.12.018. [Epub ahead of print] PMID: 29551585



354. Habbous S, McArthur E, Sarma S, Begen MA, Lam NN, **Manns B**, Lentine KL, Dipchand C, Litchfield K, McKenzie S, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Potential implications of a more timely living kidney donor evaluation. *Am J Transplant*. **2018 Mar 25**. doi: 10.1111/ajt.14732. [Epub ahead of print] PMID: 29575655
355. Tonelli M, Wiebe N, Bello A, Field CJ, Gill JS, Hemmelgarn BR, Holmes DT, Jindal K, Klarenbach SW, **Manns BJ**, Thadhani R, Kinniburgh D; Alberta Kidney Disease Network. Concentrations of Trace Elements and Clinical Outcomes in Hemodialysis Patients: A Prospective Cohort Study. *Clin J Am Soc Nephrol*. **2018 Mar 29**. pii: CJN.11451017. doi: 10.2215/CJN.11451017. [Epub ahead of print] PMID: 29599300
356. Habbous S, Sarma S, Barnieh L, McArthur E, Klarenbach S, **Manns B**, Begen MA, Lentine KL, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Health care costs for the evaluation, surgery, and follow-up care of living kidney donors. *Transplantation*. **2018 Apr 19**. doi: 10.1097/TP.0000000000002222. [Epub ahead of print] PMID: 29677068
357. Tong A, Crowe S, Gill JS, Harris T, Hemmelgarn BR, **Manns B**, Pecoits-Filho R, Tugwell P, van Biesen W, Wang AYM, Wheeler DC, Winkelmayr WC, Gutman T, Ju A, O'Lone E, Sautenet B, Viecelli A, Craig JC. Clinicians' and researchers' perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study. *BMJ Open*. **2018 Apr 20**;8(4):e021198. doi: 10.1136/bmjopen-2017-021198. PMID: 29678992
358. Donald M, Gil S, Kahlon B, Beanlands H, Straus S, Herrington G, **Manns B**, Hemmelgarn BR. Overview of Self-Management Resources Used by Canadian Chronic Kidney Disease Clinics: A National Survey. *Can J Kidney Health Dis*. **2018 May 22**;5:2054358118775098. doi: 10.1177/2054358118775098. eCollection 2018. PMID: 29844919
359. Kirkpatrick AW, Coccolini F, Ansaloni L, Roberts DJ, Tolonen M, McKee JL, Leppaniemi A, Faris P, Doig CJ, Catena F, Fabian T, Jenne CN, Chiara O, Kubes P, **Manns B**, Kluger Y, Fraga GP, Pereira BM, Diaz JJ, Sugrue M, Moore EE, Ren J, Ball CG, Coimbra R, Balogh ZJ, Abu-Zidan FM, Dixon E, Biffl W, MacLean A, Ball I, Drover J, McBeth PB, Posadas-Calleja JG, Parry NG, Di Saverio S, Ordonez CA, Xiao J, Sartelli M; Closed Or Open after Laparotomy (COOL) after Source Control for Severe Complicated Intra-Abdominal Sepsis Investigators. Closed Or Open after Source Control Laparotomy for Severe Complicated Intra-Abdominal Sepsis (the COOL trial): study protocol for a randomized controlled trial. *World J Emerg Surg*. **2018 Jun 22**;13:26. doi: 10.1186/s13017-018-0183-4. eCollection 2018. PMID: 29977328

360. **Manns B**, Agar JWM, Biyani M, Blake PG, Cass A, Culleton B, Kleophas W, Komenda P, Lobbedez T, MacRae J, Marshall MR, Scott-Douglas N, Srivastava V, Magner P. Can economic incentives increase the use of home dialysis? *Nephrol Dial Transplant*. **2018 Jul 13**. doi: 10.1093/ndt/gfy223. [Epub ahead of print] PMID: 30010852
361. Rennert-May ED, Conly J, Smith S, Puloski S, Henderson E, Au F, **Manns B**. The cost of managing complex surgical site infections following primary hip and knee arthroplasty: A population-based cohort study in Alberta, Canada. *Infect Control Hosp Epidemiol*. 2018 Oct;39(10):1183-1188. doi: 10.1017/ice.2018.199. Epub **2018 Sep 10**. PMID: 30196799
362. James M, **Manns B**. Nephilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease. *Circulation*. **2018 Oct 9**;138(15):1515-1518. doi: 10.1161/CIRCULATIONAHA.118.036523. No abstract available. PMID: 30354525
363. Irigorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E. Psoriatic arthritis screening: a systematic review and meta-analysis. Irigorri N, Hazlewood G, **Manns B**, Danthurebandara V, Spackman E. *Rheumatology (Oxford)*. **2018 Oct 31**. doi: 10.1093/rheumatology/key314. [Epub ahead of print] PMID: 30380111
364. Tonelli M, Wiebe N, **Manns BJ**, Klarenbach SW, James MT, Ravani P, Pannu N, Himmelfarb J, Hemmelgarn BR. Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System. *JAMA Netw Open*. **2018 Nov 2**;1(7):e184852. doi: 10.1001/jamanetworkopen.2018.4852. PMID:30646392
365. Kulhawy-Wibe S, King-Shier KM, Barnabe C, **Manns BJ**, Hemmelgarn BR, Campbell DJT. Exploring structural barriers to diabetes self-management in Alberta First Nations communities. *Diabetol Metab Syndr*. **2018 Dec 3**;10:87. doi: 10.1186/s13098-018-0385-7. eCollection 2018. PMID: 30524507
366. **Manns BJ**, Hemmelgarn B, Tonelli M, Au F, So H, Weaver R, Quinn AE, Scott Klarenbach, S for Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease. The cost of care for people with chronic kidney disease. *CJKHD*; **2019**; in press.
367. Spackman E, Clement F, Allan GM, Bell CM, Bjerre LM, Blackburn DF, Blais R, Hazlewood G, Klarenbach S, Nicolle LE, Persaud N, Alessi-Severini S, Tierney M, Wijeyesundera HC, **Manns B**. Developing key performance indicators for prescription medication systems. *PLoS One*. **2019 Jan 15**;14(1):e0210794. doi: 10.1371/journal.pone.0210794. eCollection 2019. PMID:30645647
368. Quinn AE, Edwards A, Senior P, McBrien K, Hemmelgarn B, Tonelli M, Au F, Ma Z, Weaver R, **Manns BJ**. The association between payment model and specialist

- physicians' selection of patients with diabetes: a descriptive study. *CMAJ Open*. **2019 Feb 18**;7(1):E109-E116. doi: 10.9778/cmajo.20180171. Print 2019 Jan-Mar.PMID:30782774
369. Liu P, Quinn RR, Karim ME, Bello A, Tam-Tham H, Weaver R, Ronksley PE, Quan H, Strippoli GFM, **Manns B**, Hemmelgarn BR, Tonelli M, Ravani P. Nephrology consultation and mortality in people with stage 4 chronic kidney disease: a population-based study. *CMAJ*. **2019 Mar 11**;191(10):E274-E282. doi: 10.1503/cmaj.181372. PMID: 30858183
  370. Memedovich KA, **Manns B**, Beall R, Hollis A, Clement F. The impact of pharmaceutical rebates on patients' drug expenditures. *CMAJ*. **2019 Mar 18**;191(11):E308-E312. doi: 10.1503/cmaj.181041. No abstract available. PMID: 30885969
  371. Tonelli M, Wiebe N, James MT, Naugler C, **Manns BJ**, Klarenbach SW, Hemmelgarn BR. Statin use and the risk of acute kidney injury in older adults. *BMC Nephrol*. **2019 Mar 25**;20(1):103. doi: 10.1186/s12882-019-1280-7. PMID: 30909872
  372. Smekal MD, Tam-Tham H, Finlay J, Donald M, Thomas C, Weaver RG, Quinn RR, Tam K, **Manns BJ**, Tonelli M, Bello A, Tangri N, Hemmelgarn BR. Patient and provider experience and perspectives of a risk-based approach to multidisciplinary chronic kidney disease care: a mixed methods study. *BMC Nephrol*. **2019 Mar 29**;20(1):110. doi: 10.1186/s12882-019-1269-2. PubMed PMID: 30922254; PubMed Central PMCID:PMC6440153.
  373. James MT, Levey AS, Tonelli M, Tan Z, Barry R, Pannu N, Ravani P, Klarenbach SW, **Manns BJ**, Hemmelgarn BR. Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System. *JAMA Netw Open*. **2019 Apr 5**;2(4):e191795. doi: 10.1001/jamanetworkopen.2019.1795. PubMed PMID: 30951162; PubMed Central PMCID:PMC6450331.
  374. Leal J, Ronksley P, Henderson EA, Conly J, **Manns B**. Predictors of Mortality and Length of Stay in Patients with Hospital-Acquired *Clostridioides difficile* Infection: A Population-Based Study in Alberta, Canada. *J Hosp Infect*. **2019 Apr 13**. pii: S0195-6701(19)30157-4. doi: 10.1016/j.jhin.2019.04.007. [Epub ahead of print] PubMed PMID: 30991081.
  375. Tonelli M, Wiebe N, Kovesdy CP, James MT, Klarenbach SW, **Manns BJ**, Hemmelgarn BR; Alberta Kidney Disease Network. Joint associations of obesity and estimated GFR with clinical outcomes: a population-based cohort study. *BMC Nephrol*. **2019 Jun 6**;20(1):204. doi: 10.1186/s12882-019-1351-9. PMID: 31170925

376. Ferguson TW, Garg AX, Sood MM, Rigatto C, Chau E, Komenda P, Naimark D, Nesrallah GE, Soroka SD, Beaulieu M, Alam A, Kim SJ, Dixon S, **Manns B**, Tangri N. Association Between the Publication of the Initiating Dialysis Early and Late Trial and the Timing of Dialysis Initiation in Canada. *JAMA Intern Med.* **2019 Jul 1**;179(7):934-941. doi: 10.1001/jamainternmed.2019.0489. PMID: 31135821
377. Rennert-May E, Conly J, Smith S, Puloski S, Henderson E, Au F, **Manns B**. A cost-effectiveness analysis of mupirocin and chlorhexidine gluconate for *Staphylococcus aureus* decolonization prior to hip and knee arthroplasty in Alberta, Canada compared to standard of care. *Antimicrob Resist Infect Control.* **2019 Jul 11**;8:113. doi: 10.1186/s13756-019-0568-5. eCollection 2019. PMID: 31338160
378. Leal JR, Conly J, Weaver R, Wick J, Henderson EA, **Manns B**, Ronksley P. Attributable costs and length of stay of hospital-acquired *Clostridioides difficile*: A population-based matched cohort study in Alberta, Canada. *Infect Control Hosp Epidemiol.* **2019 Jul 25**:1-9. doi: 10.1017/ice.2019.178. [Epub ahead of print] PMID: 31342884
379. Farragher JF, Thomas C, Ravani P, **Manns B**, Elliott MJ, Hemmelgarn BR. Protocol for a pilot randomised controlled trial of an educational programme for adults on chronic haemodialysis with fatigue (Fatigue-HD). *BMJ Open.* **2019 Jul 30**;9(7):e030333. doi: 10.1136/bmjopen-2019-030333. PMID: 31366664
380. Sporinova B, **Manns B**, Tonelli M, Hemmelgarn B, MacMaster F, Mitchell N, Au F, Ma Z, Weaver R, Quinn A. Association of Mental Health Disorders With Health Care Utilization and Costs Among Adults With Chronic Disease. *JAMA Netw Open.* **2019 Aug 2**;2(8):e199910. doi: 10.1001/jamanetworkopen.2019.9910. PMID:31441939
381. **Manns BJ**, Strilchuk A, Mork M, Wasylak T. Alberta's Strategic Clinical Networks: A roadmap for the future. *Healthc Manage Forum.* 2019 Nov;32(6):313-322. doi: 10.1177/0840470419867344. **Epub 2019 Aug 8.** PMID: 31394938
382. Tam-Tham H, Clement F, Hemmelgarn BR, **Manns BJ**, Klarenbach SW, Tonelli M, Tsuyuki RT, Al Hamarneh YN, Penko J, Weaver CGW, Au F, Weaver RG, Jones CA, McBrien KA. A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (Rx EACH). *Value Health.* 2019 Oct;22(10):1128-1136. doi: 10.1016/j.jval.2019.05.012. **Epub 2019 Aug 17.** PMID: 31563255
383. Roberts DJ, Zygun DA, Ball CG, Kirkpatrick AW, Faris PD, James MT, Mrklas KJ, Hemmelgarn BD, Manns B, Stelfox HT. Challenges and potential solutions to the evaluation, monitoring, and regulation of surgical innovations. *BMC Surg.* **2019 Aug 27**;19(1):119. doi: 10.1186/s12893-019-0586-5. PMID:31455337

384. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, Klarenbach SW, Lewanczuk R, **Manns BJ**, Ronksley P, Sargious P, Straus S, Quan H; Alberta Kidney Disease Network. Correction to: Methods for identifying 30 chronic conditions: application to administrative data. *BMJ Glob Health*. **2019 Sep 13**;4(5):e001629. doi: 10.1136/bmjgh-2019-001629. eCollection 2019. PMID: 31565409
385. Osman MA, Schick-Makaroff K, Thompson S, Bialy L, Featherstone R, Kurzawa J, Zaidi D, Okpechi I, Habib S, Shojai S, Jindal K, Braam B, Keely E, Liddy C, **Manns B**, Tonelli M, Hemmelgarn B, Klarenbach S, Bello AK. Barriers and facilitators for implementation of electronic consultations (eConsult) to enhance access to specialist care: a scoping review. *BMJ Glob Health*. **2019 Sep 13**;4(5):e001629. doi: 10.1136/bmjgh-2019-001629. eCollection 2019. PMID: 31565409
386. Ravani P, Fiocco M, Liu P, Quinn RR, Hemmelgarn B, James M, Lam N, Manns B, Oliver MJ, Strippoli GFM, Tonelli M. Influence of Mortality on Estimating the Risk of Kidney Failure in People with Stage 4 CKD. *J Am Soc Nephrol*. 2019 Nov;30(11):2219-2227. doi: 10.1681/ASN.2019060640. **Epub 2019 Sep 20**. PMID: 31540963
387. Bello A, Zaidi D, Braam B, Courtney M, Glassford J, Jindal K, Klarenbach S, Kurzawa J, Osman M, Scott-Douglas N, Szigety S, Thompson S, **Manns B**, Hemmelgarn B, Tonelli M. Protocol: Improving Access to Specialist Nephrology Care Among Rural/Remote Dwellers of Alberta: The Role of Electronic Consultation in Improving Care for Patients With Chronic Kidney Disease. *Can J Kidney Health Dis*. **2019 Sep 30**;6:2054358119878715. doi: 10.1177/2054358119878715. eCollection 2019. PMID: 31631888
388. Bello AK, Zaidi D, Braam B, Chou S, Courtney M, Deved V, Glassford J, Jindal K, Klarenbach S, Osman M, Scott-Douglas N, Shurraw S, Thompson S, **Manns B**, Hemmelgarn B, Tonelli M. Electronic Advice Request System for Nephrology in Alberta: Pilot Results and Implementation. *Can J Kidney Health Dis*. **2019 Oct 4**;6:2054358119879778. doi: 10.1177/2054358119879778. eCollection 2019. PMID: 31632683
389. Kakumanu S, **Manns BJ**, Tran S, Saunders-Smith T, Hemmelgarn BR, Tonelli M, Tsuyuki R, Ivers N, Southern D, Bakal J, Campbell DJT. Cost analysis and efficacy of recruitment strategies used in a large pragmatic community-based clinical trial targeting low-income seniors: a comparative descriptive analysis. *Trials*. **2019 Oct 7**;20(1):577. doi: 10.1186/s13063-019-3652-5. PMID: 31590686
390. Persaud N, Bedard M, Boozary AS, Glazier RH, Gomes T, Hwang SW, Jüni P, Law MR, Mamdani MM, **Manns BJ**, Martin D, Morgan SG, Oh PI, Pinto AD, Shah BR, Sullivan F, Umali N, Thorpe KE, Tu K, Laupacis A; Carefully Selected and Easily Accessible at No Charge Medicines (CLEAN Meds) Study Team. Effect on Treatment Adherence of Distributing Essential Medicines at No Charge: The CLEAN Meds Randomized Clinical

- Trial. *JAMA Intern Med.* **2019 Oct 7.** doi: 10.1001/jamainternmed.2019.4472. [Epub ahead of print] PMID: 31589276
391. Navindra Persaud, Michael Bedard, Andrew S. Boozary, Richard H. Glazier, Tara Gomes, Stephen W. Hwang, Peter Jüni, Michael R. Law, Muhammad M. Mamdani, **Braden J. Manns**, Danielle Martin, Steven G. Morgan, Paul I. Oh, Andrew D. Pinto, Baiju R. Shah, Frank Sullivan, Norman Umali, Kevin E. Thorpe, Karen Tu, Andreas Laupacis. Effect on Treatment Adherence of Distributing Essential Medicines at No Charge: The CLEAN Meds Randomized Clinical Trial. *JAMA Intern Med.* 2020 Jan; 180(1): 27–34. Published online **2019 Oct 7.** doi: 10.1001/jamainternmed.2019.4472 PMID: PMC6784757
  392. Quinn AE, Hemmelgarn BR, Tonelli M, McBrien KA, Edwards A, Senior P, Faris P, Au F, Ma Z, Weaver RG, **Manns BJ.** Association of Specialist Physician Payment Model With Visit Frequency, Quality, and Costs of Care for People With Chronic Disease. *JAMA Netw Open.* **2019 Nov 1;**2(11):e1914861. doi: 10.1001/jamanetworkopen.2019.14861. PMID: 31702800
  393. Iragorri N, Hazlewood G, **Manns B**, Bojke L, Spackman E; PROMPT study group. A model to determine the cost-effectiveness of screening psoriasis patients for psoriatic arthritis. *Arthritis Care Res (Hoboken).* **2019 Nov 15.** doi: 10.1002/acr.24110. [Epub ahead of print] PMID: 31733035
  394. **Manns BJ**, Wasylak T. Clinical networks: enablers of health system change. *CMAJ.* **2019 Nov 25;**191(47):E1299-E1305. doi: 10.1503/cmaj.190313. No abstract available. PMID:31767705
  395. Lee EJ, Patel A, Acedillo RR, Bachynski JC, Barrett I, Basile E, Battistella M, Benjamin D, Berry D, Blake PG, Chan P, Bohm CJ, Clemens KK, Cook C, Dember L, Dirk JS, Dixon S, Fowler E, Getchell L, Gholami N, Goldstein C, Hahn E, Hogeterp B, Huang S, Hughes M, Jardine MJ, Kalatharan S, Kilburn S, Lacson E Jr, Leonard S, Liberty C, Lindsay C, MacRae JM, **Manns BJ**, McCallum J, McIntyre CW, Molnar AO, Mustafa RA, Nesrallah GE, Oliver MJ, Pandes M, Pandeya S, Parmar MS, Rabin EZ, Riley J, Silver SA, Sontrop JM, Sood MM, Suri RS, Tangri N, Tascona DJ, Thomas A, Wald R, Walsh M, Weijer C, Weir MA, Vorster H, Zimmerman D, Garg AX. Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. *Can J Kidney Health Dis.* **2019 Dec 26;**6:2054358119894394. doi: 10.1177/2054358119894394. eCollection 2019. PMID: 31903190
  396. Weaver RG, James MT, Ravani P, Weaver CGW, Lamb EJ, Tonelli M, **Manns BJ**, Quinn RR, Jun M, Hemmelgarn BR. Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements.

- J Am Soc Nephrol. 2020 Mar;31(3):591-601. doi: 10.1681/ASN.2019060605. **Epub 2020 Feb 5.**
397. Trachtenberg AJ, Quinn AE, Ma Z, Klarenbach S, Hemmelgarn B, Tonelli M, Faris P, Weaver R, Au F, Zhang J, **Manns B**. Association between change in physician remuneration and use of peritoneal dialysis: a population-based cohort analysis. *CMAJ Open*. **2020 Feb 18**;8(1):E96-E104. doi: 10.9778/cmajo.20190132. PMID: 32071144; PMCID: PMC7028166.
  398. Ng-Kamstra JS, Rennert-May E, McKee J, Lundgren S, **Manns B**, Kirkpatrick AW. Protocol for a parallel economic evaluation of a trial comparing two surgical strategies in severe complicated intra-abdominal sepsis: the COOL-cost study. *World J Emerg Surg*. **2020 Feb 21**;15(1):15. doi: 10.1186/s13017-020-00294-4. PMID: 32085778; PMCID: PMC7035651.
  399. Quinn AE, Trachtenberg AJ, McBrien KA, Ogundeji Y, Souri S, Manns L, Rennert- May E, Ronksley P, Au F, Arora N, Hemmelgarn B, Tonelli M, **Manns BJ**. Impact of payment model on the behaviour of specialist physicians: A systematic review. *Health Policy*. 2020 Apr;124(4):345-358. doi: 10.1016/j.healthpol.2020.02.007. **Epub 2020 Feb 22**. PMID: 32115252.
  400. Helen Tam-Tham, Pietro Ravani, Jianguo Zhang, Robert G. Weaver, Robert R. Quinn, Matthew T. James, Ping Liu, **Braden J. Manns**, Marcello Tonelli, Paul E. Ronksley, Tyrone G. Harrison, Chandra Thomas, Sara Davison, Brenda R. Hemmelgarn. Association of Initiation of Dialysis With Hospital Length of Stay and Intensity of Care in Older Adults With Kidney Failure. *JAMA Netw Open*. 2020 Feb; 3(2): e200222. Published online **2020 Feb 28**. doi: 10.1001/jamanetworkopen.2020.0222 PMCID: PMC7049084
  401. Elliott MJ, Love S, Donald M, **Manns B**, Donald T, Premji Z, Hemmelgarn BR, Grinman M, Lang E, Ronksley PE. Outpatient Interventions for Managing Acute Complications of Chronic Diseases: A Scoping Review and Implications for Patients With CKD. *Am J Kidney Dis*. **2020 May 30**:S0272-6386(20)30720-4. doi: 10.1053/j.ajkd.2020.04.006. Epub ahead of print. PMID: 32479925.
  402. Habbous S, Barnieh L, Klarenbach S, **Manns B**, Sarma S, Begen MA, Litchfield K, Lentine KL, Singh S, Garg AX. Evaluating multiple living kidney donor candidates simultaneously is more cost-effective than sequentially. *Kidney Int*. **2020 Jun 30**:S0085-2538(20)30712-2. doi: 10.1016/j.kint.2020.06.015. Epub ahead of print. PMID: 32619496.
  403. Johnson JA, Al Sayah F, Buzinski R, Corradetti B, Davison SN, Elliott MJ, Klarenbach S, **Manns B**, Schick-Makaroff K, Short H, Thomas C, Walsh M. A cluster randomized

- controlled trial for the Evaluation of routinely Measured PATient reported outcomes in HemodialYsis care (EMPATHY): a study protocol. *BMC Health Serv Res.* **2020 Aug 10**;20(1):731. doi: 10.1186/s12913-020-05557-z. PMID: 32778102; PMCID: PMC7418420.
404. Harrison TG, Ruzycski SM, James MT, Ronksley PE, Zarnke KB, Tonelli M, **Manns BJ**, McCaughey D, Schneider P, Dixon E, Hartley RL, Owen VS, Ma Z, Hemmelgarn BR. Estimated GFR and Incidence of Major Surgery: A Population-Based Cohort Study. *Am J Kidney Dis.* 2021 Mar;77(3):365-375.e1. doi: 10.1053/j.ajkd.2020.08.009. **Epub 2020 Oct 9.** PMID: 33039431
  405. Campbell DJT, Saunders-Smith T, **Manns BJ**, Tonelli M, Ivers N, Hemmelgarn BR, Tsuyuki RT, Pannu R, King-Shier K. Exploring patient and pharmacist perspectives on complex interventions for cardiovascular prevention: A qualitative descriptive process evaluation. *Health Expect.* 2020 Dec;23(6):1485-1501. doi: 10.1111/hex.13133. **Epub 2020 Oct 13.** PMID: 33047417
  406. Fletcher JM, Saunders-Smith T, **Manns BJ**, Tsuyuki R, Hemmelgarn BR, Tonelli M, Campbell DJT. Pharmacist and patient perspectives on recruitment strategies for randomized controlled trials: a qualitative analysis. *BMC Med Res Methodol.* **2020 Oct 31**;20(1):270. doi: 10.1186/s12874-020-01140-6. PMID: 33129278
  407. Rennert-May E, Raj SR, Leal J, Exner DV, **Manns BJ**, Chew DS. Economic evaluation of an absorbable antibiotic envelope for prevention of cardiac implantable electronic device infection. *Europace.* **2020 Nov 9**:euaa291. doi: 10.1093/europace/euaa291. Online ahead of print. PMID: 33554239
  408. Chew DS, Rennert-May E, Quinn FR, Buck B, Hill MD, Spackman E, **Manns BJ**, Exner DV. Economic evaluation of extended electrocardiogram monitoring for atrial fibrillation in patients with cryptogenic stroke. *Int J Stroke.* **2020 Nov 24**:1747493020974561. doi: 10.1177/1747493020974561. Online ahead of print. PMID: 33232196
  409. Collister D, Pohl K, Herrington G, Lee SF, Rabbat C, Tennankore K, Zimmermann D, Tangri N, Wald R, **Manns B**, Suri RS, Nadeau-Fredette AC, Goupil R, Silver SA, Walsh M. The DIalysis Symptom COntrol-Restless Legs Syndrome (DISCO-RLS) Trial: A Protocol for a Randomized, Crossover, Placebo-Controlled Blinded Trial. *Can J Kidney Health Dis.* **2020 Nov 26**;7:2054358120968959. doi: 10.1177/2054358120968959. eCollection 2020.PMID: 33294203 Free PMC article.
  410. Hillier DR, Tang M, Clark W, MacDonald C, Connolly C, Large C, King M, Singer J, Levin A, **Manns B**, Konvalinka A, Scholey J, Rosenblum ND. A Framework to Ensure Patient Partners Have Equal and Contributing Voices Throughout the Research Program Evaluation Process. *Can J Kidney Health Dis.* **2020 Nov 26**;7:2054358120970093. doi: 10.1177/2054358120970093. eCollection 2020.PMID: 33294204 Free PMC article.



411. Ravani P, Saxinger L, Chandran U, Fonseca K, Murphy S, Lang E, McDougall L, **Manns B**. COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. *CMAJ Open*. **2020 Dec 18**;8(4):E887-E894. doi: 10.9778/cmajo.20200191. Print 2020 Oct-Dec.PMID: 33355274 Free PMC article.
412. **Manns BJ**. Evidence-Based Decision Making 5: Knowledge Translation and the Knowledge to Action Cycle. *Methods Mol Biol*. **2021**;2249:467-482. doi: 10.1007/978-1-0716-1138-8\_25.PMID: 33871859
413. **Manns BJ**. Evidence-Based Decision Making 7: Health Economics in Clinical Research. *Methods Mol Biol*. **2021**;2249:501-516. doi: 10.1007/978-1-0716-1138-8\_27.PMID: 33871861
414. Ogundeji YK, Quinn A, Lunney M, Chong C, Chew D, Danso G, Duggan S, Edwards A, Hopkin G, Senior P, Sumner G, Williams J, **Manns B**. Factors that influence specialist physician preferences for fee-for-service and salary-based payment models: A qualitative study. *Health Policy*. 2021 Apr;125(4):442-449. doi: 10.1016/j.healthpol.2020.12.014. **Epub 2021 Jan 12**.PMID: 33509635
415. Quinn AE, Ronksley PE, Bresee L, Au F, Wick J, Leung AA, McBrien KA, **Manns BJ**, Beall RF. Antihypertensive Prescribing for Uncomplicated, Incident Hypertension: Opportunities for Cost Savings. *CJC Open*. **2021 Jan 20**;3(6):703-713. doi: 10.1016/j.cjco.2020.12.026. eCollection 2021 Jun.PMID: 34169249
416. Quinn AE, **Manns BJ**. Commentary: Improving the Sustainability of Healthcare in Canada through Physician-Engaged Delivery System Reforms. *Health Policy*. **2021 Feb**;16(3):43-50. doi: 10.12927/hcpol.2021.26434.PMID: 33720823.
417. Benham JL, Lang R, Kovacs Burns K, MacKean G, Léveillé T, McCormack B, Sheikh H, Fullerton MM, Tang T, Boucher JC, Constantinescu C, Murali M, Oxoby RJ, **Manns BJ**, Hu J, Marshall DA. Attitudes, current behaviours and barriers to public health measures that reduce COVID-19 transmission: A qualitative study to inform public health messaging. *PLoS One*. **2021 Feb 19**;16(2):e0246941. doi: 10.1371/journal.pone.0246941. eCollection 2021.PMID: 33606782 Free PMC article. *Clinical Trial*.
418. Benham JL, Lang R, Kovacs Burns K, MacKean G, Léveillé T, McCormack B, Sheikh H, Fullerton MM, Tang T, Boucher JC, Constantinescu C, Murali M, Oxoby RJ, **Manns BJ**, Hu J, Marshall DA. Attitudes, current behaviours and barriers to public health measures that reduce COVID-19 transmission: A qualitative study to inform public health messaging. *PLoS One*. **2021 Feb 19**;16(2):e0246941. doi:

- 10.1371/journal.pone.0246941. eCollection 2021.PMID: 33606782 Free PMC article. Clinical Trial.
419. Charles O, Woods H, Ally M, **Manns B**, Shah BR, Wang R, Persaud N. Effect of free distribution of medicines on the process of care for adult patients with type 1 and type 2 diabetes and hypertension: post hoc analysis of randomised controlled trial findings. *BMJ Open*. **2021 Mar 15**;11(3):e042046. doi: 10.1136/bmjopen-2020-042046.PMID: 33722866 Free PMC article. Clinical Trial.
  420. Quinn RR, Mohamed F, Pauly R, Schwartz T, Scott-Douglas N, Morrin L, Kozinski A, **Manns BJ**, Klarenbach S, Clarke A, Fox DE, Oliver MJ. Starting Dialysis on Time, At Home on the Right Therapy (START): Description of an Intervention to Increase the Safe and Effective Use of Peritoneal Dialysis. *Can J Kidney Health Dis*. **2021 Mar 31**;8:20543581211003764. doi: 10.1177/20543581211003764. eCollection 2021.PMID: 33868692
  421. Elliott MJ, Allu S, Beaucage M, McKenzie S, Kappel J, Harvey R, Morrin L, Soroka S, Graham J, Harding C, Pinsk M, Harris H, Tang M, **Manns B**. Defining the scope of knowledge translation within a national, patient-oriented kidney research network. *Can J Kidney Health Dis*. **2021 Apr 8**;8:20543581211004803. doi: 10.1177/20543581211004803. eCollection 2021
  422. Tangri N, Garg AX, Ferguson TW, Dixon S, Rigatto C, Allu S, Chau E, Komenda P, Naimark D, Nesrallah GE, Soroka SD, Beaulieu M, Alam A, Kim SJ, Sood MM, **Manns B**. Effects of a Knowledge-Translation Intervention on Early Dialysis Initiation: A Cluster Randomized Trial. *J Am Soc Nephrol*. **2021 Apr 15**:ASN.2020091254. doi: 10.1681/ASN.2020091254. Online ahead of print.PMID: 33858985
  423. Lang R, Benham JL, Atabati O, Hollis A, Tombe T, Shaffer B, Burns KK, MacKean G, Léveillé T, McCormack B, Sheikh H, Fullerton MM, Tang T, Boucher JC, Constantinescu C, Murali M, **Manns BJ**, Marshall DA, Hu J, Oxoby RJ. Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging. *BMC Public Health*. **2021 Apr 21**;21(1):765. doi: 10.1186/s12889-021-10790-0.PMID: 33882896
  424. Persaud N, Bedard M, Boozary A, Glazier RH, Gomes T, Hwang SW, Juni P, Law MR, Mamdani M, **Manns B**, Martin D, Morgan SG, Oh P, Pinto AD, Shah BR, Sullivan F, Umali N, Thorpe KE, Tu K, Laupacis A; Carefully seLected and Easily Accessible at No Charge Medications (CLEAN Meds) study team. Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. *PLoS Med*. **2021 May 21**;18(5):e1003590. doi: 10.1371/journal.pmed.1003590. eCollection 2021 May.PMID: 34019540

425. Rennert-May E, Raj SR, Leal J, Exner DV, **Manns BJ**, Chew DS. Economic evaluation of an absorbable antibiotic envelope for prevention of cardiac implantable electronic device infection. *Europace*. **2021 May 21**;23(5):767-774. doi: 10.1093/europace/eaab291. PMID: 33554239
426. Rennert-May E, Leal J, Thanh NX, Lang E, Dowling S, **Manns B**, Wasylak T, Ronksley PE. The impact of COVID-19 on hospital admissions and emergency department visits: A population-based study. *PLoS One*. **2021 Jun 1**;16(6):e0252441. doi: 10.1371/journal.pone.0252441. eCollection 2021. PMID: 34061888
427. Chong C, Wick J, Klarenbach S, **Manns B**, Hemmelgarn B, Ronksley P. Cost of Potentially Preventable Hospitalizations Among Adults With Chronic Kidney Disease: A Population-Based Cohort Study. *Can J Kidney Health Dis*. **2021 Jun 4**;8:20543581211018528. doi: 10.1177/20543581211018528. eCollection 2021. PMID: 34158964
428. Campbell DJT, Campbell DB, Ogundeji Y, Au F, Beall R, Ronksley PE, Quinn AE, **Manns BJ**, Hemmelgarn BR, Tonelli M, Spackman E. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs. *Diabet Med*. **2021 Jun 16**:e14622. doi: 10.1111/dme.14622. Online ahead of print. PMID: 34133781
429. Ogundeji Y, Clement F, Wellstead D, Farkas B, **Manns B**. Primary care physicians' perceptions of the role of alternative payment models in recruitment and retention in rural Alberta: a qualitative study. *CMAJ Open*. 2021 Jul 20;9(3):E788-E794. doi: 10.9778/cmajo.20200202. Print 2021 Jul-Sep. PMID: 34285058 **Free PMC article**.
430. Ogundeji YK, Quinn A, Lunney M, Chong C, Chew D, Hopkin G, Senior P, Sumner G, Williams J, **Manns B**. Optimizing Physician Payment Models to Address Health System Priorities: Perspectives from Specialist Physicians. *Healthc Policy*. 2021 Aug;17(1):58-72. doi: 10.12927/hcpol.2021.26577.
431. Donald M, Smekal MD, Elliott MJ, McBrien K, Weaver RG, **Manns BJ**, Tonelli M, Bello A, Straus SE, Scott-Douglas N, Jindal K, Hemmelgarn BR. Online clinical pathway for chronic kidney disease management in primary care: a retrospective cohort study. *BMC Nephrol*. **2021 Oct 6**;22(1):332. doi: 10.1186/s12882-021-02533-5. PMID: 34615462 Free PMC article.
432. Ma B, Faris P, Har BJ, Tyrrell B, Benterud E, Spertus JA, Pannu N, **Manns BJ**, Graham MM, James MT. Development and Evaluation of an Audit and Feedback Process for Prevention of Acute Kidney Injury During Coronary Angiography and Intervention. *CJC Open*. **2021 Oct 23**;4(3):271-281. doi: 10.1016/j.cjco.2021.10.006. eCollection 2022 Mar. PMID: 35386131

433. Davison SN, Klarenbach S, **Manns B**, Schnick-Makaroff K, Buzinski R, Corradetti B, Short H, Johnson JA. Patient-reported outcome measures in the care of in-centre hemodialysis patients. *J Patient Rep Outcomes*. **2021 Oct 12**;5(Suppl 2):93. doi: 10.1186/s41687-021-00365-3. PMID: 34637030 Free PMC article.
434. Davison SN, Klarenbach S, **Manns B**, Schick-Makaroff K, Buzinski R, Corradetti B, Short H, Johnson JA. Correction to: Patient-reported outcome measures in the care of in-centre hemodialysis patients. *J Patient Rep Outcomes*. **2021 Nov 3**;5(1):115. doi: 10.1186/s41687-021-00388-w. PMID: 34731331 Free PMC article. No abstract available.
435. Harrison TG, Ronksley PE, James MT, Ruzycki SM, Tonelli M, **Manns BJ**, Zarnke KB, McCaughey D, Schneider P, Wick J, Hemmelgarn BR. Mortality and cardiovascular events in adults with kidney failure after major non-cardiac surgery: a population-based cohort study. *BMC Nephrol*. **2021 Nov 4**;22(1):365. doi: 10.1186/s12882-021-02577-7. PMID: 34736410 Free PMC article.
436. Lang R, Atabati O, Oxoby RJ, Murali M, Shaffer B, Sheikh H, Fullerton MM, Tang T, Leigh JP, **Manns BJ**, Marshall DA, Ivers NM, Ratzan SC, Hu J, Benham JL. Characterization of non-adopters of COVID-19 non-pharmaceutical interventions through a national cross-sectional survey to assess attitudes and behaviours. *Sci Rep*. **2021 Nov 5**;11(1):21751. doi: 10.1038/s41598-021-01279-2. PMID: 34741109 Free PMC article.
437. Sheldon R, Talajic M, Tang A, Becker G, Essebag V, Sultan O, Baranchuk A, Ritchie D, Morillo C, Krahn A, Brignole M, **Manns B**, Maxey C, Randomized Pragmatic Trial of Pacemaker Versus Implantable Cardiac Monitor in Syncope and Bifascicular Block. Raj SR; SPRITELY Investigators. *JACC Clin Electrophysiol*. 2022 Feb;8(2):239-248. doi: 10.1016/j.jacep.2021.10.003. **Epub 2021 Nov 24**. PMID: 35210082 Clinical Trial.
438. Shah BD, Tyan CC, Rana M, Goodridge D, Hergott CA, Osgood ND, **Manns B**, Penz ED. Rural vs urban inequalities in stage at diagnosis for lung cancer. *Cancer Treat Res Commun*. 2021;29:100495. doi: 10.1016/j.ctarc.2021.100495. **Epub 2021 Nov 26**. PMID: 34875463 Free article.
439. Papini A, **Manns BJ**, Elliott MJ. Evaluation of the Cost of a High-Dose Intravenous Iron Protocol in a Regional Hemodialysis Program: Research Letter. *Can J Kidney Health Dis*. **2021 Dec 8**;8:20543581211063984. doi: 10.1177/20543581211063984. eCollection 2021. PMID: 35186304 Free PMC article.
440. Nguyen KH, Yankey D, Lu PJ, Kriss JL, Brewer NT, Razzaghi H, Meghani M, **Manns BJ**, Lee JT, Singleton JA. Report of Health Care Provider Recommendation for COVID-19 Vaccination Among Adults, by Recipient COVID-19 Vaccination Status and Attitudes - United States, April-September 2021. *MMWR Morb Mortal Wkly Rep*. **2021 Dec 17**;70(50):1723-1730. doi: 10.15585/mmwr.mm7050a1. PMID: 34914669 Free PMC article.

441. Benham JL, Atabati O, Oxoby RJ, Mourali M, Shaffer B, Sheikh H, Boucher JC, Constantinescu C, Parsons Leigh J, Ivers NM, Ratzan SC, Fullerton MM, Tang T, **Manns BJ**, Marshall DA, Hu J, Lang R. COVID-19 Vaccine-Related Attitudes and Beliefs in Canada: National Cross-sectional Survey and Cluster Analysis. *JMIR Public Health Surveill.* **2021 Dec 23**;7(12):e30424. doi: 10.2196/30424.PMID: 34779784 Free PMC article.
442. Tonelli M, Lloyd A, Cheung WY, Hemmelgarn BR, James MT, Ravani P, **Manns B**, Klarenbach SW. Mortality and Resource Use Among Individuals With Chronic Kidney Disease or Cancer in Alberta, Canada, 2004-2015. *JAMA Netw Open.* **2022 Jan 4**;5(1):e2144713. doi: 10.1001/jamanetworkopen.2021.44713.PMID: 35076702 Free PMC article.
443. Farragher JF, Ravani P, **Manns B**, Elliott M, Thomas C, Donald M, Verdin N, Hemmelgarn BR. A pilot randomised controlled trial of an energy management programme for adults on maintenance haemodialysis: the fatigue-HD study. *BMJ Open.* **2022 Feb 10**;12(2):e051475. doi: 10.1136/bmjopen-2021-051475.PMID: 35144947 Free PMC article. Clinical Trial.
444. Garrison SR, Kolber MR, Allan GM, Bakal J, Green L, Singer A, Trueman DR, McAlister FA, Padwal RS, Hill MD, **Manns B**, McGrail K, O'Neill B, Greiver M, Froentjes LS, Manca DP, Mangin D, Wong ST, MacLean C, Kirkwood JE, McCracken R, McCormack JP, Norris C, Korownyk T. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. *BMJ Open.* **2022 Feb 24**;12(2):e059711. doi: 10.1136/bmjopen-2021-059711.PMID: 35210352 Free PMC article.
445. **Manns BJ**, Garg AX, Sood MM, Ferguson T, Kim SJ, Naimark D, Nesrallah GE, Soroka SD, Beaulieu M, Dixon SN, Alam A, Allu S, Tangri N. Multifaceted Intervention to Increase the Use of Home Dialysis: A Cluster Randomized Controlled Trial. *Clin J Am Soc Nephrol.* **2022 Mar 21**:CJN.13191021. doi: 10.2215/CJN.13191021. Online ahead of print.PMID: 35314481.
446. Campbell DJT, Ghuttura H, Mladenovic A, Smith J, Leigh R, Desveaux L, Ivers N, **Manns B**, Tonelli M, Naugler C, Hemmelgarn B, McBrien KA. Variation in Patient-Described Barriers to and Facilitators of Diabetes Management by Individual-Level Characteristics: A Cross-Sectional, Open-Ended Survey. *Clin Diabetes.* **2022 Summer**;40(3):283-296. doi: 10.2337/cd21-0060.PMID: 35983416
447. Chew DS, Au F, Xu Y, **Manns BJ**, Tonelli M, Wilton SB, Hemmelgarn B, Kong S, Exner DV, Quinn AE. Geographic and temporal variation in the treatment and outcomes of atrial fibrillation: a population-based analysis of national quality indicators. *CMAJ Open.* **2022 Aug 2**;10(3):E702-E713. doi: 10.9778/cmajo.20210246. Print 2022 Jul-Sep.PMID: 35918151

448. Gao G, Lang R, Oxoby RJ, Mourali M, Sheikh H, Fullerton MM, Tang T, **Manns BJ**, Marshall DA, Hu J, Benham JL. Drivers of downloading and reasons for not downloading COVID-19 contact tracing and exposure notification apps: A national cross-sectional survey. *PLoS One*. **2022 Jul 15**;17(7):e0269783. doi: 10.1371/journal.pone.0269783. eCollection 2022.PMID: 35839252
449. Tonelli M, Wiebe N, Joannette Y, Hemmelgarn BR, So H, Straus S, James MT, **Manns BJ**, Klarenbach SW. Age, multimorbidity and dementia with health care costs in older people in Alberta: a population-based retrospective cohort study. *CMAJ Open*. **2022 Jul 5**;10(3):E577-E588. doi: 10.9778/cmajo.20210035. Print 2022 Jul-Sep.PMID: 35790226
450. Chong C, Smekal M, Hemmelgarn B, Elliott M, Allu S, Wick J, McBrien K, Jackson W, Bello A, Jindal K, Scott-Douglas N, **Manns B**, Tonelli M, Donald M. Use of Google Analytics to Explore Dissemination Activities for an Online CKD Clinical Pathway: A Retrospective Study. *Can J Kidney Health Dis*. **2022 May 11**;9:20543581221097456. doi: 10.1177/20543581221097456. eCollection 2022.PMID: 35574262
451. Wick J, Campbell DJT, McAlister FA, **Manns BJ**, Tonelli M, Beall RF, Hemmelgarn BR, Stewart A, Ronksley PE. Identifying subgroups of adult high-cost health care users: a retrospective analysis. *CMAJ Open*. **2022 Apr 19**;10(2):E390-E399. doi: 10.9778/cmajo.20210265. Print 2022 Apr-Jun.PMID: 35440486
452. Tran SHN, Weaver RG, **Manns BJ**, Saunders-Smith T, Campbell T, Ivers N, Hemmelgarn BR, Tonelli M, Pannu R, Campbell DJT. Factors Affecting the Reception of Self-Management Health Education: A Cross-Sectional Survey Assessing Perspectives of Lower-Income Seniors with Cardiovascular Conditions. *Patience*. **2022 Apr 8**;16:971-981. doi: 10.2147/PPA.S351459. eCollection 2022.PMID: 35422615
453. Ogundeji K, Quinn A, **Manns B**. Rethinking physician contracts: A focus on non-financial incentives. *Insights*. 2022 June 2022.
454. Bagshaw SM, Abbott A, Beesoon S, Zuege DJ, Wasylak T, **Manns B**, Nguyen TX. Avoidable intensive care unit resource use and costs of unvaccinated patients with COVID-19: a historical population-based cohort study. *Can J Anaesth*. **2022 Nov**;69(11):1399-1404. doi: 10.1007/s12630-022-02299-w. Epub 2022 Jul 26.PMID: 35879485 Free PMC article.
455. Elliott MJ, McCarron TL, Schick-Makaroff K, Getchell L, **Manns B**, Fernandez N. The dynamic nature of patient engagement within a Canadian patient-oriented kidney health research network: Perspectives of researchers and patient partners. *Health Expect*. **2023 Jan 27**. doi: 10.1111/hex.13716. Online ahead of print.PMID: 36704935
456. Baragar B, Schick-Makaroff K, **Manns B**, Love S, Donald M, Santana M, Corradetti B, Finlay J, Johnson JA, Walsh M, Elliott MJ. "You need a team": perspectives on interdisciplinary symptom management using patient-reported outcome measures in

- hemodialysis care-a qualitative study. *Patient Rep Outcomes*. **2023 Jan 20** doi: 10.1186/s41687-022-00538-8.PMID: 36662325
457. Campbell DB, Campbell DJT, Au F, Beall RF, Ronksley PE, Chew DS, Ogundeji Y, **Manns BJ**, Hemmelgarn BR, Tonelli M, Quinn AE. Patterns and Patients' Characteristics Associated with Use of Sodium-Glucose Cotransporter-2 Inhibitors among Adults with Type 2 Diabetes: A Population-based Cohort Study. *Can J Diabetes*. **2023 Feb**; doi: 10.1016/j.jcjd.2022.08.002. Epub 2022 Aug 9.PMID: 36184371
458. Tyrone G Harrison , Brenda R Hemmelgarn , Matthew T James , Simon Sawhney, **Braden J Manns** , Marcello Tonelli , Shannon M Ruzycki, Kelly B Zarnke , Todd A Wilson , Deirdre McCaughey 2, Paul E Ronksley. Prediction of major postoperative events after non-cardiac surgery for people with kidney failure: derivation and internal validation of risk models. . **2023 Mar** doi: 10.1186/s12882-023-03093-6.PMID: 36894895.
459. Campbell DJT, Mitchell C, Hemmelgarn BR, Tonelli M, Faris P, Zhang J, Tsuyuki RT, Fletcher J, Au F, Klarenbach S, Exner DV, Manns BJ. Eliminating Medication Copayments for Low-income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial. . **2023 Mar 5**. Doi: 10.1161/CIRCULATIONAHA.123.064188. Online ahead of print.PMID: 36871215.
460. Campbell DJT, Tonelli M, Hemmelgarn BR, Faris P, Zhang J, Au F, Tsuyuki RT, Mitchell C, Pannu R, Campbell T, Ivers N, Fletcher J, Exner DV, **Manns BJ**; Self-management Support Using Advertising Principles for Older Low Income Adults at High Cardiovascular Risk: a Randomized Controlled Trial. **2023 Mar 5**. doi: 10.1161/CIRCULATIONAHA.123.064189. Online ahead of print.PMID: 36871212
461. Yogasingam S, Konnyu KJ, Lépine J, Sullivan K, Alabousi M, Edwards A, Hillmer M, Karunanathan S, Lavis JN, Linklater S, Moher D, **Manns BJ**, Mortazhejri S, Nazarali S, Paprica PA, Ramsay T, Ryan PM, Sargious P, Shojania KG, Straus SE, Tonelli M, Tricco A, Vachon B, Yu CH, Zahradnik M, Trikalinos TA, Grimshaw JM, Ivers N; Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes. **2023 May 31** doi: 10.1002/14651858.CD014513.PMID: 37254718
462. Persaud N, Bedard M, Boozary A, Glazier RH, Gomes T, Hwang SW, Jüni P, Law MR, Mamdani M, **Manns B**, Martin D, Morgan SG, Oh P, Pinto AD, Shah BR, Sullivan F, Umali N, Thorpe KE, Tu K, Wu F, Laupacis A; CLEAN Meds study team Effect of Free Medicine Distribution on Health Care Costs in Canada Over 3 Years: A Secondary Analysis of the CLEAN Meds Randomized Clinical Trial. **2023 May 5** doi: 10.1001/jamahealthforum.2023.1127.PMID: 37234014

463. Zare-Zadeh S, **Manns BJ**, Chew DS, Harrison TG, Au F, Quinn AE. Low-value preoperative cardiac testing before low-**risk** surgical procedures: a population-based cohort study. **2023 May 23** doi: 10.9778/cmajo.20220049 PMID: 37220955
464. Elliott MJ, McCarron TL, Schick-Makaroff K, Getchell L, **Manns B**, Fernandez N The dynamic nature of patient engagement within a Canadian patient-oriented kidney health research network: Perspectives of researchers and patient partners. **2023 Apr;26** doi: 10.1111/hex.13716 PMID: 36704935



### Working Papers / Papers produced for External Health Agencies:

1. **Manns BJ**, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients with End-Stage Renal Disease on Hemodialysis or Peritoneal Dialysis: What are the important determinants? Institute of Health Economics Working paper 02-05, 2002.
2. Helen Lee, **Braden J. Manns**, Christopher James Doig, David Johnson, Cam Donaldson. A cost-effectiveness analysis of recombinant human activated protein C for severe sepsis in the Intensive Care Unit. ASCHUR / Institute of Health Economics Working Paper 02-06, 2002.
3. Browman G, **Manns B**, Hagen N, Chambers C. Five Steps: Evaluation framework for ranking cancer drugs for funding decisions in Alberta. Alberta Cancer Board, 2006.
4. **BJ Manns** et al, Sevelamer in Patients with End-Stage Renal Disease: A systematic review and Economic evaluation. CADTH report 71, Nov 2006.
5. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Doig C, **Manns B**. A Systematic Review and Economic Evaluation of Continuous Renal Replacement Therapy (CRRT) in Adult Patients with Acute Renal Failure (ARF). CADTH report, 2007.
6. Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, **Manns B**. Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation [Technology report number 106]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
7. Marcello Tonelli, Anita Lloyd, Helen Lee, Natasha Wiebe, Brenda Hemmelgarn, Anthony Reiman, **Braden Manns**, Neil Reaume, Scott Klarenbach. Erythropoiesis-Stimulating Agents for Anemia of Cancer or of Chemotherapy: Systematic Review and Economic Evaluation [Technology Report]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
8. Ho C, Heitman S, Membe SK, Morrison A, Moulton K, **Manns B**, Au F, Reed M, Hilsden R. Computed tomographic colonography for colorectal cancer screening in an average risk population: Systematic review and economic evaluation [Technology report number 114]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008.
9. The state of health economics in Alberta: A review of need, capacity and action. A Special Institute of Health Economics / Uof C Svare Chair in Health Economics report. May 2015. <http://www.ihe.ca/advanced-search/the-state-of-health-economics-in-alberta-a-review-of-need-capacity-and-action>
10. Fiona M. Clement, Lesley J.J. Soril, David Campbell, Herbert Emery, **Braden J. Manns**. Canadian Publicly Funded Prescription Drug Plans, Expenditures and an Overview of Patient Impacts. For Alberta Health 2016. <http://www.health.alberta.ca/documents/Health-Spending-PubliclyFundedDrugPlans-2016.pdf>

11. Fiona M. Clement, Lesley J.J. Soril, Herbert Emery, David J.T. Campbell, **Braden J. Manns**. Canadian Publicly Funded Prescription Drug Plans, Expenditures and an Overview of Patient Impacts. Prepared for Alberta Health. February 1, 2016.
12. Eldon Spackman, Fiona M. Clement, **Braden J. Manns**. Measuring the Performance of the Provincial Drug Care System. A report on the development of key performance indicators. Prepared for Alberta Health. June 30, 2017.
13. **Braden J. Manns**, Fiona M. Clement. Assessing the impact of potential changes to publicly funded medication insurance in Alberta: Premiums, deductibles and coverage for essential medications. Prepared for Alberta Health. April 28, 2017.
14. Fiona M. Clement, Eldon Spackman, **Braden J. Manns**. Preferences for Different Characteristics of Publicly Funded Drug Plans. A Report on the Results of an Alberta Survey. Prepared for Alberta Health. May 1, 2017.
15. Brenlea Farkas, Laura Dowsett, **Dr. Braden Manns**, Dr. Tom Noseworthy and Dr. Fiona Clement. A Proposed Framework for Supporting Physicians to be Stewards of Health Care Resources: A Report Brief. February 4, 2020.
16. Farkas, B., **Manns, B.**, Ogundeji, Y., Wellstead, D., Clement, F., (2020). Recruitment and Retention of Rural and Remote Physicians – the Role of Alternate Payment Models. Produced by the HTA Unit at the University of Calgary with support from the SPOR Evidence Alliance. July 8, 2020.